

CITATION REPORT

List of articles citing

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

DOI: 10.1056/nejmoa065044

New England Journal of Medicine, 2007, 356, 115-24.

Source: <https://exaly.com/paper-pdf/42191123/citation-report.pdf>

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2263	Forty-nine-month survival in a metastatic renal cell carcinoma patient across six lines of targeted therapy. 2014 , 8, 406		1
2262	Lymphangiogenesis in kidney cancer: Expression of VEGF-C, VEGF-D and VEGFR-3 in clear cell and papillary renal cell carcinoma. 1994 , 20, 721		1
2261	Palliative systemic antineoplastic therapy. 2001 , 399-420		
2260	Primary intracranial myxopapillary ependymomas: report of two cases and review of the literature. 2004 , 45, 344-7		23
2259	Toxicité hâle des antiangiogéniques. 2006 , 1, 1-6		
2258	Patterns of recurrence and surveillance strategies for renal cell carcinoma following surgical resection. 2007 , 7, 847-62		32
2257	Prognostic biomarkers in renal cell carcinoma. 2007 , 7, 293-307		4
2256	Current status of cytoreductive nephrectomy in metastatic renal cell carcinoma. 2007 , 7, 1749-61		2
2255	Emerging drugs for the treatment of metastatic renal cancer. 2007 , 12, 605-18		12
2254	Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer. 2007 , 25, 3288-95		155
2253	Multitarget tyrosine kinase inhibition: [and the winner is...]. 2007 , 25, 2340-2		9
2252	Treatment options in renal cell carcinoma: past, present and future. 2007 , 18 Suppl 10, x25-31		49
2251	Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. <i>New England Journal of Medicine</i> , 2007 , 356, 2271-81	59.2	3025
2250	Sunitinib. 2007 , 8, 2359-69		52
2249	Early experience with novel immunomodulators for cancer treatment. 2007 , 16, 1391-403		25
2248	Modulation of angiogenesis for cancer prevention: strategies based on antioxidants and copper deficiency. 2007 , 13, 3584-90		11
2247	Phase 2 study of ABT-510 in patients with previously untreated advanced renal cell carcinoma. 2007 , 13, 6689-95		70

2246	Introduction to 'A multitargeted approach: clinical advances in the treatment of solid tumours'. 2007 , 18 Suppl 10, x1-2	1
2245	Zoledronic acid - a multiplicity of anti-cancer action. 2007 , 14, 2126-35	72
2244	Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers. 2007 , 25, 4033-42	117
2243	CCR drug updates: sorafenib and sunitinib in renal cell carcinoma. 2007 , 13, 3765-70	56
2242	New challenges in kidney cancer therapy: sunitinib. 2007 , 18 Suppl 9, ix83-6	6
2241	Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group. 2007 , 25, 3296-301	144
2240	Targeted therapy in metastatic renal cell carcinoma. 2007 , 18 Suppl 9, ix98-102	7
2239	Reversible cognitive disorders after sunitinib for advanced renal cell cancer in patients with preexisting arteriosclerotic leukoencephalopathy. 2007 , 18, 1747-50	31
2238	Sunitinib: bridging present and future cancer treatment. 2007 , 18 Suppl 6, vi31-4	17
2237	Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose. 2007 , 25, 4542-9	187
2236	Immunotherapy for metastatic renal cell carcinoma: is it a therapeutic option yet?. 2007 , 18 Suppl 6, vi149-52	14
2235	Clinical and fundamental aspects of angiogenesis and anti-angiogenesis. 2007 , 62, 162-9	12
2234	What are the indications for sorafenib treatment in patients with renal cell carcinoma?. 2007 , 4, 456-7	1
2233	Report on the ISBTC mini-symposium on biologic effects of targeted therapeutics. 2007 , 30, 577-90	2
2232	Temsirolimus for advanced renal-cell carcinoma. <i>New England Journal of Medicine</i> , 2007 , 357, 1050; author reply 1050-1	59.2 4
2231	Smoldering multiple myeloma. <i>New England Journal of Medicine</i> , 2007 , 357, 1048; author reply 1049-50	59.2
2230	Salvation by registration. <i>New England Journal of Medicine</i> , 2007 , 356, 184-5	59.2 17
2229	[Interdisciplinary recommendations on targeted therapy in the treatment of renal cell carcinoma]. 2007 , 38, 328-30	1

2228	Interdisziplinäre Therapieempfehlungen zur Behandlung des metastasierten Nierenzellkarzinoms. 2007 , 28, 239-241	
2227	Drug insight: advances in renal cell carcinoma and the role of targeted therapies. 2007 , 4, 470-9	26
2226	Sunitinib and hypothyroidism. <i>New England Journal of Medicine</i> , 2007 , 356, 1580; author reply 1580-1	59.2 31
2225	Targeting the PI3K-Akt pathway in kidney cancer. 2007 , 7, 863-70	18
2224	Outcomes and prognosis in advanced renal cell carcinoma. 2007 , 7, 839-45	4
2223	Inhibition of VEGF-A prevents the angiogenic switch and results in increased survival of Apc ⁺ /min mice. 2007 , 104, 10625-30	56
2222	Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. 2007 , 99, 974-5; author reply 976-7	20
2221	Pharmacodynamic and pharmacokinetic study of chronic low-dose metronomic cyclophosphamide therapy in mice. 2007 , 6, 2280-9	40
2220	Surrogate biomarkers in evaluating response to anti-angiogenic agents: focus on sunitinib. 2007 , 18 Suppl 10, x11-9	46
2219	Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies. 2007 , 12, 1404-15	99
2218	Integrated therapy of kidney cancer. 2007 , 18 Suppl 6, vi141-8	24
2217	Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. 2007 , 99, 975-6; author reply 976-7	16
2216	Sunitinib (Sutent): a novel agent for the treatment of metastatic renal cell carcinoma. 2007 , 13, 5-15	15
2215	Renal cell cancer: is immunotherapy dead?. 2007 , 18 Suppl 9, ix94-7	3
2214	A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities. 2007 , 18 Suppl 10, x3-10	105
2213	Response: Re: Hypothyroidism in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib. 2007 , 99, 976-977	5
2212	Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. 2007 , 25, 4793-9	131
2211	Targeting the nuclear factor-kappaB rescue pathway has promising future in human renal cell carcinoma therapy. 2007 , 67, 11668-76	54

2210	Identification of Toll-like receptor 3 as a potential therapeutic target in clear cell renal cell carcinoma. 2007 , 13, 5703-9	72
2209	Molecular therapy in urologic oncology. 2007 , 79, 1-7	18
2208	Combinatorial protein therapy of angiogenic and arteriogenic factors remarkably improves collaterogenesis and cardiac function in pigs. 2007 , 104, 12140-5	90
2207	Sunitinib improves response and survival rates in metastatic RCC. 2007 , 4, 208-208	
2206	Managing side effects of angiogenesis inhibitors in renal cell carcinoma. 2007 , 30, 519-24	17
2205	Capecitabine as third-line treatment in patients with metastatic renal cell carcinoma after failing immunotherapy. 2007 , 18, 817-20	9
2204	Prognostic markers in renal cell carcinoma. 2007 , 17, 303-8	69
2203	Recent advances in targeted therapy for renal cell carcinoma. 2007 , 17, 331-6	14
2202	Renal cell cancer. 2007 , 13, 282-6	11
2201	Phase 1/2 clinical trial of interferon alpha2b and weekly liposome-encapsulated all-trans retinoic acid in patients with advanced renal cell carcinoma. 2007 , 30, 655-62	43
2200	Antiangiogenic therapy for cancer: an update. 2007 , 13, 345-8	53
2199	New therapies in renal cell carcinoma. 2007 , 1, 174-9	7
2198	Kidney cancer: past, present, and future. 2007 , 25, 188-95	22
2197	[Anti-angiogenetic agents for solid tumors]. 2007 , 28 Suppl 1, S7-8	2
2196	Allergic interstitial nephritis possibly related to sunitinib use. 2007 , 5, 341-4	24
2195	Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies. 2007 , 10, 81-100	62
2194	Natural history of metastatic renal cell carcinoma in patients who underwent consultation for allogeneic hematopoietic stem cell transplantation. 2007 , 13, 975-85	4
2193	Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors. 2007 , 29, 1338-53	135

2192	ASCO 2006 highlights: targeted therapy for renal cell carcinoma. 2007 , 33, 381-90	5
2191	Vascular endothelial growth factor: biology and therapeutic applications. 2007 , 39, 1349-57	129
2190	Sunitinib malate and sorafenib may be beneficial at the treatment of advanced bladder cancer due to their anti-angiogenic effects. 2007 , 69, 892-5	10
2189	VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects. 2007 , 13, 223-30	111
2188	Roles for VEGF in the adult. 2007 , 74, 100-13	142
2187	The Role of Cytokine Therapy in Metastatic Renal Cell Cancer. 2007 , 6, 658-664	9
2186	Bisphosphonates Can Prevent Skeletal Complications of Malignant Bone Disease from Prostate Cancer and Renal Cell Carcinoma. 2007 , 6, 683-688	10
2185	Current Status of Targeted Therapy in Metastatic Renal Cell Carcinoma. 2007 , 6, 665-671	4
2184	Kidney Cancer: Highlights from 2006. 2007 , 6, 745-753	1
2183	Tumour lysis syndrome in a patient with renal-cell carcinoma treated with sunitinib malate. 2007 , 369, 1923-4	23
2182	Cardiac toxicity of sunitinib. 2007 , 370, 1978-80	26
2181	Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. 2007 , 370, 2011-9	843
2180	Targeted drugs for metastatic renal cell carcinoma. 2007 , 370, 2071-3	68
2179	Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. 2007 , 370, 2103-11	1856
2178	Molecular therapeutic targets for bladder cancer. 2007 , 7, 1691-3	
2177	Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. 2007 , 8, 975-84	385
2176	Targeting VEGF receptors in kidney cancer. 2007 , 8, 956-7	14
2175	Targeted therapy in metastatic renal cell carcinoma: efficacy, adverse-event management and key considerations. 2007 , 5, 1-3	1

2174	Current options for the treatment of locally advanced and metastatic renal cell carcinoma: focus on sunitinib. 2007 , 5, 4-11	2
2173	Optimisation of sunitinib therapy in metastatic renal cell carcinoma: adverse-event management. 2007 , 5, 12-19	19
2172	Key considerations in patient selection for the use of targeted therapy in metastatic renal cell carcinoma. 2007 , 5, 20-27	4
2171	Case Report 1. Sunitinib malate in patients with pre-existing haematological abnormalities. 2007 , 5, 28-29	
2170	Case Report 3. Sunitinib malate in patients with cerebellar metastases. 2007 , 5, 32-34	10
2169	Recent developments in renal cell cancer immunotherapy. 2007 , 7, 727-37	11
2168	Safety and tolerability of sorafenib in clear-cell renal cell carcinoma: a Phase III overview. 2007 , 7, 1193-202	13
2167	Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941. 2007 , 178, 1901-5	53
2166	Modulating hypoxia-inducible transcription by disrupting the HIF-1-DNA interface. 2007 , 2, 561-71	111
2165	Do the results of the new trials change the standard treatment of metastatic renal cell cancer?. 2007 , 30, 260-4	5
2164	Gene therapy of gynaecological diseases. 2007 , 7, 1347-61	13
2163	Biomarkers in clear cell renal cell carcinoma. 2007 , 7, 1737-47	12
2162	5T4-modified vaccinia ankara: progress in tumor-associated antigen-based immunotherapy. 2007 , 7, 1463-9	8
2161	Renal-cell carcinoma--molecular pathways and therapies. <i>New England Journal of Medicine</i> , 2007 , 356, 185-7	59.2 214
2160	Targeted agents: the rules of combination. 2007 , 13, 5232-7	47
2159	Bevacizumab in the treatment of colorectal cancer. 2007 , 7, 739-49	19
2158	Small molecule signal transduction inhibitors for the treatment of solid tumors. 2007 , 25, 347-65	12
2157	Vascular disrupting agents in clinical development. 2007 , 96, 1159-65	194

2156	[Sunitinib and hypothyroidism]. 2007 , 68, 332-6	5
2155	[Kidney tumors]. 2007 , 17, 1101-44	7
2154	Current immunotherapeutic strategies in renal cell carcinoma. 2007 , 16, 975-86, xi-xii	4
2153	Editorial Comment. 2007 , 177, 2018-2019	
2152	Sunitinib efficacy against advanced renal cell carcinoma. 2007 , 178, 1883-7	163
2151	[Renal cell carcinoma with liver extension: a report of a new case and literature review]. 2007 , 31, 541-7	3
2150	Basal cytokines profile in metastatic renal cell carcinoma patients treated with subcutaneous IL-2-based therapy compared with that of healthy donors. 2007 , 5, 51	21
2149	TOR (target of rapamycin) as an anti-cancer target. 2007 , 4, 211-217	2
2148	Protein kinases as targets for cancer treatment. 2007 , 8, 1005-16	60
2147	Genetic causes of brain tumors: neurofibromatosis, tuberous sclerosis, von Hippel-Lindau, and other syndromes. 2007 , 25, 925-46, viii	102
2146	Inhibition of angiogenesis and invasion in malignant gliomas. 2007 , 7, 1537-60	44
2145	Targeted therapy for renal cell carcinoma: a new treatment paradigm. 2007 , 20, 244-8	16
2144	Interleukin-2 in the treatment of unresectable or metastatic renal cell cancer: a systematic review and practice guideline. 2007 , 1, 27-38	15
2143	Cytokine-based immunotherapy for advanced kidney cancer: past results and future perspectives in the era of molecularly targeted agents. 2007 , 7, 837-49	21
2142	Renal cell cancer: overview and immunochemotherapy. 1-16	
2141	Anti-angiogenic and Anti-stromal Therapy. 2007 ,	
2140	Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. 2007 , 109, 2257-67	298
2139	Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. 2007 , 110, 543-50	198

2138	The times they are a-changin' (Bob Dylan, 1964). 2007 , 110, 2366-9	2
2137	Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer. 2007 , 110, 2628-39	16
2136	Frequent loss of expression of the pro-apoptotic protein Bim in renal cell carcinoma: evidence for contribution to apoptosis resistance. 2007 , 26, 7038-48	75
2135	Trial watch. 2007 , 7, 74-74	
2134	Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. 2007 , 7, 332-44	628
2133	Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. 2007 , 7, 475-85	418
2132	Molecular basis for sunitinib efficacy and future clinical development. 2007 , 6, 734-45	522
2131	Temsirolimus. 2007 , 6, 599-600	36
2130	Nuclear E-cadherin and VHL immunoreactivity are prognostic indicators of clear-cell renal cell carcinoma. 2007 , 87, 1252-64	38
2129	Photosensitizing and radiosensitizing effects of hypericin on human renal carcinoma cells in vitro. 2008 , 84, 228-35	11
2128	Signal-transduction inhibitors in renal cell carcinoma. 2007 , 99, 1289-95	9
2127	Glucose transporter-1 expression in renal cell carcinoma and its correlation with hypoxia inducible factor-1 alpha. 2008 , 101, 480-4	33
2126	Novel targeted therapies for advanced esophageal cancer. 2007 , 20, 365-71	9
2125	Phase I trial of personalized peptide vaccination for cytokine-refractory metastatic renal cell carcinoma patients. 2007 , 98, 1965-8	32
2124	Learning management better to help kill two birds with one stone. 2007 , 3, 165-166	
2123	Sunitinib malate in the treatment of renal cell carcinoma and gastrointestinal stromal tumor: Recommendations for patient management*. 2007 , 3, 167-176	10
2122	Treatment of advanced renal cell carcinoma with the combination bevacizumab/erlotinib/imatinib: a phase I/II trial. 2007 , 5, 427-32	62
2121	Prolonged complete responses and near-complete responses to sunitinib in metastatic renal cell carcinoma. 2007 , 5, 446-51	29

2120	Sorafenib and sunitinib: novel targeted therapies for renal cell cancer. 2007 , 27, 1125-44	82
2119	Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations. 2007 , 35, 1522-6	43
2118	Renal cell carcinoma guideline. 2007 , 51, 1502-10	382
2117	Re: Sorafenib in Advanced Clear-Cell Renal Cell Carcinoma. 2007 , 52, 279-280	1
2116	Re: Björn Ljungberg, Damian C. Hanbury, Marcus A. Kuczyk, Axel S. Merseburger, Peter F.A. Mulders, Jean-Jaques Patard and Ioanel C. Sinescu. Renal cell carcinoma guideline. Eur Urol 2007;51:1502-10. 2007 , 52, 926-8; author reply 928	
2115	Highlights from: The 43rd Annual Meeting of the American Society of Clinical Oncology; June 1-5, 2007; Chicago, IL. 2007 , 5, 362-370	
2114	Targeting vascular endothelial growth factor (VEGF)-receptor-signaling in renal cell carcinoma. 2007 , 25, 59-72	9
2113	Key clinical issues in renal cancer: a challenge for proteomics. 2007 , 25, 537-56	25
2112	[Efficacy of multikinase inhibitors in the treatment of advanced renal cell cancer. A snapshot]. 2007 , 46, 504-8, 510	2
2111	[Transcriptome analyses in renal cell carcinoma. Combination of laser microdissection and microarrays]. 2007 , 46, 1170-5	1
2110	[The value of imaging techniques for bone metastases]. 2007 , 46, 891-6	
2109	[Inductive systemic therapy of urological tumors with curative intent]. 2007 , 46, 1400-3	0
2108	Symptomatic pituitary metastases from renal cell carcinoma. 2007 , 10, 251-9	37
2107	Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib. 2007 , 7, 127-34	129
2106	Pharmacologie des thérapeutiques ciblées. 2007 , 9, 773-777	
2105	Urologische Aspekte in der Palliativmedizin. 2007 , 13, 602-608	
2104	Symptomkontrollierende Effekte der Chemotherapie. 2007 , 13, 619-624	1
2103	Tyrosine kinase inhibitors and anti-angiogenic therapies in kidney cancer. 2007 , 8, 211-26	8

2102	Transitions to palliation: two solitudes or inevitable integration?. 2007 , 9, 285-9	9
2101	ASCO 2007: "Translating Research into Practice" Report from the 34th annual meeting of the American Society of Clinical Oncology. 2007 , 1, 65-72	
2100	Temisorlimus in the treatment of advanced renal cell carcinoma. 2007 , 1, 73-80	3
2099	Renal cell carcinoma: evolving approaches to advanced non-clear cell carcinoma. 2007 , 1, 170-176	5
2098	VEGF: a key therapeutic target for the treatment of cancer-insights into its role and pharmacological inhibition. 2007 , 2, 153-164	8
2097	Targeted therapy in advanced colorectal cancer, an update. 2007 , 2, 165-172	2
2096	The intersection of sunitinib with the immunosuppressive microenvironment of renal cell carcinoma: implications for future therapeutics. 2007 , 2, 225-234	4
2095	Renal cancer. 2007 , 64, 247-62	23
2094	Clinical biomarkers of angiogenesis inhibition. 2008 , 27, 415-34	39
2093	Regression of brain metastases of renal cell carcinoma with antiangiogenic therapy. 2008 , 86, 243-4	27
2092	Phase II trial of lenalidomide in patients with metastatic renal cell carcinoma. 2008 , 26, 273-6	14
2091	Phase-I study of Innacell gammadelta, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma. 2008 , 57, 1599-609	184
2090	A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period. 2008 , 61, 515-24	120
2089	A Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma. 2008 , 61, 689-94	24
2088	Phase I trial of PEG-interferon and recombinant IL-2 in patients with metastatic renal cell carcinoma. 2008 , 62, 347-54	12
2087	[Renal cell carcinoma 2008. Histopathology, molecular genetics and new therapeutic options]. 2008 , 29, 354-63	7
2086	[Molecular basis of targeted therapy in metastatic renal cancer]. 2008 , 29 Suppl 2, 184-6	1
2085	Targeted therapy in renal cell carcinoma. 2008 , 26, 135-40	39

2084	Tumor vaccines in renal cell carcinoma. 2008 , 26, 147-54	13
2083	Risk stratification and prognostication of renal cell carcinoma. 2008 , 26, 115-25	36
2082	[Molecular tumour therapy: antibodies and small molecules]. 2008 , 49, 581-92	1
2081	[Volumetry of metastases from renal cell carcinoma: comparison with the RECIST criteria]. 2008 , 48, 850-6	10
2080	[Value of targeted therapies for renal cell cancer]. 2008 , 47, 1303-10	5
2079	[Value of targeted therapy for penile cancer]. 2008 , 47, 1320-7	8
2078	[Clinical network structures in uro-oncology. A model for the future?]. 2008 , 47, 1128-32	1
2077	[Preclinical studies on the influence of the tyrosine kinase inhibitor AEE788 on malignant properties of renal cell carcinoma cells]. 2008 , 47, 1175-81	2
2076	[Systemic therapy of metastasizing renal cell carcinoma]. 2008 , 47, 1357-67	0
2075	Targeted therapy des metastasierten Nierenzellkarzinoms (mRCC). 2008 , 1, 82-90	
2074	Current status of studies on targeted therapy for renal cell carcinoma. 2008 , 5, 294-298	
2073	Adjuvant therapy for renal cell carcinoma. 2008 , 10, 245-52	10
2072	Current status of debulking nephrectomy in the era of tyrosine kinase inhibitors. 2008 , 10, 253-8	6
2071	The current role of immunotherapy for renal cell carcinoma in the era of targeted therapeutics. 2008 , 10, 259-63	4
2070	Genomics and proteomics in renal cell carcinoma: diagnosis, prognosis, and treatment selection. 2008 , 9, 9-14	4
2069	Angiogenesis and angiogenic inhibitors in renal cell carcinoma. 2008 , 9, 26-33	11
2068	Treatment options in localised and metastatic renal cell carcinoma. 2008 , 1, 167-170	
2067	Systems biology: a therapeutic target for tumor therapy. 2008 , 1, 159-70	52

2066	Cardiac toxicity: old and new issues in anti-cancer drugs. 2008 , 10, 35-46	56
2065	Allogeneic transplantation following non-myeloablative conditioning in renal carcinoma. New evidence of the immune mechanisms responsible for the activity of this form of immunotherapy and the pathogenetic role of endogenous retroviruses. 2008 , 2, 1-3	
2064	Differenzialtherapie beim metastasierenden Nierenzellkarzinom. 2008 , 14, 191-197	4
2063	Bevacizumab plus Interferon alfa-2a in der Therapie des metastasierten Nierenzellkarzinoms. 2008 , 14, 535-538	
2062	Molekulare Therapie beim Nierenzellkarzinom. 2008 , 14, 1055-1064	
2061	Clinical outcome and prognostic survival factors in patients with advanced renal cell carcinoma treated with very low-dose interleukin-2, interferon-alpha, and tegafur-uracil: a single-institution experience. 2008 , 13, 257-62	4
2060	Cr�ation d'une unit� de coordination de la prise en charge des tumeurs rares du rein de l'adulte. 2008 , 10, 437-442	
2059	Bevacizumab et temsirolimus: quel apport dans la strat�gie de prise en charge du cancer du rein m�tastatique ?. 2008 , 10, 653-656	
2058	Tetraiodothyroacetic acid, a small molecule integrin ligand, blocks angiogenesis induced by vascular endothelial growth factor and basic fibroblast growth factor. 2008 , 11, 183-90	94
2057	Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib. 2008 , 16, 557-66	94
2056	The management of cancer in the elderly: targeted therapies in oncology. 2008 , 5, 16	9
2055	Serum biomarker discovery in renal cancer using 2-DE and prefractionation by immunodepletion and isoelectric focusing; increasing coverage or more of the same?. 2008 , 8, 5074-85	30
2054	Cancer invasion and metastasis: changing views. 2008 , 214, 283-93	220
2053	[Inhibition of the VEGF receptor system with tyrosine kinase inhibitors. Angiogenesis inhibition in oncology]. 2008 , 37, 404-15	4
2052	Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program. 2008 , 51, 42-8	79
2051	Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. 2008 , 112, 2500-8	208
2050	Oncofetal protein IMP3: a novel molecular marker that predicts metastasis of papillary and chromophobe renal cell carcinomas. 2008 , 112, 2676-82	66
2049	Validation by calibration of the UCLA integrated staging system prognostic model for nonmetastatic renal cell carcinoma after nephrectomy. 2008 , 113, 65-71	30

2048	Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinoma. 2008 , 113, 72-7	35
2047	High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma : a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. 2008 , 113, 293-301	277
2046	Predicting disease progression after nephrectomy for localized renal cell carcinoma: the utility of prognostic models and molecular biomarkers. 2008 , 113, 450-60	74
2045	Rationale for combination use of targeted agents in ovarian cancer: do we have one?. 2008 , 113, 665-7	2
2044	The von Hippel-Lindau gene: turning discovery into therapy. 2008 , 113, 1768-78	35
2043	Systemic cancer therapy: evolution over the last 60 years. 2008 , 113, 1857-87	42
2042	Performance status and cytoreductive nephrectomy: redefining management in patients with poor performance. 2008 , 113, 1324-31	33
2041	Sunitinib-induced macrocytosis in patients with metastatic renal cell carcinoma. 2008 , 113, 1309-14	29
2040	Brain metastasis from renal cell carcinoma: presentation, recurrence, and survival. 2008 , 113, 1641-8	125
2039	Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. 2008 , 113, 1552-8	162
2038	Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005): a benchmark for emerging targeted cancer therapies. 2008 , 113, 2457-63	69
2037	Metastasis is promoted by a bioenergetic switch: new targets for progressive renal cell cancer. 2008 , 122, 2422-8	99
2036	Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma. 2008 , 123, 395-400	134
2035	A three-gene expression signature model to predict clinical outcome of clear cell renal carcinoma. 2008 , 123, 1126-32	42
2034	Systemic IGF-I administration stimulates the in vivo growth of early, but not advanced, renal cell carcinoma. 2008 , 123, 1286-91	12
2033	Molecular targeted therapies in hepatocellular carcinoma. 2008 , 48, 1312-27	801
2032	Antiangiogenic therapy and surgical practice. 2008 , 95, 281-93	8
2031	Molecularly targeted therapy and cancer surgery. 2008 , 95, 537-8	

2030	Hemostatic complications of angiogenesis inhibitors in cancer patients. 2008 , 83, 862-70	54
2029	Targeting the VEGF pathway: antiangiogenic strategies in the treatment of non-small cell lung cancer. 2008 , 68, 183-96	26
2028	Mast cells and cancer--no longer just basic science. 2008 , 68, 115-30	67
2027	Disillusionment bias in clinical trials testing new drugs. 2008 , 20, 267	
2026	A case of prolonged type 1 hypersensitivity reaction to pegfilgrastim. 2008 , 20, 315-6	3
2025	An update on a case of regression of lung metastases after radiotherapy for bone metastasis in renal cell carcinoma. 2008 , 20, 316	
2024	Severe epistaxis with tyrosine kinase inhibitors. 2008 , 20, 318-9	5
2023	Axitinib for renal cell carcinoma. 2008 , 17, 741-8	46
2022	Recent Advances in Angiogenesis Drug Development. 2008 , 421-430	
2021	Rare presentation of renal cell carcinoma: Solitary sternal metastasis. 2008 , 12, 99-101	2
2020	Classification of renal cell carcinoma based on expression of VEGF and VEGF receptors in both tumor cells and endothelial cells. 2008 , 88, 962-72	43
2019	Met expression is an independent prognostic risk factor in patients with oesophageal adenocarcinoma. 2008 , 98, 1102-8	44
2018	Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings. 2008 , 98, 1336-41	55
2017	Circulating endothelial cells in oncology: pitfalls and promises. 2008 , 98, 1731-5	82
2016	Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer. 2008 , 99, 259-65	98
2015	Survival from kidney cancer in England and Wales up to 2001. 2008 , 99 Suppl 1, S96-7	1
2014	mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work?. 2008 , 99, 1197-203	82
2013	Blood glucose levels in patients with metastatic renal cell carcinoma treated with sunitinib. 2008 , 99, 1380-2	55

2012	Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours. 2008 , 99, 1579-85	21
2011	Lessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer. 2008 , 8, 309-16	143
2010	Paul Ehrlich's magic bullet concept: 100 years of progress. 2008 , 8, 473-80	811
2009	VEGF-targeted therapy: mechanisms of anti-tumour activity. 2008 , 8, 579-91	1334
2008	The von Hippel-Lindau tumour suppressor protein: O ₂ sensing and cancer. 2008 , 8, 865-73	536
2007	VEGF-A splicing: the key to anti-angiogenic therapeutics?. 2008 , 8, 880-7	379
2006	Potential benefit of Sunitinib in recurrent and refractory ovarian clear cell adenocarcinoma. 2008 , 18, 934-6	28
2005	Establishing the role of cytokine therapy in advanced renal cell carcinoma. 2008 , 101, 1063-70	5
2004	Sunitinib therapy in renal cell carcinoma. 2008 , 101, 1339-42	16
2003	Renal cell carcinoma: what does the future hold?. 2008 , 102, 5-6	2
2002	Carbonic anhydrase IX as a predictive biomarker of response to kidney cancer therapy. 2008 , 101 Suppl 4, 31-5	12
2001	Management of renal cancer in the tyrosine kinase inhibitor era: a view from 3 years on. 2008 , 102, 162-5	12
2000	High nuclear Livin expression is a favourable prognostic indicator in renal cell carcinoma. 2008 , 102, 1700-6	13
1999	The National Institute of Health and Clinical Excellence rejects new treatments for renal cell cancer: Cinderella's invitation is cancelled. 2008 , 102, 1491-2	2
1998	Factors associated with outcome in patients with advanced renal cell carcinoma in the era of antiangiogenic agents. 2008 , 6, 15-20	6
1997	A University of Chicago consortium phase II trial of SB-715992 in advanced renal cell cancer. 2008 , 6, 21-4	24
1996	Phase II trial of pegylated interferon-alpha 2b in patients with advanced renal cell carcinoma. 2008 , 6, 25-30	16
1995	Human immunodeficiency virus--associated renal cell carcinoma: a transatlantic case series. 2008 , 6, 86-90	5

1994	Novel antiangiogenic agents in the treatment of refractory renal cell carcinoma. 2008 , 6 Suppl 1, S29-36	3
1993	Genetics and epigenetics of renal cell cancer. 2008 , 1785, 133-55	68
1992	High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor. 2008 , 53, 376-81	83
1991	Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. 2008 , 53, 917-30	175
1990	Cytoreductive nephrectomy in the era of targeted molecular agents: is it time to consider presurgical systemic therapy?. 2008 , 54, 489-92	22
1989	Update on the medical treatment of metastatic renal cell carcinoma. 2008 , 54, 315-25	40
1988	Re: Pierre I. Karakiewicz, Nazareno Suardi, Claudio Jeldres, et al. Neoadjuvant Sutent induction therapy may effectively down-stage renal cell carcinoma atrial thrombi. Eur Urol 2008;53:845-8. 2008 , 54, 950-1; author reply 951-3	0
1987	The new medical treatment of metastatic renal cell carcinoma: a good debut, a lot of open questions. 2008 , 54, 252-5	4
1986	Will we be able to "cure" metastatic renal cell carcinoma like we cure testicular tumours?. 2008 , 54, 712-4	3
1985	Words of wisdom. Re: Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Escudier B, Pluzanska A, Koralewski P, et al., for the AVOREN Trial investigators. 2008 , 54, 948-9	2
1984	Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis. 2008 , 54, 1373-8	77
1983	Words of wisdom. Re: efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. 2008 , 54, 1200-1	
1982	Cardiotoxicity of the new cancer therapeutics--mechanisms of, and approaches to, the problem. 2008 , 13, 778-84	77
1981	Highlights from: The 2008 Genitourinary Cancers Symposium; February 14-16, 2008; San Francisco, CA. 2008 , 6, 9-14	
1980	Highlights from: The 2008 meeting of the American Society of Clinical Oncology; May 30-June 3, 2008; Chicago, IL. 2008 , 6, 65-72	1
1979	Targeted agents in cancer therapy. 2008 , 36, 33-37	4
1978	Targeted therapies for patients with germ cell tumors. 2008 , 17, 511-22	17
1977	Renal cell carcinoma: a model system for novel drug development?. 2008 , 6, 7-8	5

1976	Motexafin gadolinium for the treatment of metastatic renal cell carcinoma: phase II study results. 2008 , 6, 73-8	18
1975	Phase I/II trial of 5-fluorouracil and a noncytotoxic dose level of suramin in patients with metastatic renal cell carcinoma. 2008 , 6, 79-85	10
1974	Current algorithms and prognostic factors in the treatment of metastatic renal cell carcinoma. 2008 , 6 Suppl 1, S7-13	30
1973	What role do combinations of interferon and targeted agents play in the first-line therapy of metastatic renal cell carcinoma?. 2008 , 6 Suppl 1, S14-21	4
1972	Vascular endothelial growth factor pathway-targeted therapy as initial systemic treatment of patients with renal cancer. 2008 , 6 Suppl 1, S22-8	6
1971	Multitargeted inhibitors in lung cancer: new clinical data. 2008 , 9 Suppl 3, S92-9	6
1970	[Current strategies in the treatment of renal-cell cancer: targeted therapies]. 2008 , 130, 380-92	2
1969	Virtual karyotyping with SNP microarrays reduces uncertainty in the diagnosis of renal epithelial tumors. 2008 , 3, 44	23
1968	Novel therapies in genitourinary cancer: an update. 2008 , 1, 11	1
1967	Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. 2008 , 179, 81-6; discussion 86	110
1966	Molecular genetics of hereditary renal cancer: new genes and diagnostic and therapeutic opportunities. 2008 , 8, 895-905	7
1965	Challenges in the treatment of ErbB2 (HER2)-positive breast cancer. 2008 , 6, 7-14	1
1964	Prognostic factors in advanced renal cell cancer. 2008 , 6, 35-37	1
1963	Management of toxicity in patients treated with tyrosine kinase inhibitors (TKI). 2008 , 6, 42-45	1
1962	Target therapy in metastatic renal cell carcinoma. 2008 , 6, 38-41	1
1961	Prognostic models and algorithms in renal cell carcinoma. 2008 , 35, 613-25; vii	63
1960	Tongue metastasis as an initial presentation of renal cell carcinoma: a case report and literature review. 2008 , 2, 249	41
1959	Targeted therapy for advanced renal cell carcinoma. 2008 , CD006017	57

1958	Tumoral angiogenesis: review of the literature. 2008 , 26, 104-8	74
1957	Surgical resection of isolated retroperitoneal lymph node recurrence of renal cell carcinoma following nephrectomy. 2008 , 180, 99-103; discussion 103	37
1956	Thfapeutiques antiangioghiques en cancfologie. 2008 ,	
1955	Targeted Cancer Therapy. 2008 ,	6
1954	[Renal cell carcinoma and antiangiogenic therapies]. 2008 , 37, 628-33	2
1953	Development of novel agents and combinations for renal carcinoma. 2008 , 3, 97-103	
1952	Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy. 2008 , 72, 864-8	75
1951	Phase II trial of capecitabine and weekly docetaxel in metastatic renal cell carcinoma. 2008 , 72, 898-902	10
1950	Editorial Comment. 2008 , 72, 776	
1949	Reply. 2008 , 72, 776-777	2
1948	The once and future role of cytoreductive nephrectomy. 2008 , 26, 346-52	6
1947	Phase II studies of antiangiogenic four drug regimens for the treatment of advanced renal cell carcinoma: FUNIL-retinoid and the FUNIL-thalidomide protocols. 2008 , 26, 610-5	4
1946	[Angiogenesis: all a radiation oncologist should know]. 2008 , 12, 50-60	1
1945	An evaluation of a preparation of Mycobacterium vaccae (SRL172) as an immunotherapeutic agent in renal cancer. 2008 , 44, 216-23	35
1944	Prognostic versus predictive value of biomarkers in oncology. 2008 , 44, 946-53	228
1943	No improvement in renal cell carcinoma survival: a population-based study in the Netherlands. 2008 , 44, 1701-9	18
1942	Recent advances in the treatment of renal cell carcinoma and the role of targeted therapies. 2008 , 44, 2152-61	49
1941	Metastatic renal cell carcinoma: results of a population-based study with 25 years follow-up. 2008 , 44, 2485-95	34

1940	The use of bevacizumab in colorectal, lung, breast, renal and ovarian cancer: where does it fit?. 2008 , 44, 2350-6	47
1939	Economic evaluation of sunitinib malate in second-line treatment of metastatic renal cell carcinoma in Finland. 2008 , 30, 382-92	37
1938	Molecular-targeted therapies: lessons from years of clinical development. 2008 , 34, 61-80	41
1937	New developments in multitargeted therapy for patients with solid tumours. 2008 , 34, 37-48	50
1936	Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. 2008 , 34, 193-205	682
1935	Exploring the role of novel agents in the treatment of renal cell carcinoma. 2008 , 34, 750-60	6
1934	Novel agents changing the outlook for renal cell carcinoma. 2008 , 5, 206-209	
1933	Targeted therapies and biological modifiers in urologic tumors: pathobiology and clinical implications. 2008 , 25, 232-44	9
1932	Challenges of Antiangiogenic Therapy of Tumors. 2008 , 461-475	1
1931	[Vascular and renal effects of anti-angiogenic therapy]. 2008 , 4, 602-15	35
1930	Treatment Approaches in Renal Cell Carcinoma: Past, Present, and Future Perspectives. 2008 , 7, 36-45	5
1929	European Association of Urology Guidelines for Systemic Therapy in Metastatic Renal Cell Carcinoma: What is Recommended and Why?. 2008 , 7, 46-54	4
1928	The Role of Multitargeted Therapies in the Adjuvant Setting in Renal Cell Carcinoma. 2008 , 7, 63-70	1
1927	The Oncologist's View: Targeted Therapies in Advanced Renal Cell Carcinoma. 2008 , 7, 55-62	6
1926	Recent Developments in Research on Kidney Cancer: Highlights from Urological and Oncological Congresses in 2007. 2008 , 7, 494-507	2
1925	New Treatment Options for Renal Cell Cancer—Critical Evaluation. 2008 , 7, 443-446	3
1924	Tyrosine Kinase Inhibitors in Clinical Practice: Patient Selection. 2008 , 7, 601-609	4
1923	Continued Progress in the Treatment of Advanced Renal Cell Carcinoma: An Update on the Role of Sunitinib. 2008 , 7, 579-584	2

1922	Clinical Management of Patients Receiving Tyrosine Kinase Inhibitors for Advanced Renal Cell Carcinoma. 2008 , 7, 593-600	7
1921	Sunitinib in Advanced Renal Cell Carcinoma: Clinical Evidence. 2008 , 7, 585-592	3
1920	Cardiotoxicity associated with sunitinib. 2008 , 371, 1244-5; author reply 1245	3
1919	Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. 2008 , 372, 449-56	2451
1918	Progression-free survival as endpoint in metastatic RCC?. 2008 , 372, 427-9	24
1917	Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. 2008 , 9, 342-51	225
1916	Combined antiangiogenic therapy is superior to single inhibitors in a model of renal cell carcinoma. 2008 , 179, 326-32	13
1915	von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. 2008 , 180, 860-5; discussion 865-6	170
1914	A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents. 2008 , 180, 867-72; discussion 872	50
1913	[Prise en charge of metastatic renal carcinoma]. 2008 , 18 Suppl 7, S298-308	6
1912	Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma. 2008 , 2008, 115-116	1
1911	Cutaneous reactions to chemotherapy: commonly seen, less described, little understood. 2008 , 26, 103-19, ix	39
1910	[The advantages of antiangiogenics in neoadjuvant and adjuvant locally advanced and metastatic kidney cancer: two case studies]. 2008 , 18 Suppl 4, S88-91	
1909	Proteomic identification of interleukin-2 therapy response in metastatic renal cell cancer. 2008 , 179, 730-6	9
1908	[Antiangiogenic treatment and kidney cancer: ongoing trials and future perspectives]. 2008 , 18 Suppl 4, S77-80	1
1907	[Targeted therapies]. 2008 , 18 Suppl 7, S228-33	0
1906	Systemic therapy for metastatic renal cell carcinoma. 2008 , 35, 687-701; ix	28
1905	Remission of diabetes while on sunitinib treatment for renal cell carcinoma. 2008 , 19, 824-5	46

1904	Pathologic features of renal cortical tumors. 2008 , 35, 551-61; v	28
1903	[Cutaneous side effects of sorafenib and sunitinib]. 2008 , 135, 148-53; quiz 147, 154	22
1902	Targeted therapy for solid tumors: current status. 2008 , 17, 279-301, vii-viii	10
1901	[Urologist's role in the treatment with new targeted therapies in advanced renal cell carcinoma]. 2008 , 32, 865-7	
1900	[Antiangiogenics: new therapeutic standards in metastatic kidney cancer]. 2008 , 18 Suppl 4, S69-76	3
1899	Molecular biology of renal cortical tumors. 2008 , 35, 573-80; vi	27
1898	Combined anti-proliferative and anti-angiogenic strategies for cancer. 2008 , 9, 701-15	14
1897	An update on the medical therapy of advanced metastatic renal cell carcinoma. 2008 , 42, 501-6	7
1896	Oncologic, endocrine & metabolic emerging drugs in B-cell non-Hodgkin's lymphoma. 2008 , 13, 323-43	1
1895	Novel drugs for renal cell carcinoma. 2008 , 17, 1501-16	5
1894	Improving outcomes in patients with advanced renal cell carcinoma. 2008 , 8, 481-90	4
1893	Angiogenesis as a therapeutic target in cancer. 2008 , 8, 455-8	12
1892	Le Cancer du rein. 2008 ,	
1891	Oligosaccharides as anti-angiogenic agents. 2008 , 8, 351-62	17
1890	References. 124-132	
1889	Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma. 2008 , 17, 253-61	68
1888	[The role of surgery in bone metastases of renal cell carcinoma: 13 case reports]. 2008 , 18, 1045-9	1
1887	Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. 2008 , 14, 6674-82	394

1886	Angiogenesis. 2008 ,	25
1885	Comment gfer au mieux la toxicit`des traitements antiangioghiques?. 2008 , 197-205	
1884	Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. 2008 , 26, 3743-8	346
1883	Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense?. 2008 , 26, 3791-6	127
1882	Bevacizumab reduces the growth rate constants of renal carcinomas: a novel algorithm suggests early discontinuation of bevacizumab resulted in a lack of survival advantage. 2008 , 13, 1055-62	61
1881	Renal cell carcinoma: the translation of molecular biology into new treatments, new patient outcomes, and nursing implications. 2008 , 35, 699-708	7
1880	Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. 2008 , 26, 5204-12	513
1879	Sirolimus in metatastic renal cell carcinoma. 2008 , 26, 3457-60	13
1878	What is the risk of intracranial bleeding during anti-VEGF therapy?. 2008 , 10, 624-30	65
1877	Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor. 2008 , 14, 3470-6	161
1876	Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival. 2008 , 14, 5884-92	115
1875	Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics. 2008 , 118, 84-95	260
1874	Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma. 2008 , 14, 5150-7	200
1873	Cost effectiveness of sunitinib. 2008 , 26, 5829; author reply 5829-30	2
1872	Predicting outcome to VEGF-targeted therapy in metastatic clear-cell renal cell carcinoma: data from recent studies. 2008 , 4, 85-92	19
1871	Efficacy of sunitinib and sorafenib in non-clear cell renal cell carcinoma: results from expanded access studies. 2008 , 26, 3469-71; author reply 2471	9
1870	Immunotherapy for renal cell cancer in the era of targeted therapy. 2008 , 8, 907-19	23
1869	Access to cancer drugs: local autonomy or local tyranny?. 2008 , 69, 436-7	

1868	New treatments for kidney cancer. 2008 , 336, 681-2	
1867	Treatment of brucellosis. 2008 , 336, 678-9	13
1866	African sleeping sickness. 2008 , 336, 679-80	9
1865	Renal complications of childhood type 1 diabetes. 2008 , 336, 677-8	4
1864	Health of the working age population. 2008 , 336, 682	6
1863	Clinical approaches toward tumor angiogenesis: past, present and future. 2008 , 14, 3820-34	26
1862	Understanding and managing renal cell carcinoma: can proteomic studies contribute to clinical practice?. 2008 , 160, 88-106	7
1861	Continuous daily dosing of sunitinib in patients with metastatic renal cell cancer. 2008 , 31, 432-3	3
1860	Sunitinib (SUTENT [®]) for the treatment of metastatic renal cell carcinoma. 2008 , 8, 1723-1731	3
1859	Interleukin-21: biology and application to cancer therapy. 2008 , 8, 1295-307	35
1858	Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. 2008 , 14, 7272-83	467
1857	Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. 2008 , 19, 1387-1392	124
1856	Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. 2008 , 26, 5422-8	780
1855	Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis. 2008 , 47, 176-86	169
1854	Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC. 2008 , 5, 601-9	21
1853	Lapatinib therapy for patients with advanced renal cell carcinoma. 2008 , 5, 626-7	1
1852	The role of cytoreductive nephrectomy for renal cell carcinoma in the era of targeted therapy. 2008 , 5, 698-9	4
1851	Molecular biomarkers for urothelial carcinoma of the bladder: challenges in clinical use. 2008 , 5, 676-85	29

1850	Anti-VEGF agents confer survival advantages to tumor-bearing mice by improving cancer-associated systemic syndrome. 2008 , 105, 18513-8	56
1849	Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial. 2008 , 26, 2285-91	80
1848	Activity of sunitinib in patients with advanced neuroendocrine tumors. 2008 , 26, 3403-10	514
1847	Identification of pro-MMP-7 as a serum marker for renal cell carcinoma by use of proteomic analysis. 2008 , 54, 574-81	47
1846	Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. 2008 , 14, 4726-34	422
1845	Cooperative relationship between pharmaceutical companies, academia, and media explains sharp decrease in frequency of pulmonary complications after bortezomib in Japan. 2008 , 26, 5820-3	15
1844	In Reply. 2008 , 26, 3471-3471	
1843	Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. 2008 , 13, 1084-96	168
1842	Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. 2008 , 13, 1001-11	273
1841	Health-related quality of life during treatment for renal cell carcinoma: results from a phase II study of axitinib. 2008 , 47, 843-51	18
1840	Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. 2008 , 19, 1613-8	193
1839	Commentary: Novel therapies for cancer: why dirty might be better. 2008 , 13, 277-83	47
1838	Stereotactic body radiotherapy of primary and metastatic renal lesions for patients with only one functioning kidney. 2008 , 47, 1578-83	77
1837	Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. 2008 , 19, 1955-61	175
1836	Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. 2008 , 26, 4672-8	536
1835	Principles of Molecular Oncology. 2008 ,	1
1834	Temsirolimus, an mTOR inhibitor for treatment of patients with advanced renal cell carcinoma. 2008 , 12, 639-46	35
1833	Handling side-effects of targeted therapies: safety of targeted therapies in solid tumours. 2008 , 19 Suppl 7, vii146-52	8

1832	Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial. 2008 , 26, 3763-9	103
1831	In Reply. 2008 , 26, 5829-5830	2
1830	Stopping a trial early in oncology: for patients or for industry?. 2008 , 19, 1347-1353	33
1829	Opioids in context: relieving the pain of cancer. The role of comprehensive cancer management. 2008 , 22, 303-9	8
1828	How I treat renal cell carcinoma. 2008 , 4, 150-2	
1827	Small Molecules: Big Changes in the Cancer Treatment Paradigm. 2008 , 21, 17-35	1
1826	Combination of antiangiogenesis with chemotherapy for more effective cancer treatment. 2008 , 7, 3670-84	263
1825	Randomized study of intravenous versus subcutaneous interleukin-2, and IFNalpha in patients with good prognosis metastatic renal cancer. 2008 , 14, 5907-12	20
1824	Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. 2008 , 26, 1810-6	421
1823	Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. 2008 , 26, 4572-8	196
1822	Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. 2008 , 26, 127-31	328
1821	Acute cardiac failure after sunitinib. 2008 , 19, 597-9	13
1820	Combination of quantitative IMP3 and tumor stage: a new system to predict metastasis for patients with localized renal cell carcinomas. 2008 , 14, 5579-84	72
1819	Sunitinib for treatment of advanced renal cell cancer: primary tumor response. 2008 , 14, 2431-6	137
1818	In Reply. 2008 , 26, 5828-5829	
1817	Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma. 2008 , 26, 3995-4000	66
1816	Documentation of thyroid function in clinical studies with sunitinib: why does it matter?. 2008 , 26, 5131-2; author reply 5132-3	18
1815	Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada clinical trials group. 2008 , 26, 1871-8	111

1814	Pathways mediating resistance to vascular endothelial growth factor-targeted therapy. 2008 , 14, 6371-5		219
1813	[New drugs for metastatic kidney cancer]. 2008 , 39, 41-52		
1812	Renal cell carcinoma: diagnosis, staging, and surveillance. 2008 , 191, 1220-32		157
1811	Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations?. 2008 , 5, 378-91		130
1810	Recent advances in the development of multi-kinase inhibitors. 2008 , 8, 1312-27		68
1809	Targeting angiogenesis in renal cell carcinoma. 2008 , 8, 349-58		23
1808	Experimental therapy for advanced renal cell carcinoma. 2008 , 17, 1693-702		7
1807	Chemokines as therapeutic targets in renal cell carcinoma. 2008 , 8, 887-93		19
1806	The challenge of selecting protein kinase assays for lead discovery optimization. 2008 , 3, 607-621		142
1805	Transplantation of allogeneic hematopoietic stem cells: an emerging treatment modality for solid tumors. 2008 , 5, 256-67		68
1804	Using Molecular Biology to Develop Drugs for Renal Cell Carcinoma. 2008 , 3, 311-327		13
1803	Home blood-pressure monitoring in patients receiving sunitinib. <i>New England Journal of Medicine</i> , 2008 , 358, 95-7	59.2	150
1802	Scrotal cutaneous side effects of sunitinib. <i>New England Journal of Medicine</i> , 2008 , 359, 975-6; discussion 976	59.2	25
1801	Case records of the Massachusetts General Hospital. Case 17-2008. A 63-year-old man with metastatic renal-cell carcinoma. <i>New England Journal of Medicine</i> , 2008 , 358, 2389-96	59.2	6
1800	Dual-targeted contrast agent for US assessment of tumor angiogenesis in vivo. 2008 , 248, 936-44		175
1799	Bevacizumab plus interferon alpha in patients with metastatic renal cell carcinoma. 2008 , 5, 436-7		1
1798	Molecular targeting agents in renal cell carcinoma: present strategies and future perspectives. 2008 , 14, 1058-77		6
1797	Is sorafenib plus interferon alpha 2b safe and effective in patients with renal cell carcinoma?. 2008 , 5, 132-3		6

1796	Antiangiogenic therapy in renal cell carcinoma: a plethora of choices. 2008 , 5, 422-3	2
1795	Acute exacerbation of hemorrhagic rectocolitis during antiangiogenic therapy with sunitinib and sorafenib. 2008 , 19, 1975	20
1794	VHL inactivation in renal cell carcinoma: implications for diagnosis, prognosis and treatment. 2008 , 8, 63-73	53
1793	Biopsy-proven acute interstitial nephritis associated with the tyrosine kinase inhibitor sunitinib: a class effect?. 2009 , 24, 673-5	43
1792	Mechanism of action of rapalogues: the antiangiogenic hypothesis. 2008 , 17, 1619-21	13
1791	FLEX data, KRAS and ERCC1 testing in oncology. 2008 , 4, 471-3	2
1790	Current status of antivasular therapy and targeted treatment in the clinic. 2008 , 24, 97-110	0
1789	Individualized medicine for renal cell carcinoma: establishment of primary cell line culture from surgical specimens. 2008 , 22, 2361-6	11
1788	Self-reported practices and attitudes of US oncologists regarding off-protocol therapy. 2008 , 26, 5994-6000	16
1787	Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma. 2008 , 2008, 167-168	
1786	Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma. 2008 , 2008, 97-98	
1785	Targeting angiogenesis in the treatment of lung cancer. 2008 , 3, 1173-84	32
1784	Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. 2008 , 111, 5610-20	225
1783	Tumor cavitation during therapy with antiangiogenesis agents in patients with lung cancer. 2008 , 3, 351-7	56
1782	Cytostatic and cytotoxic drugs. 2008 , 520-532	1
1781	Remarkable shrinkage of sarcomatoid renal cell carcinoma with single-agent gemcitabine. 2008 , 19, 431-3	5
1780	Targeted therapies in the treatment of renal cell carcinoma. 2008 , 15, 1166-74	4
1779	Targeted therapy for advanced renal cell cancer: cytokines and beyond. 2008 , 14, 2229-51	11

1778	Anti-angiogenic targets in the treatment of advanced renal cell carcinoma. 2008 , 8, 676-82	36
1777	Novel therapeutic options in metastatic renal cancer - review and post ASCO 2007 update. 2008 , 3, 212-6	6
1776	Wnt signaling in renal cancer. 2008 , 9, 591-600	32
1775	Signaling inhibitors in metastatic renal cell carcinoma. 2008 , 14, 325-9	9
1774	A Review of the Cardiovascular Effects of Oncology Agents. 2008 , 21, 146-158	6
1773	Will targeted therapy hold its promise? An evidence-based review. 2008 , 20, 104-11	35
1772	Surgical and Medical Treatment. 377-399	
1771	Bibliography. Current world literature. Head and neck. 2008 , 20, 327-36	
1770	Adjuvant and neoadjuvant therapy in renal cell carcinoma. 2008 , 14, 315-9	11
1769	The role of lymph node dissection in renal cell carcinoma: the pendulum swings back. 2008 , 14, 308-14	29
1768	Metastatic renal cell carcinoma: recent advances and current therapeutic options. 2008 , 19, 235-45	18
1767	Renal cell carcinoma. 2008 , 20, 300-6	104
1766	Sorafenib for metastatic renal cancer: the Princess Margaret experience. 2008 , 31, 182-7	48
1765	Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma: a clinical phase 1/2 trial. 2008 , 31, 771-80	80
1764	Melanoma presenting as circulating tumor cells associated with failed angiogenesis. 2008 , 18, 289-94	4
1763	Phase II study of combination thalidomide/interleukin-2 therapy plus granulocyte macrophage-colony stimulating factor in patients with metastatic renal cell carcinoma. 2008 , 31, 237-43	19
1762	Ocular von Hippel-Lindau disease: clinical update and emerging treatments. 2008 , 19, 213-7	47
1761	Cytoreductive nephrectomy in metastatic renal cell carcinoma. 2008 , 18, 474-80	16

1760	Targeted therapy in renal cell carcinoma. 2008 , 18, 481-7	12
1759	The interaction of radiation therapy and antiangiogenic therapy. 2008 , 14, 207-13	7
1758	Immunotherapy of metastatic renal cell carcinoma. 2008 , 14, 320-4	27
1757	PharmaForum. 2008 , 31, 713-717	
1756	. 2008 ,	9
1755	. 2008 ,	5
1754	Sunitinib for advanced renal cell cancer. 2008 , 2, 97-105	8
1753	Targeted therapies in the management of renal cell carcinoma: role of bevacizumab. 2008 , 2, 517-30	10
1752	Drug-induced immune thrombocytopenic purpura secondary to sunitinib. 2008 , 15, 152-4	14
1751	Suppression of renal cell carcinoma growth by inhibition of Notch signaling in vitro and in vivo. 2008 , 118, 217-28	142
1750	2007 Publications of the Baylor Health Care System Medical and Scientific Staff. 2008 , 21, 210-223	
1749	Magnetic resonance imaging features of renal synovial sarcoma: a case report. 2008 , 8, 45-7	15
1748	Target-Directed Drug Discovery. 223-243	3
1747	Lymph node dissection during the surgical treatment of renal cancer in the modern era. 2008 , 34, 132-42	14
1746	In vitro evidence for a new therapeutic approach in renal cell carcinoma. 2008 , 34, 492-502	12
1745	11-amino-5-N-methyl-7-fluorine- quindoline derivatives: The Potential Anti-angiogenic Agents Targeting G-quadruplex Structure in Vascular Endothelial Cell Growth Factor. 2008 ,	
1744	Antiangiogenic Therapy and Ovarian Cancer. 2008 , 4, 33-44	
1743	Managing the side effects of sunitinib: a guide to empowering the patient. 2008 , 7, 42-46	2

1742	[Revolution in treatment of renal carcinoma: molecular rational and clinical approach]. 2008 , 24, 697-9	0
1741	The efficacy and safety of irinotecan cisplatin and mitomycin chemotherapy in sunitinib pre-treated metastatic clear cell renal cancer. 2008 , 1, 35-9	1
1740	Management of side effects associated with sunitinib therapy for patients with renal cell carcinoma. 2009 , 2, 51-61	24
1739	Renal cell carcinoma: biological features and rationale for molecular-targeted therapy. 2009 , 58, 1-11	14
1738	11C-Acetate PET for Early Prediction of Sunitinib Response in Metastatic Renal Cell Carcinoma. 2009 , 95, 382-384	27
1737	Role of everolimus in the treatment of renal cell carcinoma. 2009 , 5, 699-706	6
1736	Targeted Therapy in Metastatic Renal Cell Carcinoma. 2009 , 50, 1	
1735	Metastatic renal cell carcinoma management. 2009 , 35, 256-70	9
1734	First-line therapy with sunitinib in advanced renal cell carcinoma: interpretation of the overall survival data from ASCO 2008. 2009 , 16 Suppl 1, S24-6	1
1733	Managing toxicities and optimal dosing of targeted drugs in advanced kidney cancer. 2009 , 16 Suppl 1, S52-9	10
1732	Inhibition of mTOR in kidney cancer. 2009 , 16 Suppl 1, S33-9	12
1731	Sorafenib in the management of metastatic renal cell carcinoma. 2009 , 16 Suppl 1, S27-32	9
1730	Concomitant renal cell carcinoma and chronic myelogenous leukemia: use of a targeted approach. 2009 , 16, 44-7	3
1729	Adjuvant and Neoadjuvant Small Molecule Targeted Therapy. 2009 , 16,	2
1728	[Angiogenesis: a new therapeutic target of thoracic and laryngopharyngeal carcinoma]. 2009 , 96 Suppl 1, S45-55	
1727	A Re-assessment of the Safety and Efficacy of Interleukin-2 for the Treatment of Renal Cell Carcinoma. 2009 , 1, CMT.S2037	0
1726	Novel developments in angiogenesis cancer therapy. 2009 , 16, 50-4	11
1725	New treatments for renal cell carcinoma: targeted therapies. 2009 , 7, 645-56	14

1724	Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers. 2009 , 2009, 567486	85
1723	Biopsy of renal masses: when and why. 2009 , 9, 44-55	57
1722	On the origin of (CD105+) circulating endothelial cells. 2009 , 102, 347-51	18
1721	Crosstalk of VEGF and Notch pathways in tumour angiogenesis: therapeutic implications. 2009 , 14, 3094-110	103
1720	Cellular and Animal Models in Oncology and Tumor Biology. 2009 , 47, 14.0.1	
1719	VEGF-A: a critical regulator of blood vessel growth. 2009 , 20, 158-63	228
1718	Effets vasculaires et r̃aux des m̃dicaments anti-angiogh̃iques : recommandations frañaises pour la pratique. 2009 , 21, 151-166	
1717	Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. 2009 , 27, 3027-35	417
1716	Patient with malignant paraganglioma responding to the multikinase inhibitor sunitinib malate. 2009 , 27, 460-3	34
1715	A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients. 2009 , 15, 2497-506	193
1714	Targeting the hypoxia-inducible factor (HIF) pathway in cancer. 2009 , 11, e26	151
1713	Pazopanib: an antiangiogenic drug in perspective. 2009 , 5, 1335-48	21
1712	Targeting multiple kinases in glioblastoma multiforme. 2009 , 18, 277-92	36
1711	Toxicity associated with the long-term use of targeted therapies in patients with advanced renal cell carcinoma. 2009 , 9, 795-805	29
1710	Is hypothyroidism a clinically relevant toxicity of tyrosine kinase inhibitors?. 2009 , 19, 539-40	10
1709	Relationship between tumor-infiltrating T lymphocytes and clinical response after reduced-intensity allogeneic hematopoietic stem cell transplantation for advanced renal cell carcinoma: a single center prospective study. 2009 , 39, 807-12	4
1708	From theoretical synergy to clinical supra-additive toxicity. 2009 , 27, 1359-61	29
1707	Dual degradation of aurora A and B kinases by the histone deacetylase inhibitor LBH589 induces G2-M arrest and apoptosis of renal cancer cells. 2009 , 15, 840-50	93

1706	Targeted therapy: comprehensive review. 2009 , 26, 137-46	5
1705	Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. 2009 , 27, 4406-12	161
1704	Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. 2009 , 27, 1432-9	268
1703	Hematology: dasatinib regimens for patients with chronic myeloid leukemia. 2009 , 6, 680-2	1
1702	Targeted therapies: sunitinib in RCC-expanded access equals expanded benefit?. 2009 , 6, 679-80	3
1701	Absence of VHL gene alteration and high VEGF expression are associated with tumour aggressiveness and poor survival of renal-cell carcinoma. 2009 , 101, 1417-24	78
1700	Multimodality treatment paradigms for renal cell carcinoma: surgery versus targeted agents. 2009 , 9, 763-71	2
1699	Health policy: The UK 'postcode lottery' in renal cell carcinoma. 2009 , 6, 636-8	2
1698	Therapy for metastatic RCC--questions remain. 2009 , 6, 580-1	2
1697	Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer. 2009 , 101, 1222-3; author reply 1224	4
1696	Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. 2009 , 20, 1535-1542	155
1695	Metastatic renal cell carcinoma: A guide to therapy based on current evidence. 2009 , 1, 9	1
1694	Metastatic adrenocortical carcinoma treated with sunitinib: a case report. 2009 , 39, 183-5	25
1693	Multicenter phase II trial of combination therapy with meloxicam, a cox-2 inhibitor, and natural interferon-alpha for metastatic renal cell carcinoma. 2009 , 39, 720-6	22
1692	Hypoxia-induced pathological angiogenesis mediates tumor cell dissemination, invasion, and metastasis in a zebrafish tumor model. 2009 , 106, 19485-90	204
1691	Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib. 2009 , 77, 257-71	143
1690	Patient-reported outcomes in a phase III, randomized study of sunitinib versus interferon- α as first-line systemic therapy for patients with metastatic renal cell carcinoma in a European population. 2009 , 20, 1803-12	17
1689	Pharmacokinetics of sunitinib in hemodialysis. 2009 , 20, 190-2	45

1688	Renal Cell Carcinoma. 2009 ,	3
1687	Toxic dermatolysis, tissue necrosis and impaired wound healing due to sunitinib treatment leading to forefoot amputation. 2009 , 82, 246-8	7
1686	Targeting Akt3 signaling in malignant melanoma using isoselenocyanates. 2009 , 15, 1674-85	87
1685	Quality of life predicts progression-free survival in patients with metastatic renal cell carcinoma treated with sunitinib versus interferon alfa. 2009 , 5, 66-70	26
1684	Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer. 2009 , 15, 3600-9	81
1683	Effect of vascular endothelial growth factor and its receptor inhibitor on proliferation and invasion in bladder cancer. 2009 , 83, 98-106	35
1682	Prostatic metastasis of renal cell carcinoma successfully treated with sunitinib. 2009 , 83, 122-4	7
1681	Multifocal brain metastases in clear cell renal cell carcinoma with complete response to sunitinib. 2009 , 83, 482-5	16
1680	The future of targeted therapies in ovarian cancer. 2009 , 14, 706-16	45
1679	Combination systemic therapy for advanced renal cell carcinoma. 2009 , 14, 1218-24	15
1678	Thrombotic events in patients with cancer receiving antiangiogenesis agents. 2009 , 27, 4865-73	167
1677	Chronically administered immunotherapy with low-dose IL-2 and IFN-alpha in metastatic renal cell carcinoma: a feasible option for patients with a good prognostic profile. 2009 , 76, 69-76	9
1676	Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib. 2009 , 76, 350-4	72
1675	Nephrotic Syndrome and Acute Renal Failure Apparently Induced by Sunitinib. 2009 , 2, 172-176	22
1674	Targeted therapy in the treatment of metastatic renal cell cancer. 2009 , 77 Suppl 1, 122-31	4
1673	Targeting vascular endothelial growth factor in renal cell carcinoma. 2009 , 30, 292-9	10
1672	Systemic therapies in hepatocellular carcinoma. 2009 , 27, 175-88	50
1671	FN13762 murine breast cancer: region-by-region correlation of first-pass perfusion CT indexes with histologic vascular parameters. 2009 , 251, 721-30	16

1670	Diagnosis and management of hypertension in advanced renal cell carcinoma: prospective evaluation of an algorithm in patients treated with sunitinib. 2009 , 21, 347-50	17
1669	Amplification of chromosomal segment 4q12 in non-small cell lung cancer. 2009 , 8, 2042-50	65
1668	Sunitinib is superior to interferon alpha with respect to quality of life for patients with renal cell carcinoma. 2009 , 6, 6-7	3
1667	Renal cell carcinoma: dynamic contrast-enhanced MR imaging for differentiation of tumor subtypes--correlation with pathologic findings. 2009 , 250, 793-802	235
1666	Mode of action and clinical impact of VEGF signaling inhibitors. 2009 , 9, 649-62	23
1665	Brain magnetic resonance imaging changes after sorafenib and sunitinib chemotherapy in patients with advanced renal cell and breast carcinoma. 2009 , 111, 497-503	16
1664	Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. 2009 , 15, 2148-57	700
1663	Safety, tolerability and biological effects of long-term metronomic administration of non-cytotoxic anti-angiogenic agents. 2009 , 77, 358-65	8
1662	Copper chelation in cancer therapy using tetrathiomolybdate: an evolving paradigm. 2009 , 18, 541-8	50
1661	Management of metastatic renal cell carcinoma: current trends. 2009 , 9, 75-83	15
1660	Tumor suppressor genes in myeloid differentiation and leukemogenesis. 2009 , 5, 245-57	6
1659	Limits on Medicare's ability to control rising spending on cancer drugs. <i>New England Journal of Medicine</i> , 2009 , 360, 626-33	59.2 301
1658	Medikamentöse Therapie des metastasierten Nierenzellkarzinoms: Eine Standortbestimmung nach Einführung der Multi-Tyrosinkinaseinhibitoren in Deutschland. 2009 , 30, 77-82	
1657	Target-Therapie in der Uroonkologie. 2009 , 41, 10-14	3
1656	Innovative zielgerichtete Therapie des fortgeschrittenen Nierenzellkarzinoms. 2009 , 41, 152-157	
1655	Cytoreductive nephrectomy for metastatic RCC in the era of targeted therapy. 2009 , 6, 375-83	41
1654	Dynamic contrast-enhanced MR imaging for differentiation of renal cell carcinoma subtypes: myth or reality?. 2009 , 252, 929; author reply 930-1	4
1653	Early development of sunitinib in hepatocellular carcinoma. 2009 , 9, 143-50	27

1652	Update on novel agents in renal cell carcinoma. 2009 , 9, 1817-27	14
1651	Angiogenesis inhibition in the treatment of prostate cancer. 2009 , 9, 1070-8	6
1650	[Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma]. 2009 , 40, 27-30	0
1649	Current status of cediranib: the rapid development of a novel anti-angiogenic therapy. 2009 , 5, 421-32	35
1648	Systemic therapy of kidney cancer: tyrosine kinase inhibitors, antiangiogenesis or IL-2?. 2009 , 5, 871-88	3
1647	The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy. 2009 , 76, 939-45	78
1646	Targeted Therapies: Bevacizumab and interferon-alpha in metastatic renal-cell carcinoma. 2009 , 6, 253-4	3
1645	[Medical treatment of metastatic renal cell carcinoma after the approval and market entry of multitargeted tyrosine kinase inhibitors in Germany]. 2009 , 40, 31-6	0
1644	Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects. 2009 , 10, 470-81	388
1643	Targeted therapies in solid tumours: pinpointing the tumour's Achilles heel. 2009 , 15, 207-42	9
1642	Laparoscopic radical nephrectomy after shrinkage of a caval tumor thrombus with sunitinib. 2009 , 6, 338-43	27
1641	Role of cytoreductive nephrectomy in renal cell carcinoma. 2009 , 5, 859-69	7
1640	Biochemical and pathological response of prostate cancer in a patient with metastatic renal cell carcinoma on sunitinib treatment. 2009 , 39, 833-6	2
1639	Spontaneous regression of renal cell carcinoma lung metastases in a patient with psoriasis. 2009 , 48, 925-7	15
1638	Reversible myocardial dysfunction in a young woman with metastatic renal cell carcinoma treated with sunitinib. 2009 , 48, 921-5	6
1637	Management of vascular endothelial growth factor and multikinase inhibitor side effects. 2009 , 13 Suppl, 13-8	23
1636	Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors. 2009 , 27, 4169-76	39
1635	Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. 2009 , 27, 235-41	184

1634	Systemic therapy for advanced renal cell carcinoma. 2009 , 1, 15-27	7
1633	Impact of anti-angiogenic treatments on metastatic renal cell carcinoma. 2009 , 9, 1793-805	17
1632	The kinase inhibitors sunitinib and sorafenib differentially affect NK cell antitumor reactivity in vitro. 2009 , 183, 8286-94	76
1631	Future developments in renal cell carcinoma. 2009 , 20 Suppl 1, i13-17	10
1630	Ligand-dependent platelet-derived growth factor receptor (PDGFR)-alpha activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors. 2009 , 69, 3937-46	86
1629	How can second-line therapy for metastatic renal cell carcinoma help to define an overall management strategy?. 2009 , 77, 82-91	5
1628	In Reply. 2009 , 27, 320-320	
1627	Renal cell carcinoma with an emphasis on drug therapy of advanced disease, part 2. 2009 , 66, 1625-33	4
1626	Renal cell carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. 2009 , 20 Suppl 4, 81-2	28
1625	Response to sunitinib malate in advanced alveolar soft part sarcoma. 2009 , 15, 1096-104	123
1624	Expanding the boundaries of clinical practice: building on experience with targeted therapies. 2009 , 20 Suppl 1, i1-6	2
1623	How to optimise treatment compliance in metastatic renal cell carcinoma with targeted agents. 2009 , 20 Suppl 1, i7-12	24
1622	Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. 2009 , 27, 4076-81	145
1621	Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy. 2009 , 6, 219-28	149
1620	Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. 2009 , 27, 3154-60	258
1619	Interferons: therapy for cancer. 2009 , 277-301	1
1618	Incremental advance or seismic shift? The need to raise the bar of efficacy for drug approval. 2009 , 27, 5868-73	75
1617	Targeting both HIF-1 and HIF-2 in human colon cancer cells improves tumor response to sunitinib treatment. 2009 , 8, 1148-56	50

1616	Treatment of hemodialyzed patient with sunitinib. 2009 , 20, 392-3	8
1615	The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. 2009 , 69, 2514-22	449
1614	Activity of sunitinib in patients with advanced neuroendocrine tumors. 2009 , 27, 319-20; author reply 320	7
1613	Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer. 2009 , 27, 4469-74	114
1612	Tyrosine kinase inhibition in renal cell carcinoma and gastrointestinal stromal tumours: case reports. 2009 , 20 Suppl 1, i25-i30	8
1611	Targeting renal cell carcinoma. 2009 , 27, 3274-6	53
1610	A phase I study of sunitinib plus bevacizumab in advanced solid tumors. 2009 , 15, 6277-83	77
1609	Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. 2009 , 69, 2506-13	399
1608	Targeted therapy in renal cancer. 2009 , 1, 183-205	13
1607	Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411. 2009 , 27, 4096-102	111
1606	Effective therapy for metastatic renal cancer, whither to now. 2009 , 27, 3573-4	9
1605	Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. 2009 , 27, 5794-9	1390
1604	Dominant effect of antiangiogenesis in combination therapy involving cyclophosphamide and axitinib. 2009 , 15, 578-88	34
1603	Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy. 2009 , 18, 894-900	133
1602	Cytoreductive nephrectomy in metastatic clear-cell renal cell carcinoma: perspectives in the tyrosine kinase inhibitor era. 2009 , 14, 52-9	21
1601	Angiogenesis as a therapeutic target in malignant gliomas. 2009 , 14, 621-36	87
1600	Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. 2009 , 27, 3557-65	225
1599	A Comparison of the Renal Cell Carcinoma-Symptom Index (RCC-SI) and the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI). 2009 , 38, 291-8	32

1598	Drug resistance associated with antiangiogenesis therapy. 2009 , 19, 310-7	52
1597	Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells. 2009 , 9, 161	23
1596	Plexin D1 is ubiquitously expressed on tumor vessels and tumor cells in solid malignancies. 2009 , 9, 297	35
1595	Metastatic renal cell cancer treatments: an indirect comparison meta-analysis. 2009 , 9, 34	46
1594	Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers. 2009 , 9, 82	77
1593	Response to sorafenib after sunitinib-induced acute heart failure in a patient with metastatic renal cell carcinoma: case report and review of the literature. 2009 , 29, 473-8	19
1592	Novel agents on the horizon for cancer therapy. 2009 , 59, 111-37	241
1591	Tyrosine kinase inhibitors in advanced renal cell carcinoma: the evolving treatment paradigm. 2009 , 7, 9-10	3
1590	Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis. 2009 , 7, 11-9	72
1589	Phase I trial of sunitinib malate plus interferon-alpha for patients with metastatic renal cell carcinoma. 2009 , 7, 28-33	52
1588	Neoadjuvant sunitinib facilitates nephron-sparing surgery and avoids long-term dialysis in a patient with metachronous contralateral renal cell carcinoma. 2009 , 7, E39-41	19
1587	A differential response to sunitinib: sustained systemic response paralleled by intra-dural progression in the spine. Should standard response criteria be reviewed?. 2009 , 7, E42-4	2
1586	Safety and efficacy of PF-3512676 for the treatment of stage IV renal cell carcinoma: an open-label, multicenter phase I/II study. 2009 , 7, E58-65	40
1585	Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase. 2009 , 2, 15-25	177
1584	Comparison of temsirolimus pharmacokinetics in patients with renal cell carcinoma not receiving dialysis and those receiving hemodialysis: a case series. 2009 , 31, 1812-9	22
1583	Translating preclinical findings of (endothelial) progenitor cell mobilization into the clinic; from bedside to bench and back. 2009 , 1796, 41-9	7
1582	Cancer therapy targeted at cellular signal transduction mechanisms: strategies, clinical results, and unresolved issues. 2009 , 625, 6-22	18
1581	Mode-of-action, efficacy, and safety of a homologous multi-epitope vaccine in a murine model for adjuvant treatment of renal cell carcinoma. 2009 , 56, 123-31	14

- 1580 Editorial comment on: Mode-of-action, efficacy, and safety of a homologous multi-epitope vaccine in a murine model for adjuvant treatment of renal cell carcinoma. **2009**, 56, 131-2
- 1579 Editorial comment on: Mode-of-action, efficacy, and safety of a homologous multi-epitope vaccine in a murine model for adjuvant treatment of renal cell carcinoma. **2009**, 56, 132-3
- 1578 Treatment with sunitinib enabled complete resection of massive lymphadenopathy not previously amenable to excision in a patient with renal cell carcinoma. **2009**, 55, 237-9; quiz 239 22
- 1577 Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis. **2009**, 55, 1430-8 73
- 1576 Editorial comment on: Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis. **2009**, 55, 1439
- 1575 Successful sorafenib treatment for metastatic renal cell carcinoma in a case with chronic renal failure. **2009**, 55, 986-8; quiz 988 17
- 1574 Case study of the month. Complete histologic remission after sunitinib neoadjuvant therapy in T3b renal cell carcinoma. **2009**, 55, 1477-80 50
- 1573 Salvage therapy with bevacizumab-sunitinib combination after failure of sunitinib alone for metastatic renal cell carcinoma: a case series. **2009**, 56, 207-11; quiz 211 18
- 1572 Castration-resistant prostate cancer: from new pathophysiology to new treatment targets. **2009**, 56, 594-605 123
- 1571 Metastatic renal cell carcinoma: recent advances in the targeted therapy era. **2009**, 56, 959-71 47
- 1570 Clinical trial experience with temsirolimus in patients with advanced renal cell carcinoma. **2009**, 36 Suppl 3, S26-36 45
- 1569 Effects of sunitinib on tumor hemodynamics and delivery of chemotherapy. **2009**, 124, 1293-300 47
- 1568 Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. **2009**, 115, 61-7 142
- 1567 A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer. **2009**, 115, 776-83 53
- 1566 Patterns of disease progression in metastatic renal cell carcinoma patients treated with antivasular agents and interferon: impact of therapy on recurrence patterns and outcome measures. **2009**, 115, 1859-66 27
- 1565 Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma. **2009**, 115, 2188-98 64
- 1564 Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma. **2009**, 115, 2306-12 71
- 1563 Circulating biomarkers for vascular endothelial growth factor inhibitors in renal cell carcinoma. **2009**, 115, 2346-54 22

1562	Hereditary kidney cancer: unique opportunity for disease-based therapy. 2009 , 115, 2252-61	89
1561	Treatment selection for patients with metastatic renal cell carcinoma. 2009 , 115, 2327-33	27
1560	Treatment of kidney cancer: insights provided by the VHL tumor-suppressor protein. 2009 , 115, 2262-72	92
1559	Tissue biomarkers in renal cell carcinoma: issues and solutions. 2009 , 115, 2290-7	31
1558	Combination targeted therapy in advanced renal cell carcinoma. 2009 , 115, 2368-75	39
1557	Novel therapeutics for metastatic renal cell carcinoma. 2009 , 115, 2361-7	17
1556	Immunotherapy of metastatic renal cell carcinoma. 2009 , 115, 2298-305	86
1555	Sequential therapy in renal cell carcinoma. 2009 , 115, 2321-6	60
1554	A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer. 2009 , 115, 2438-46	184
1553	Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma. 2009 , 115, 3618-30	63
1552	Phase 1 study of concurrent sunitinib and image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases: acute toxicity and preliminary response. 2009 , 115, 3571-80	76
1551	Analysis of PTEN and HIF-1alpha and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-alpha. 2009 , 115, 3651-60	79
1550	Where does the combination of sorafenib and interferon in renal cell carcinoma stand?. 2010 , 116, 4-7	3
1549	Gastric cancer in the era of molecularly targeted agents: current drug development strategies. 2009 , 135, 855-66	57
1548	VEGF inhibition: insights from preclinical and clinical studies. 2009 , 335, 261-9	158
1547	Stratégie de la prise en charge médicale dans les stades métastatiques. 2009 , 11, 278-284	0
1546	Carcinomes à cellules rénales: de la pathologie aux voies moléculaires de la carcinogénèse. 2009 , 11, 254-259	
1545	Les effets secondaires des anti-angiogéniques (à l'exception des effets cutanés). 2009 , 11, 285-290	2

1544	Effets vasculaires et r̃aux des m̃dicaments anti-angiog̃hiques: recommandations frañaises pour la pratique. 2009 , 11, 476-489	
1543	Kardiotoxizit̃ten bei Chemo- und Radiotherapie. 2009 , 15, 157-162	2
1542	Einsatz von RAD001 bei Patienten mit metastasiertem Nierenzellkarzinom. 2009 , 15, 512-518	
1541	Increased numbers of small circulating endothelial cells in renal cell cancer patients treated with sunitinib. 2009 , 12, 69-79	51
1540	Antiangiogenic strategies for treatment of malignant gliomas. 2009 , 6, 513-26	30
1539	New therapeutic developments in renal cell cancer. 2009 , 69, 56-63	4
1538	The medical treatment of metastatic renal cell cancer in the elderly: position paper of a SIOG Taskforce. 2009 , 69, 64-72	74
1537	Is age a prognostic factor for treatment outcome in renal cell cancer-A comprehensive review. 2009 , 72, 83-9	2
1536	Colonic pneumatosis and intestinal perforations with sunitinib treatment for renal cell carcinoma. 2009 , 27, 83-7	29
1535	Prolonged use of the tyrosine kinase inhibitor in a peritoneal dialysis patient with metastatic renal cell carcinoma: possible beneficial effects on peritoneal membrane and peritonitis rates. 2009 , 41, 431-4	4
1534	Blood Levels of Carbonic Anhydrase 9 Correlate with Clear Cell Renal Cell Carcinoma Activity. 2009 , 5, 37-45	6
1533	Imbalance and gait disturbance from tyrosine kinase inhibition in hepatocellular cancer. 2009 , 40, 119-22	1
1532	Treatment selection for patients with metastatic renal cell carcinoma: identification of features favoring upfront IL-2-based immunotherapy. 2009 , 26 Suppl 1, 18-22	20
1531	Everolimus for renal cell carcinoma: predictive factors for response and future directions. 2009 , 26, 46-53	
1530	The application of high-dose interleukin-2 for metastatic renal cell carcinoma. 2009 , 26 Suppl 1, 13-7	20
1529	Everolimus (RAD001) in the treatment of advanced renal cell carcinoma: biology and pathways. 2009 , 26, 40-45	
1528	Mechanism of action of everolimus in renal cell carcinoma. 2009 , 26, 32-39	29
1527	Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. 2009 , 26, 202-9	217

1526	The role of antiangiogenesis therapy: bevacizumab and beyond. 2009 , 11, 349-55	20
1525	Cardiac dysfunction induced by novel targeted anticancer therapy: an emerging issue. 2009 , 11, 167-74	20
1524	Axitinib treatment in patients with cytokine-refractory metastatic renal cell cancer. 2009 , 11, 81-3	1
1523	VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy. 2009 , 11, 94-101	108
1522	Optimizing recent advances in metastatic renal cell carcinoma. 2009 , 11, 218-26	9
1521	Integration of surgery and systemic therapy in the management of metastatic renal cancer. 2009 , 10, 35-41	6
1520	Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors. 2009 , 4, 67-76	25
1519	Renal toxicity of targeted therapies. 2009 , 4, 121-33	41
1518	Axitinib--a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor. 2009 , 4, 297-305	69
1517	Sunitinib paves the way for targeted therapies in neuroendocrine tumors. 2009 , 4, 253-4	16
1516	Temsirolimus in patients with advanced renal cell carcinoma: an overview. 2009 , 26, 55-67	17
1515	Mise au point sur le traitement médical du cancer du rein métastatique. 2009 , 1, 154-158	
1514	[Can systemic treatment for lymph node metastases be given with curative intent?]. 2009 , 48, 62-5	
1513	[Prognostic factors for survival of patients with metastatic renal cell carcinoma]. 2009 , 48, 625-7	3
1512	[Systemic chemotherapy for bladder cancer: news in 2009]. 2009 , 48, 655-62	
1511	[Current state of systemic therapy of metastatic renal cell carcinoma]. 2009 , 48, 983-4, 986, 988-9	5
1510	[Uro-oncology--update 2009]. 2009 , 48, 1056-8	
1509	[Systemic therapy of metastatic renal cell carcinoma: from many options to the therapeutic strategy]. 2009 , 48, 1308-17	0

1508	Identification of molecular targets in urologic oncology. 2009 , 27, 3-8	3
1507	Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery. 2009 , 27, 533-9	54
1506	Inhaled IL-2 induces systemic immunomodulation in patients with renal cell carcinoma and lung metastasis. 2009 , 58, 235-45	
1505	Intravesical administration of gammadelta T cells successfully prevents the growth of bladder cancer in the murine model. 2009 , 58, 493-502	50
1504	TGF-alpha as a candidate tumor antigen for renal cell carcinomas. 2009 , 58, 1207-18	18
1503	Vaccination strategies in patients with renal cell carcinoma. 2009 , 58, 1169-74	26
1502	Experiences and practical conclusions concerning temsirolimus use and adverse event management in advanced renal cell carcinoma within a compassionate use program in Germany. 2009 , 63, 1097-102	15
1501	Recommendations from the Spanish Oncology Genitourinary Group for the treatment of metastatic renal cancer. 2009 , 63 Suppl 1, S1-13	8
1500	Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors. 2009 , 64, 1165-72	44
1499	Treatment of metastatic renal cell carcinoma. 2009 , 64, 11-25	62
1498	Sensitivity analysis to investigate the impact of a missing covariate on survival analyses using cancer registry data. 2009 , 28, 1498-511	6
1497	Renal cell carcinoma in the pediatric population: Results from the California Cancer Registry. 2009 , 52, 237-41	45
1496	The application of bespoke spending functions in group-sequential designs and the effect of delayed treatment switching in survival trials. 2010 , 9, 151-61	
1495	CD 9 and vimentin distinguish clear cell from chromophobe renal cell carcinoma. 2009 , 9, 9	24
1494	Low expression of microphthalmia-associated transcription factor, a potential molecular target for interferon-alpha susceptibility, is associated with metastasis in renal cell carcinoma. 2009 , 100, 1714-8	1
1493	The dynamics of tumour-vasculature interaction suggests low-dose, time-dense anti-angiogenic schedulings. 2009 , 42, 317-29	35
1492	CSF1R copy number changes, point mutations, and RNA and protein overexpression in renal cell carcinomas. 2009 , 22, 744-52	19
1491	Long-term follow-up of metastatic renal cancer patients undergoing reduced-intensity allografting. 2009 , 44, 237-42	14

1490	Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. 2009 , 15, 392-400	390
1489	Biomarkers of response and resistance to antiangiogenic therapy. 2009 , 6, 327-38	487
1488	Decreased expression of CXXC4 promotes a malignant phenotype in renal cell carcinoma by activating Wnt signaling. 2009 , 28, 297-305	67
1487	Treatment in advanced colorectal cancer: what, when and how?. 2009 , 100, 1704-19	81
1486	Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. 2009 , 101, 1717-23	179
1485	Cutaneous side effects of inhibition of VEGF signal transduction. 2010 , 8, 243-9	12
1484	INVITED SPEAKERS' ABSTRACTS. 2009 , 5, A47-A52	
1483	Cardiac toxicity from sunitinib: Do we need to be more vigilant?. 2009 , 5, 217-218	0
1482	Review article: How cells sense oxygen: lessons from and for the kidney. 2009 , 14, 86-93	15
1481	The role of cytoreductive nephrectomy in the era of molecular targeted therapy. 2009 , 16, 227-33	15
1480	Type-I interferon receptor expression: its circadian rhythm and downregulation after interferon-alpha administration in peripheral blood cells from renal cancer patients. 2009 , 16, 356-9	7
1479	Recent advances in molecular targeted therapy for metastatic renal cell carcinoma. 2009 , 16, 444-8	6
1478	Prediction of response to combined immunotherapy with interferon- γ and low-dose interleukin-2 in metastatic renal cell carcinoma: Expression patterns of potential molecular markers in radical nephrectomy specimens. 2009 , 16, 465-471	10
1477	Prognostic factors for cases with metastatic renal cell carcinoma in the era of targeted medicine. 2009 , 16, 855-61	3
1476	Pre-surgical targeted molecular therapy in renal cell carcinoma. 2009 , 103, 150-3	12
1475	The feasibility of establishing a programme of adjuvant autologous vaccination for renal cell carcinoma. 2009 , 103, 740-6	3
1474	Race affects access to nephrectomy but not survival in renal cell carcinoma. 2009 , 103, 889-93	21
1473	The medical management of metastatic renal cell carcinoma: integrating new guidelines and recommendations. 2009 , 103, 572-7	37

1472	Targeted therapies in metastatic renal cancer in 2009. 2009 , 103, 1334-42	17
1471	Optimal management of metastatic renal cell carcinoma: an algorithm for treatment. 2009 , 104, 10-8	19
1470	Vascular endothelial growth factor and mTOR pathways in renal cell carcinoma: differences and synergies of two targeted mechanisms. 2009 , 104, 1585-9	35
1469	Use of systemic therapy and factors affecting survival for patients undergoing cytoreductive nephrectomy. 2010 , 106, 218-23	52
1468	Using the Rasch model to validate and enhance the interpretation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index--Disease-Related Symptoms scale. 2009 , 12, 580-6	6
1467	A routine feasible HPLC analysis for the anti-angiogenic tyrosine kinase inhibitor, sunitinib, and its main metabolite, SU12662, in plasma. 2009 , 877, 3757-61	32
1466	Effect of the UK postcode lottery on survival of patients with metastatic renal cancer: an audit of outcomes in patients with metastatic renal cancer suitable for treatment with tyrosine kinase inhibitors. 2009 , 21, 610-6	3
1465	Hypoxia-inducible factor in cancer angiogenesis: structure, regulation and clinical perspectives. 2009 , 70, 93-102	52
1464	The vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor cediranib (Recentin; AZD2171) inhibits endothelial cell function and growth of human renal tumor xenografts. 2009 , 73, 897-903	13
1463	Metastatic renal cell carcinoma: many treatment options, one patient. 2009 , 27, 3225-34	90
1462	Management of hypertension in angiogenesis inhibitor-treated patients. 2009 , 20, 807-15	250
1461	[Necrotizing hand-foot skin reaction induced by antiangiogenic in a patient with Thevenard neuroacropathy]. 2009 , 34, 222-5	0
1460	18F-FDG PET/CT imaging for an early assessment of response to sunitinib in metastatic renal carcinoma: preliminary study. 2009 , 24, 137-44	56
1459	Predictors of oncological outcome after resection of locally recurrent renal cell carcinoma. 2009 , 181, 2044-51	75
1458	Tolerability of first-line therapy for metastatic renal cell carcinoma. 2009 , 35, 297-307	36
1457	Novel agents for renal cell carcinoma require novel selection paradigms to optimise first-line therapy. 2009 , 35, 289-96	15
1456	Quality of life in patients with metastatic renal cell carcinoma: the importance of patient-reported outcomes. 2009 , 35, 733-7	28
1455	A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: a study of the National Cancer Institute of Canada Clinical Trials Group. 2009 , 45, 788-9	59

1454	EORTC-GU group expert opinion on metastatic renal cell cancer. 2009 , 45, 765-73	92
1453	The role of angiogenesis in solid tumours: an overview. 2009 , 20, 663-71	103
1452	Sorafenib and surgical complications: a case report of adverse reaction to sorafenib during treatment for renal cell carcinoma. 2009 , 35, 219-21	12
1451	Synergistic effect of Sorafenib and Sunitinib with Enzastaurin, a selective protein kinase C inhibitor in renal cell carcinoma cell lines. 2009 , 277, 218-26	10
1450	Hypoxia-independent angiogenesis in adipose tissues during cold acclimation. 2009 , 9, 99-109	251
1449	Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies. 2009 , 30, 624-30	122
1448	Metastatic renal cell carcinoma with partial response to sunitinib complicated by ureteral obstruction from necrotic tumor. 2009 , 73, 444.e11-2	2
1447	Combined radiofrequency ablation and antiangiogenic drug for the treatment of recurrent renal tumor. 2009 , 73, 928.e11-2	2
1446	Population-based assessment of survival after cytoreductive nephrectomy versus no surgery in patients with metastatic renal cell carcinoma. 2009 , 73, 342-6	52
1445	Editorial Comment. 2009 , 73, 668-669	8
1444	Rapamycin inhibits in vitro growth and release of angiogenetic factors in human bladder cancer. 2009 , 73, 665-8; discussion 668-9	30
1443	Reply. 2009 , 73, 669	
1442	Treatment of metastatic renal cell cancer with sunitinib during chronic hemodialysis. 2009 , 73, 868-70	12
1441	A population-based analysis of the rate of cytoreductive nephrectomy for metastatic renal cell carcinoma in the United States. 2009 , 74, 837-41	23
1440	Debulking nephrectomy followed by a "watch and wait" approach in metastatic renal cell carcinoma. 2009 , 27, 149-54	16
1439	Clinical implications of hypoxia inducible factor in renal cell carcinoma. 2009 , 27, 238-45	47
1438	P-glycoprotein activity in renal clear cell carcinoma. 2009 , 27, 363-6	12
1437	Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model. 2009 , 27, 391-9	66

1436	Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma. 2009 , 27, 598-603	26
1435	EAU-a work in progress-what comes next?. 2009 , 27, 125-6	
1434	A medical oncologist's perspective on the treatment of patients with genitourinary malignancies. 2009 , 27, 122-5	0
1433	The clinical implications of the genetics of renal cell carcinoma. 2009 , 27, 131-6	48
1432	Kidney cancer in the elderly. 2009 , 27, 673-6	6
1431	Adjuvant interferon therapy for patients with uveal melanoma at high risk of metastasis. 2009 , 116, 2206-12	62
1430	[Targeted therapies and their indications in solid neoplasias]. 2009 , 30, 416-24	4
1429	Apical ballooning syndrome during treatment with a vascular endothelial growth factor receptor antagonist. 2009 , 131, e92-4	20
1428	Triple-negative breast cancer: novel therapies and new directions. 2009 , 63, 269-74	41
1427	Renal effects of anti-angiogenesis therapy: update for the internist. 2009 , 122, 322-8	130
1426	Sunitinib in solid tumors. 2009 , 18, 821-34	88
1425	Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. 2009 , 53, 2231-47	885
1424	Thrombosis associated with angiogenesis inhibitors. 2009 , 22, 115-28	93
1423	Surgery and stem cell niches: An Achilles' heel of metastatic cancer. 2009 , 2, 345-349	
1422	Cardiotoxicity induced by tyrosine kinase inhibitors. 2009 , 48, 964-70	190
1421	Angiogenesis in cutaneous malignant melanoma and potential therapeutic strategies. 2009 , 9, 1583-98	20
1420	Benefit-risk assessment of sunitinib in gastrointestinal stromal tumours and renal cancer. 2009 , 32, 717-34	27
1419	Onset of male gynaecomastia in a patient treated with sunitinib for metastatic renal cell carcinoma. 2009 , 29, 487-490	19

1418	Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma. 2009 , 7, 24-7	132
1417	The high-dose aldesleukin (IL-2) "select" trial: a trial designed to prospectively validate predictive models of response to high-dose IL-2 treatment in patients with metastatic renal cell carcinoma. 2009 , 7, E7-9	32
1416	A case of adult metastatic Xp11 translocation renal cell carcinoma treated successfully with sunitinib. 2009 , 7, E93-4	23
1415	Tolerance of sunitinib in dialyzed patients with metastatic renal cell carcinoma. 2009 , 7, E104-6	9
1414	Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. 2009 , 27, 3584-90	1729
1413	Pathologic Features of Adult Renal Cortical Tumors. 2009 , 2, 1-25	1
1412	Molecular Pathology of the Genitourinary Tract: Molecular Pathology of Kidney and Testes. 2009 , 2, 199-223	1
1411	The sonic hedgehog signaling pathway is reactivated in human renal cell carcinoma and plays orchestral role in tumor growth. 2009 , 8, 123	80
1410	From bench to bedside: current and future applications of molecular profiling in renal cell carcinoma. 2009 , 8, 20	53
1409	DCE-MRI assessment of the effect of vandetanib on tumor vasculature in patients with advanced colorectal cancer and liver metastases: a randomized phase I study. 2009 , 1, 5	41
1408	Immunotherapeutic strategies in kidney cancer--when TKIs are not enough. 2009 , 6, 478-87	41
1407	Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. 2009 , 48, 9-17	251
1406	Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors. 2009 , 9, 263-71	90
1405	Immune therapy for cancer. 2009 , 27, 83-117	476
1404	Functional Preservation and Quality of Life in Head and Neck Radiotherapy. 2009 ,	
1403	Therapeutic potential of manipulating VEGF splice isoforms in oncology. 2009 , 5, 703-12	23
1402	Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes. 2009 , 100, 1111-9	152
1401	Anti-VEGF therapies for malignant glioma: treatment effects and escape mechanisms. 2009 , 13, 455-68	67

1400	Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness. 2009 , 101, 238-43	50
1399	Adverse effects of anticancer agents that target the VEGF pathway. 2009 , 6, 465-77	393
1398	Molecular targeted therapies for solid tumors: management of side effects. 2009 , 32, 129-38	10
1397	Chromophobe renal cell cancer--review of the literature and potential methods of treating metastatic disease. 2009 , 28, 134	36
1396	Targeting targeted agents: open issues for clinical trial design. 2009 , 28, 66	15
1395	Multitarget drugs: the present and the future of cancer therapy. 2009 , 10, 589-600	53
1394	Against: The case for cytoreductive nephrectomy for the management of metastatic renal cell carcinoma. 2009 , 182, 833-4	
1393	Current insights on the biology and clinical aspects of VEGF regulation. 2008 , 42, 517-30	58
1392	Pre-clinical models of renal carcinoma and their utility in drug development. 2009 , Chapter 14, Unit 14.13	3
1391	Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma. 2009 , 94, 5-9	128
1390	Emerging drugs for esophageal cancer. 2009 , 14, 329-39	13
1389	Cost implications of IV versus oral anti-angiogenesis therapies in patients with advanced renal cell carcinoma: retrospective claims database analysis. 2009 , 25, 2081-90	16
1388	Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies. 2009 , 23, 377-89	119
1387	Lestaurtinib: a multi-targeted FLT3 inhibitor. 2009 , 2, 17-26	12
1386	Increased hemoglobin associated with VEGF inhibitors in advanced renal cell carcinoma. 2009 , 27, 851-6	14
1385	Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. 2009 , 27, 4462-8	295
1384	Zoledronic acid induces caspase-dependent apoptosis in renal cancer cell lines. 2009 , 43, 98-103	22
1383	Everolimus (RAD001): an mTOR inhibitor for the treatment of metastatic renal cell carcinoma. 2009 , 9, 705-17	30

1382	Anti-angiogenesis approach to genitourinary cancer treatment. 2009 , 3, 182-188	16
1381	Treatment of Advanced and Metastatic Renal Cancer: A Revolution?. 2009 , 8, 483-488	4
1380	Treatment Decisions for Advanced Genitourinary Cancers: From Symptoms to Risk Assessment. 2009 , 8, 738-746	4
1379	Advances in the Management of Metastatic Renal Cell Cancer. 2009 , 8, 758-761	
1378	Current Perspectives in Metastatic Renal Cell Carcinoma Treatment: The Role of Mammalian Target of Rapamycin (mTOR) Inhibition. 2009 , 8, 785-786	
1377	Metastatic Renal Cell Carcinoma: Pathogenesis and the Current Medical Landscape. 2009 , 8, 787-792	3
1376	Molecular Pathways in Metastatic Renal Cell Carcinoma: The Evolving Role of Mammalian Target of Rapamycin Inhibitors. 2009 , 8, 793-798	3
1375	Current and Future Treatment Options for Metastatic Renal Cell Carcinoma. 2009 , 8, 799-808	3
1374	Treatment Algorithms in Metastatic Renal Cell Carcinoma, Including the Potential Role of the Novel Oral Mammalian Target of Rapamycin Inhibitor Everolimus. 2009 , 8, 809-814	2
1373	Mammalian Target of Rapamycin Inhibitors in Clinical Practice: Case Reports of Everolimus in Renal Cell Carcinoma. 2009 , 8, 815-819	1
1372	Identification of TNF-alpha and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array. 2009 , 101, 1876-83	71
1371	Renal cell cancer, part II: traditional and emerging therapies. 2009 , 6, 167-172	
1370	Renal cell cancer: clinical presentation and prognosis part I. 2009 , 6, 24-28	
1369	Emergency surgery in the era of molecular treatment of solid tumours. 2009 , 10, 157-63	42
1368	Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. 2009 , 10, 757-63	478
1367	Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. 2009 , 10, 794-800	248
1366	Sunitinib in renal-cell carcinoma: expanded indications. 2009 , 10, 740	4
1365	Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. 2009 , 10, 967-74	219

1364	Cardiovascular toxicity of molecularly targeted agents. 2009 , 45 Suppl 1, 318-31	16
1363	Renal cell carcinoma. 2009 , 373, 1119-32	1078
1362	Recent advances in the systemic treatment of metastatic papillary renal cancer. 2009 , 9, 373-9	25
1361	[Treatment of metastatic kidney cancer in elderly subjects]. 2009 , 19 Suppl 3, S129-32	
1360	Sequential sorafenib and sunitinib for renal cell carcinoma. 2009 , 182, 29-34; discussion 34	126
1359	Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. 2009 , 181, 518-23; discussion 523	126
1358	[Novel therapeutic targets in metastatic renal cell carcinoma. Results of the treatment with single-agent bevacizumab in a single institution]. 2009 , 33, 138-42	
1357	[New cell target treatments: indications, results and tolerance]. 2009 , 33, 609-14	
1356	Editorial Comment. 2009 , 181, 2469-2469	0
1355	[Critical analysis of prognostic factors for metastatic renal cell carcinoma]. 2009 , 19, 383-8	0
1354	Guía del carcinoma de células renales. 2009 , 33, 270-279	1
1353	Re: Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. A. A. Thomas, B. I. Rini, B. R. Lane, J. Garcia, R. Dreicer, E. A. Klein, A. C. Novick And S. C. Campbell. J Urol 2009; 181: 518-523. 2009 , 182, 797; author reply 797-8	1
1352	Dynamic contrast-enhanced magnetic resonance imaging of vascular changes induced by sunitinib in papillary renal cell carcinoma xenograft tumors. 2009 , 11, 910-20	50
1351	[Renal cell carcinoma and antiangiogenic agents: ongoing controversies are seeking answers for improvement of therapeutic management]. 2009 , 19, 596-605	2
1350	Presence of tumor necrosis is not a significant predictor of survival in clear cell renal cell carcinoma: higher prognostic accuracy of extent based rather than presence/absence classification. 2009 , 181, 1558-64; discussion 1563-4	58
1349	Surgical resection of renal cell carcinoma after targeted therapy. 2009 , 182, 881-6	91
1348	Response of renal cell carcinoma pancreatic metastasis to sunitinib treatment: a retrospective analysis. 2009 , 181, 2470-5; discussion 2475	21
1347	Cardiovascular effects of tyrosine kinase inhibitors used for gastrointestinal stromal tumors. 2009 , 23, 97-107, viii-ix	14

1346	A Population-based Study Evaluating the Impact of Sunitinib on Overall Survival in the Treatment of Patients With Metastatic Renal Cell Cancer. 2009 , 2009, 88-89	
1345	New treatment approaches in renal cell carcinoma. 2009 , 20, 893-900	33
1344	Critical care management of cancer patients: cause for optimism and need for objectivity. 2009 , 21, 318-26	68
1343	A phase ii study of gemcitabine and capecitabine in patients with advanced renal cell cancer: Southwest Oncology Group Study S0312. 2009 , 32, 453-9	15
1342	Development of sunitinib in hepatocellular carcinoma: rationale, early clinical experience, and correlative studies. 2009 , 15, 263-8	29
1341	Progression-free survival: gaining on overall survival as a gold standard and accelerating drug development. 2009 , 15, 386-94	36
1340	Stable disease is not preferentially observed with targeted therapies and as currently defined has limited value in drug development. 2009 , 15, 366-73	12
1339	The nasal septum: an unusual presentation of metastatic renal cell carcinoma. 2009 , 20, 1204-6	7
1338	Cardiovascular and renal toxicity during angiogenesis inhibition: clinical and mechanistic aspects. 2009 , 27, 2297-309	57
1337	Other paradigms: growth rate constants and tumor burden determined using computed tomography data correlate strongly with the overall survival of patients with renal cell carcinoma. 2009 , 15, 441-7	27
1336	Advanced renal cell carcinoma: what to do after first line antiangiogenic therapy?. 2009 , 3, 153-6	
1335	Targeted therapies to treat non-AIDS-defining cancers in patients with HIV on HAART therapy: treatment considerations and research outlook. 2009 , 21, 445-54	35
1334	Sorafenib: a multitargeted oral agent for the treatment of advanced renal cell cancer. 2009 , 6, 111-124	
1333	Current world literature. Head and neck. 2009 , 21, 284-93	
1332	Cytoreductive nephrectomy in metastatic renal cell carcinoma: the evolving role of surgery in the era of molecular targeted therapy. 2009 , 3, 157-65	4
1331	Successful sunitinib treatment of metastatic renal cell carcinoma in a patient with end stage renal disease on hemodialysis. 2009 , 20, 848-9	8
1330	Renal cell carcinoma. 2009 , 21, 266-71	30
1329	Overall survival: a gold standard in search of a surrogate: the value of progression-free survival and time to progression as end points of drug efficacy. 2009 , 15, 395-400	41

1328	Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell carcinoma. 2009 , 32, 181-5	43
1327	Vaccination of patients with metastatic renal cancer with modified vaccinia Ankara encoding the tumor antigen 5T4 (TroVax) given alongside interferon-alpha. 2009 , 32, 424-9	40
1326	State of the art management in spine oncology: a worldwide perspective on its evolution, current state, and future. 2009 , 34, S7-20	27
1325	Non-clear cell renal cancer: features and medical management. 2009 , 7, 659-65	27
1324	[Pharmacology profile of sunitinib malate (Sutent) Capsules) and clinical findings on this drug]. 2009 , 133, 215-26	
1323	[Standard chemotherapy for solid cancers. 3) Liver and kidney cancers]. 2009 , 98, 1874-9	
1322	PTEN suppression of YY1 induces HIF-2 activity in von-Hippel-Lindau-null renal-cell carcinoma. 2009 , 8, 1389-401	38
1321	Interffons' utilisation thfapeutique. 2009 , 4, 1-6	
1320	[EGFR and VEGF-targeted drugs: clinical evidence for their effects from evaluation of biomarkers]. 2009 , 133, 69-72	
1319	Management of sorafenib, sunitinib, and temsirolimus toxicity in metastatic renal cell carcinoma. 2009 , 3, 170-9	33
1318	Essentials of pharmacoeconomics. 2009 , 15, 92-94	1
1317	NCCN clinical practice guidelines in oncology: kidney cancer. 2009 , 7, 618-30	168
1316	UK guidelines for the systemic treatment of renal cell carcinoma. 2009 , 70, 284-6	6
1315	Proteomic Analysis of Primary and Established Cell Lines for the Investigation of Renal Cell Carcinoma. 149-166	
1314	Targeted therapies in the treatment of advanced renal cell carcinoma. 2009 , 4, 146-56	7
1313	Role of the Akt pathway in prostate cancer. 2009 , 9, 163-75	17
1312	Angiogenesis Inhibition: State of the Art, Forgotten Strategies and New Perspectives in Cancer Therapy. 2009 , 5, 203-216	1
1311	Sorafenib tosylate in advanced kidney cancer: past, present and future. 2009 , 20, 409-15	18

1310	Evaluation of response to multikinase inhibitor in metastatic renal cell carcinoma by FDG PET/contrast-enhanced CT. 2010 , 35, 918-23	25
1309	Angiogenesis inhibitors: implications for combination with conventional therapies. 2010 , 16, 3921-31	10
1308	Renal cell carcinoma: complete response. 2010 , 21 Suppl 1, S17-8	6
1307	Renal cell carcinoma: complete pathological response in a patient with gastric metastasis of renal cell carcinoma. 2010 , 21 Suppl 1, S13-5	16
1306	Renal cell cancer: state of the art in adjuvant therapy. 2010 , 5, 242-50	1
1305	Thromboembolic events in patients treated with anti-angiogenic drugs. 2010 , 8, 102-13	30
1304	Cancer du rein. 2010 , 3, 1-30	2
1303	Targeted therapy for metastatic renal cell cancer. 2010 , 65, 115-21	0
1302	[Renal cell carcinoma management and therapies in 2010]. 2010 , 97, 17-28	4
1301	[Targeted therapies: sequential and combined treatments]. 2010 , 97, 65-71	1
1300	Dose-finding trial of a combined regimen with bevacizumab, immunotherapy, and chemotherapy in patients with metastatic renal cell cancer: An Italian Oncology Group for Clinical Research (GOIRC) study. 2010 , 33, 735-41	9
1299	Breast cancer: complete response with the combination of sunitinib and trastuzumab in a patient with grade III ductal carcinoma. 2010 , 21 Suppl 1, S19-22	3
1298	Inhibiting the VEGF-VEGFR pathway in angiosarcoma, epithelioid hemangioendothelioma, and hemangiopericytoma/solitary fibrous tumor. 2010 , 22, 351-5	127
1297	Changes in dendritic cell phenotype after a new high-dose weekly schedule of interleukin-2 therapy for kidney cancer and melanoma. 2010 , 33, 817-27	37
1296	A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients. 2010 , 33, 991-8	161
1295	Women survive breast cancer but fall victim to heart failure: the shadows and lights of targeted therapy. 2010 , 11, 861-8	36
1294	Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib. 2010 , 21 Suppl 1, S3-11	83
1293	Factors affecting outcome in renal cell carcinoma. 2010 , 20, 355-60	6

1292	Surgery for renal cell carcinoma metastases. 2010 , 20, 375-81	31
1291	Kidney cancer: neoadjuvant targeted therapies in renal cell carcinoma. 2010 , 7, 63-4	12
1290	Radiotherapy in combination with vascular-targeted therapies. 2010 , 44, 67-78	18
1289	[Recent advancements in the treatment of renal cell carcinoma--focus on international guidelines]. 2010 , 54, 369-76	2
1288	[Interests in angiogenesis inhibitor drugs approved for the treatment of cancers]. 2010 , 65, 95-105	1
1287	Multifaceted role of vascular endothelial growth factor signaling in adult tissue physiology: an emerging concept with clinical implications. 2010 , 17, 206-12	20
1286	Sorafenib after combination therapy with gemcitabine plus doxorubicine in patients with sarcomatoid renal cell carcinoma: a prospective evaluation. 2010 , 15, 287-91	25
1285	Identification of a set of genes associated with response to interleukin-2 and interferon- γ combination therapy for renal cell carcinoma through genome-wide gene expression profiling. 2010 , 1, 955-961	6
1284	Cytoreductive nephrectomy vs medical therapy as initial treatment: a rational approach to the sequence question in metastatic renal cell carcinoma. 2010 , 17, 269-78	5
1283	[Advanced renal carcinomas with special situations. How to treat them?]. 2010 , 97, 83-90	1
1282	Pazopanib for the treatment of patients with advanced renal cell carcinoma. 2010 , 4, 95-105	10
1281	Tumor vasculature as target for therapeutic intervention. 2010 , 19, 1321-38	16
1280	Recent concepts of antiangiogenic therapy. 2010 , 40, 494-500	14
1279	Chronotherapy and the molecular clock: Clinical implications in oncology. 2010 , 62, 979-1001	118
1278	Phase III, randomised, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 and interferon-alpha for metastatic renal cell cancer. 2010 , 59, 553-61	19
1277	Ten-year survival analysis for renal carcinoma patients treated with an autologous tumour lysate vaccine in an adjuvant setting. 2010 , 59, 687-95	37
1276	Endostatin gene therapy enhances the efficacy of IL-2 in suppressing metastatic renal cell carcinoma in mice. 2010 , 59, 1357-65	18
1275	A phase-II study of combination of pegylated interferon alfa-2a and capecitabine in locally advanced or metastatic renal cell cancer. 2010 , 66, 59-67	7

1274	Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study. 2010 , 66, 669-80	32
1273	An early phase II trial of S-1 in Japanese patients with cytokine-refractory metastatic renal cell carcinoma. 2010 , 66, 1065-70	6
1272	Experimental anticancer therapy with vascular-disruptive peptide and liposome-entrapped chemotherapeutic agent. 2010 , 58, 235-45	5
1271	[Targeted therapy of urological tumours. Experimental field or established therapeutic approach?]. 2010 , 49, 1260-5	4
1270	Strategies for kinome profiling in cancer and potential clinical applications: chemical proteomics and array-based methods. 2010 , 397, 3163-71	27
1269	Update on systemic therapies of metastatic renal cell carcinoma. 2010 , 28, 303-9	28
1268	Prognostic factors in renal cell carcinoma. 2010 , 28, 319-27	113
1267	Treatment with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma is associated with drug-induced hyperparathyroidism: a single center experience in 59 patients. 2010 , 28, 311-7	1
1266	Management of sunitinib-related adverse events: an evidence- and expert-based consensus approach. 2010 , 28, 343-51	16
1265	Bioanalytical method for the quantification of sunitinib and its n-desethyl metabolite SU12662 in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometry. 2010 , 51, 934-41	44
1264	Metastasis of genitourinary tumors to the head and neck region. 2010 , 267, 273-9	23
1263	Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastases. 2010 , 136, 371-8	24
1262	The role of surgery in clinical management of patients with metastatic papillary renal cell carcinoma. 2010 , 136, 905-10	6
1261	Defining risk status in the first-line treatment of metastatic renal cell carcinoma. 2010 , 136, 961-8	5
1260	Metastasectomy for renal cell carcinoma as a strategy to obtain complete remission. 2010 , 15, 519-22	4
1259	Metastatic renal cell carcinoma complicated with diffuse alveolar hemorrhage: a rare adverse effect of sunitinib. 2010 , 15, 638-41	5
1258	Carcinome papillaire du rein: tude rtrospective ^ propos de six cas. 2010 , 12, 40-44	
1257	Adjuvante postoperative Therapie beim Nierenzellkarzinom. 2010 , 16, 150-156	

1256	Targeted therapy bei metastasiertem Nierenzellkarzinom. 2010 , 16, 157-167	1
1255	Biomarkers of angiogenesis and their role in clinical oncology. 2010 , 3, 27-32	1
1254	A digest on the role of the tumor microenvironment in gastrointestinal cancers. 2010 , 3, 167-76	23
1253	Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors. 2010 , 27, 495-511	20
1252	Gastrointestinal bleeding during anti-angiogenic peptide vaccination in combination with gemcitabine for advanced pancreatic cancer. 2010 , 3, 307-17	4
1251	Emerging molecular classification in renal cell carcinoma: implications for drug development. 2010 , 5, 75-84	5
1250	Targeted therapies in renal cell cancer: recent developments in imaging. 2010 , 5, 95-112	43
1249	Targeted therapy for locally advanced renal cell carcinoma. 2010 , 5, 113-8	5
1248	Targeted therapies for non-clear renal cell carcinoma. 2010 , 5, 119-29	27
1247	Vascular endothelial growth factor inhibitors in malignant gliomas. 2010 , 5, 167-74	9
1246	Examining the safety profile of angiogenesis inhibitors: implications for clinical practice. 2010 , 5, 257-67	3
1245	Feasibility of sequential use of sunitinib and temsirolimus in advanced renal cell carcinoma. 2010 , 27, 373-8	27
1244	The combined administration of partially HLA-matched irradiated allogeneic lymphocytes and thalidomide in advanced renal-cell carcinoma: a case report. 2010 , 27, 554-8	4
1243	Recovery of paraneoplastic hypercalcemia by sunitinib treatment for renal cell carcinoma: a case report and review of the literature. 2010 , 27, 1023-6	8
1242	Molecular basis for the treatment of renal cell carcinoma. 2010 , 12, 15-21	15
1241	Tyrosine kinase inhibitors in treating soft tissue sarcomas: sunitinib in non-GIST sarcomas. 2010 , 12, 468-72	7
1240	A phase II trial of first-line sorafenib in patients with metastatic renal cell carcinoma unwilling to receive or with early intolerance to immunotherapy: SOGUG Study 06-01. 2010 , 12, 503-8	9
1239	Impact of the incorporation of tyrosine kinase inhibitor agents on the treatment of patients with a diagnosis of advanced renal cell carcinoma: study based on experience at the Hospital Universitario Central de Asturias. 2010 , 12, 562-7	2

1238	Targeting cytoskeleton reorganisation as antimetastatic treatment. 2010 , 12, 662-9	11
1237	Biomarkers for Therapies Directed at Angiogenesis. 2010 , 6, 133-143	4
1236	The expanding role of bevacizumab in the treatment of human epidermal growth factor receptor 2-negative breast cancer. 2010 , 12, 22-5	5
1235	Is Pazopanib Safe and Efficacious in Patients with Metastatic Renal Cell Carcinoma?. 2010 , 12, 77-79	
1234	Vascular endothelial growth factor polymorphisms: role in response and toxicity of tyrosine kinase inhibitors. 2010 , 12, 102-8	33
1233	Targeted therapies in der Behandlung solider Tumoren. 2010 , 3, 48-51	
1232	Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer. 2010 , 123, 463-9	39
1231	Updated recommendations from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma. 2010 , 29 Suppl 1, 1-10	3
1230	Update from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma: focus on special populations. 2010 , 29 Suppl 1, 11-20	1
1229	In-silico approaches to multi-target drug discovery : computer aided multi-target drug design, multi-target virtual screening. 2010 , 27, 739-49	108
1228	Sunitinib inducing tumor lysis syndrome in a patient treated for renal carcinoma. 2010 , 28, 690-3	18
1227	Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors. 2010 , 28, 523-8	55
1226	An in vitro study, evaluating the effect of sunitinib and/or lapatinib on two glioma cell lines. 2010 , 28, 554-60	23
1225	Phase II study of sunitinib malate in head and neck squamous cell carcinoma. 2010 , 28, 677-83	70
1224	Cardiac toxicity from systemic cancer therapy: a comprehensive review. 2010 , 53, 94-104	125
1223	Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapy. 2010 , 125, 196-218	100
1222	Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. 2010 , 11, 311-9	13
1221	Prognostic stratification of patients with advanced renal cell carcinoma treated with sunitinib: comparison with the Memorial Sloan-Kettering prognostic factors model. 2010 , 10, 45	22

1220	Extracerebral metastases determine the outcome of patients with brain metastases from renal cell carcinoma. 2010 , 10, 480	22
1219	Brain natriuretic peptide precursor (NT-pro-BNP) levels predict for clinical benefit to sunitinib treatment in patients with metastatic renal cell carcinoma. 2010 , 10, 489	9
1218	Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma. 2010 , 10, 524	111
1217	Impact of maximum standardized uptake value (SUVmax) evaluated by 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report. 2010 , 10, 667	74
1216	Abscess formation mimicking disease progression, in a patient with metastatic renal cell carcinoma during sunitinib treatment. 2010 , 8, 45	1
1215	External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology. 2010 , 57, 102-9	113
1214	Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy. 2010 , 58, 75-83	153
1213	Integrating surgery with targeted therapies for renal cell carcinoma: current evidence and ongoing trials. 2010 , 58, 819-28	73
1212	Molecularly targeted therapy in hepatocellular carcinoma. 2010 , 80, 550-60	98
1211	Building on a foundation of VEGF and mTOR targeted agents in renal cell carcinoma. 2010 , 80, 638-46	15
1210	[Use of sorafenib in patients with hepatocellular or renal carcinoma]. 2010 , 34, 161-7	3
1209	Angiogenesis: What can it offer for future medicine?. 2010 , 316, 1304-8	30
1208	A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184. 2010 , 116, 163-7	92
1207	A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. 2010 , 119, 32-7	199
1206	Stage migration and increasing proportion of favorable-prognosis metastatic renal cell carcinoma patients: implications for clinical trial design and interpretation. 2010 , 116, 347-54	41
1205	Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. 2010 , 116, 1272-80	219
1204	Pretreatment assessment of tumor enhancement on contrast-enhanced computed tomography as a potential predictor of treatment outcome in metastatic renal cell carcinoma patients receiving antiangiogenic therapy. 2010 , 116, 2332-42	46
1203	Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. 2010 , 116, 4256-65	904

1202	Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab. 2010 , 116, 5383-90	59
1201	Sunitinib rechallenge in metastatic renal cell carcinoma patients. 2010 , 116, 5400-6	106
1200	Emergence of potential biomarkers of response to anti-angiogenic anti-tumour agents. 2010 , 127, 1251-8	7
1199	A novel targeting modality for renal cell carcinoma: human osteocalcin promoter-mediated gene therapy synergistically induced by vitamin C and vitamin D α . 2010 , 12, 892-903	9
1198	The potential role of sunitinib in gastrointestinal cancers other than GIST. 2010 , 76, 36-43	2
1197	Clinical trials with anti-angiogenic agents in hematological malignancies. 2010 , 2, 10	27
1196	VHL and HIF signalling in renal cell carcinogenesis. 2010 , 221, 125-38	213
1195	Cost-effectiveness of sorafenib for second-line treatment of advanced renal cell carcinoma. 2010 , 13, 55-60	20
1194	Cost-effectiveness of temsirolimus for first line treatment of advanced renal cell carcinoma. 2010 , 13, 61-8	33
1193	How do cost-effectiveness analyses inform reimbursement decisions for oncology medicines in Canada? The example of sunitinib for first-line treatment of metastatic renal cell carcinoma. 2010 , 13, 837-45	29
1192	Unerwünschte dermatologische Wirkungen bei therapeutischer Inhibition des VEGF-Signalweges. 2010 , 8, 243-249	19
1191	New systemic treatment options for metastatic renal-cell carcinoma in the era of targeted therapies. 2010 , 6, 5-18	5
1190	It takes two to tango: combinations of conventional cytotoxics with compounds targeting the vascular endothelial growth factor-vascular endothelial growth factor receptor pathway in patients with solid malignancies. 2010 , 101, 7-15	24
1189	The management of kidney cancer. 2010 , 19, 706-706	
1188	A cost-effectiveness analysis of sunitinib in patients with metastatic renal cell carcinoma intolerant to or experiencing disease progression on immunotherapy: perspective of the Spanish National Health System. 2010 , 35, 429-38	12
1187	RKTG inhibits angiogenesis by suppressing MAPK-mediated autocrine VEGF signaling and is downregulated in clear-cell renal cell carcinoma. 2010 , 29, 5404-15	63
1186	Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib. 2010 , 102, 80-6	52
1185	Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. 2010 , 102, 8-18	189

1184	Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-alpha in a phase III trial: final results and geographical analysis. 2010 , 102, 658-64	45
1183	Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. 2010 , 102, 803-9	135
1182	NUB1, an interferon-inducible protein, mediates anti-proliferative actions and apoptosis in renal cell carcinoma cells through cell-cycle regulation. 2010 , 102, 873-82	23
1181	Regarding: 'Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib'. 2010 , 102, 1196-7	1
1180	Quality of life in patients with advanced renal cell carcinoma treated with temsirolimus or interferon-alpha. 2010 , 102, 1456-60	27
1179	Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism. 2010 , 102, 1371-7	101
1178	Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies. 2010 , 102, 1699-706	14
1177	Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience. 2010 , 103, 196-200	77
1176	Myelosuppression by sunitinib is flt-3 genotype dependent. 2010 , 103, 757-8	19
1175	A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours. 2010 , 103, 993-1000	16
1174	Angiotensin-2 receptors (AT1-R and AT2-R), new prognostic factors for renal clear-cell carcinoma?. 2010 , 103, 1698-705	53
1173	Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib. 2010 , 103, 796-801	21
1172	A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer. 2010 , 103, 1154-62	151
1171	Reply: Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon- α 2a compared with sunitinib. 2010 , 103, 1309-1310	1
1170	Gene-modified tumor vaccine secreting a designer cytokine Hyper-Interleukin-6 is an effective therapy in mice bearing orthotopic renal cell cancer. 2010 , 17, 465-75	13
1169	Targeting the cancer kinome through polypharmacology. 2010 , 10, 130-7	542
1168	Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. 2010 , 10, 241-53	410
1167	Adipose tissue angiogenesis as a therapeutic target for obesity and metabolic diseases. 2010 , 9, 107-15	281

1166	Pazopanib. 2010 , 9, 17-8	87
1165	New cancer targets emerging from studies of the Von Hippel-Lindau tumor suppressor protein. 2010 , 1210, 1-7	9
1164	Effects of combined valproic acid and the epidermal growth factor/vascular endothelial growth factor receptor tyrosine kinase inhibitor AEE788 on renal cell carcinoma cell lines in vitro. 2010 , 105, 549-57	16
1163	Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review. 2010 , 105, 1247-54	56
1162	Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy. 2010 , 106, 772-8	73
1161	Association of percentage of tumour burden removed with debulking nephrectomy and progression-free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. 2010 , 106, 1266-9	53
1160	Feasibility and efficacy of neoadjuvant sunitinib before nephron-sparing surgery. 2010 , 106, 1270-6	65
1159	The application of the National Institute of Clinical Excellence guidelines for treatment of metastatic renal cell carcinoma in the United Kingdom: friend or foe?. 2010 , 106, 453-7	2
1158	Evidence-based urology in practice: randomized controlled trials stopped early for benefit. 2010 , 106, 962-3	2
1157	Economic evaluation in clinical nephrology: part 2. Applying economic evaluations in clinical nephrology. 2010 , 15, 533-9	
1156	Molecular genetic events associated with renal cell carcinoma and its implication to treatment by molecular target therapy. 2010 , 17, 198-205	
1155	Treatment outcomes of sorafenib for first line or cytokinerefractory advanced renal cell carcinoma in Japanese patients. 2010 , 17, 811-5	13
1154	The bevacizumab experience in advanced renal cell carcinoma. 2010 , 3, 179-89	8
1153	Pazopanib and anti-VEGF therapy. 2010 , Volume 2, 35-40	
1152	Drug utilization, adherence, and unique side effects of targeted therapy in older adults. 41-51	
1151	Management of renal and bladder cancer in older adults. 171-185	
1150	Sunitinib causes macrocytosis in patients with advanced renal cell carcinoma. 2010 , 17, 30-3	8
1149	Efficacy and safety of surgical and chemoimmunotherapy combination treatment in patients with renal carcinoma and pulmonary metastases. 2010 , 1, 39-43	

1148	Angiogenesis Signaling Pathways as Targets in Cancer Therapy. 2010 , 2895-2905	2
1147	Metastatic clear cell carcinoma of the kidney: therapeutic role of bevacizumab. 2010 , 2, 83-96	11
1146	Anti-angiogenesis therapies: their potential in cancer management. 2010 , 3, 69-82	32
1145	Targeted therapies in epithelial ovarian cancer. 2010 , 2, 88-113	11
1144	Molecular and clinical aspects of targeting the VEGF pathway in tumors. 2010 , 2010, 652320	15
1143	Vascular endothelial growth factor-related pathways in hemato-lymphoid malignancies. 2010 , 2010, 729725	36
1142	Profile of temsirolimus in the treatment of advanced renal cell carcinoma. 2010 , 3, 191-6	10
1141	New advancements and developments in treatment of renal cell carcinoma: focus on pazopanib. 2010 , 3, 147-55	12
1140	Peptide-mediated liposomal drug delivery system targeting tumor blood vessels in anticancer therapy. 2010 , 2010, 723798	27
1139	Role of myeloid cells in vascular endothelial growth factor-independent tumor angiogenesis. 2010 , 17, 219-24	112
1138	Soluble isoforms of vascular endothelial growth factor are predictors of response to sunitinib in metastatic renal cell carcinomas. 2010 , 5, e10715	37
1137	Suppressive effects of vascular endothelial growth factor-B on tumor growth in a mouse model of pancreatic neuroendocrine tumorigenesis. 2010 , 5, e14109	40
1136	[mTOR inhibitors: temsirolimus and everolimus in the treatment of renal cell carcinoma]. 2010 , 97, 45-51	7
1135	[Angiogenesis inhibition: review of the activity of sorafenib, sunitinib and bevacizumab]. 2010 , 97, 29-43	12
1134	Rationale for targeted therapies and potential role of pazopanib in advanced renal cell carcinoma. 2010 , 4, 187-97	1
1133	Renal cell carcinoma: focus on safety and efficacy of temsirolimus. 2010 , 4, 143-54	37
1132	Management of metastatic renal cell carcinoma in patients with poor prognosis. 2010 , 123	2
1131	Is It Possible to Optimize the use of Targeted Therapies in the Treatment of Renal Cell Carcinoma?. 2010 , 96, 794-795	1

1130	Palliative Hepatic Arterial Infusion in Renal Cell Carcinoma Spreading to the Liver: A Retrospective Analysis. 2010 , 96, 177-180	1
1129	10. Perspectives in the Development of Novel Treatment Approaches. 2010 , 96, 858-873	
1128	Novel targeted agents for the treatment of bladder cancer: translating laboratory advances into clinical application. 2010 , 36, 273-82	7
1127	Gene expression profile of renal cell carcinoma clear cell type. 2010 , 36, 410-8; discussion 418-9	6
1126	Comparative Analysis between Immunochemotherapy and Target Therapy for Metastatic Renal Cell Carcinoma: Overview of Treatment-Related Adverse Events and the Dropout Rate in Korea. 2010 , 51, 379-85	3
1125	Efficacy and safety of sunitinib on metastatic renal cell carcinoma: a single-institution experience. 2010 , 51, 450-5	13
1124	Safety and clinical efficacy of everolimus in the treatment of advanced renal cell carcinoma (RCC). 2010 , 2, 85-91	1
1123	Adrenomedullin as a therapeutic target in angiogenesis. 2010 , 14, 1059-72	17
1122	Fatigue in renal cell carcinoma: the hidden burden of current targeted therapies. 2010 , 15, 1135-46	26
1121	Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma. 2010 , 28, 1502-7	149
1120	Advances in renal cell carcinoma treatment. 2010 , 2, 11-7	17
1119	Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors. 2010 , 16, 2187-97	11
1118	Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2010 , 21 Suppl 5, v137-9	80
1117	Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinib. 2010 , 21, 936-41	75
1116	Multicenter phase II trial of S-1 in patients with cytokine-refractory metastatic renal cell carcinoma. 2010 , 28, 5022-9	22
1115	Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target?. 2010 , 15, 130-41	96
1114	Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors. 2010 , 16, 3044-56	105
1113	Kidney Cancer Working Group report. 2010 , 40 Suppl 1, i51-56	43

1112	Role of the RNA-binding protein HuR in human renal cell carcinoma. 2010 , 31, 1018-26	43
1111	Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma. 2010 , 70, 1053-62	182
1110	Which patients with renal cancer may benefit from sunitinib therapy?. 2010 , 2, 69-74	2
1109	Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. 2010 , 28, 475-80	245
1108	Reply to D.J. Stewart. 2010 , 28, e652-e653	3
1107	Targeting STAT3 in adoptively transferred T cells promotes their in vivo expansion and antitumor effects. 2010 , 70, 9599-610	96
1106	Tyrosine kinase inhibitors. 2010 , 10, 462-83	33
1105	Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. 2010 , 28, 2280-5	346
1104	Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. 2010 , 28, 69-76	543
1103	Successful desensitization protocol for hypersensitivity reaction caused by sunitinib in a patient with a gastrointestinal stromal tumor. 2010 , 40, 163-5	11
1102	Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network. 2010 , 21, 1834-1838	153
1101	Pazopanib trial data cannot support first-line use. 2010 , 7, 307-8	3
1100	Emerging drugs for renal cell carcinoma. 2010 , 15, 343-53	4
1099	Two-protein signature of novel serological markers apolipoprotein-A2 and serum amyloid alpha predicts prognosis in patients with metastatic renal cell cancer and improves the currently used prognostic survival models. 2010 , 21, 1472-1481	37
1098	Sunitinib, sorafenib, temsirolimus or bevacizumab in the treatment of metastatic renal cell carcinoma: a review of health economic evaluations. 2010 , 22, 75-82	7
1097	Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies. 2010 , 12, 304-16	112
1096	Genomic deregulation during metastasis of renal cell carcinoma implements a myofibroblast-like program of gene expression. 2010 , 70, 9682-92	23
1095	Presurgical targeted therapy with tyrosine kinase inhibitors for advanced renal cell carcinoma: clinical results and histopathological therapeutic effects. 2010 , 40, 1173-9	29

1094	Metastatic mucinous tubular and spindle cell carcinoma of the kidney responding to sunitinib. 2010 , 28, e539-40	31
1093	Quantitative parametric perfusion images using 15O-labeled water and a clinical PET/CT scanner: test-retest variability in lung cancer. 2010 , 51, 1684-90	36
1092	Renal cell carcinoma: diffusion-weighted MR imaging for subtype differentiation at 3.0 T. 2010 , 257, 135-43	168
1091	Metastatic renal cell carcinoma treated with sunitinib: early evaluation of treatment response using dynamic contrast-enhanced ultrasonography. 2010 , 16, 1216-25	153
1090	New strategies in kidney cancer: therapeutic advances through understanding the molecular basis of response and resistance. 2010 , 16, 1348-54	71
1089	Evaluating patient-centered outcomes in the randomized controlled trial and beyond: informing the future with lessons from the past. 2010 , 16, 5963-71	20
1088	Downsizing a tumor thrombus of advanced renal cell carcinoma with neoadjuvant systemic therapy and resulting histopathological effects. 2010 , 84, 479-84	5
1087	Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01. 2010 , 28, 21-8	146
1086	A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors. 2010 , 28, 4513-20	38
1085	Successful outcomes using combination therapy of interleukin-2 and interferon-alpha for renal cell carcinoma patients with lung metastasis. 2010 , 40, 684-9	21
1084	Towards nanomedicines: design protocols to assemble, visualize and test carbon nanotube probes for multi-modality biomedical imaging. 2010 , 368, 3683-712	23
1083	Targeted therapy for metastatic renal cell carcinoma: current treatment and future directions. 2010 , 2, 39-49	15
1082	Hunting and trapping the vascular endothelial growth factor. 2010 , 28, 185-7	11
1081	How to interpret phase II data for everolimus plus bevacizumab in renal cell carcinoma. 2010 , 28, 2125-6	10
1080	Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24. 2010 , 21, 2220-2226	37
1079	Treatment of hemodialyzed patients with sunitinib in renal cell carcinoma. 2010 , 56, 485-91	16
1078	Life-threatening complications associated with the tyrosine kinase inhibitor sunitinib malate. 2010 , 85, 475-8	4
1077	Plasma N-terminal pro-brain natriuretic peptide as prognostic marker in fatal cardiac decompensation with sunitinib malate therapy. 2010 , 84, 119-21	1

1076	Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. 2010 , 28, 780-7	432
1075	Targeting vascular endothelial growth factor receptor in thyroid cancer: the intracellular and extracellular implications. 2010 , 16, 778-83	29
1074	Metabolism, excretion, and pharmacokinetics of oral brivanib in patients with advanced or metastatic solid tumors. 2010 , 38, 1962-6	24
1073	Genetic and pharmacological targeting of activin receptor-like kinase 1 impairs tumor growth and angiogenesis. 2010 , 207, 85-100	145
1072	How to select targeted therapy in renal cell cancer. 2010 , 21 Suppl 7, vii59-62	13
1071	Phase II study of sunitinib in patients with metastatic urothelial cancer. 2010 , 28, 1373-9	155
1070	mRNA levels of CD31, CD144, CD146 and von Willebrand factor do not serve as surrogate markers for circulating endothelial cells. 2010 , 104, 318-26	3
1069	Updates on novel therapies for metastatic renal cell carcinoma. 2010 , 2, 209-19	17
1068	The cost of a QALY. 2010 , 103, 715-20	22
1067	Treatment of metastatic renal cell carcinoma. 2010 , 7, 327-38	75
1066	Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). 2010 , 12, 855-61	151
1065	Phase II trials of single-agent anti-VEGF therapy for patients with chronic lymphocytic leukemia. 2010 , 51, 2222-9	25
1064	Phase 1 trial of allogeneic gene-modified tumor cell vaccine RCC-26/CD80/IL-2 in patients with metastatic renal cell carcinoma. 2010 , 21, 285-97	16
1063	Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. 2010 , 70, 1063-71	342
1062	Progression of intramedullary metastasis during perioperative cessation of sunitinib. 2010 , 7, 634-7	6
1061	Off-tumor target--beneficial site for antiangiogenic cancer therapy?. 2010 , 7, 604-8	41
1060	Sunitinib for the management of advanced renal cell carcinoma. 2010 , 10, 305-17	19
1059	Novel strategies for treating relapsed/refractory urothelial carcinoma. 2010 , 10, 1917-32	13

1058 Angiokinase Inhibitors. 527-565

1057	Does axitinib (AG-01376) have a future role in metastatic renal cell carcinoma and other malignancies?. 2010 , 10, 1545-57	8
1056	Can vaccination or tyrosine kinase inhibitor therapy play a role in the adjuvant treatment of renal cell carcinoma?. 2010 , 10, 813-23	2
1055	Sunitinib induces hypothyroidism with a markedly reduced vascularity. 2010 , 20, 323-6	54
1054	Phase 1 first-in-human trial of the vascular disrupting agent plinabulin(NPI-2358) in patients with solid tumors or lymphomas. 2010 , 16, 5892-9	79
1053	(Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor. 2010 , 15, 539-47	104
1052	Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. 2010 , 28, 2144-50	669
1051	Toxicity of sunitinib plus bevacizumab in renal cell carcinoma. 2010 , 28, e284-5; author reply e286-7	38
1050	Elicitation of health state utilities in metastatic renal cell carcinoma. 2010 , 26, 1091-6	43
1049	Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. 2010 , 28, 2137-43	661
1048	Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer. 2010 , 28, 193-201	123
1047	Is there a role for presurgical therapy for renal cell carcinoma?. 2010 , 10, 807-12	1
1046	Current and predicted cost of metastatic renal cell carcinoma in Finland. 2010 , 49, 837-43	12
1045	Akt inhibitors in clinical development for the treatment of cancer. 2010 , 19, 1355-66	181
1044	Pazopanib: a multikinase inhibitor with activity in advanced renal cell carcinoma. 2010 , 10, 635-45	27
1043	Tumor infiltrating regulatory T cells: tractable targets for immunotherapy. 2010 , 29, 461-84	5
1042	Differences in effects on myocardium and mitochondria by angiogenic inhibitors suggest separate mechanisms of cardiotoxicity. 2010 , 38, 691-702	43
1041	Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer. 2010 , 28, 3131-7	120

1040	Renal cancer resistance to antiangiogenic therapy is delayed by restoration of angiostatic signaling. 2010 , 9, 2793-802	57
1039	Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. 2010 , 21, 319-324	109
1038	Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?. 2010 , 21, 2324-2332	89
1037	North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer. 2010 , 21, 269-274	23
1036	Bevacizumab demonstrates prolonged disease stabilization in patients with heavily pretreated metastatic renal cell carcinoma: a case series and review of the literature. 2010 ,	10
1035	Pharmacological management of gastrointestinal stromal tumours: an update on the role of sunitinib. 2010 , 21, 208-215	31
1034	Combining allogeneic immunotherapy with an mTOR inhibitor for advanced renal cell carcinoma. 2010 , 45, 1360-2	4
1033	Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. 2010 , 102, 596-604	327
1032	Influence of an independent review committee on assessment of response rate and progression-free survival in phase III clinical trials. 2010 , 21, 19-26	31
1031	Rare tumors research in emerging countries. 2010 , 2, e49	6
1030	Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategies. 2010 , 15, 683-94	32
1029	Arzneiverordnungs-Report 2010. 2010 ,	28
1028	Sunitinib and sorafenib in metastatic renal cell carcinoma patients with renal insufficiency. 2010 , 21, 1618-1622	39
1027	Pediatric CNS Tumors. 2010 ,	10
1026	Functional imaging of renal cell carcinoma. 2010 , 7, 258-66	32
1025	Circulating endothelial cells are an early predictor in renal cell carcinoma for tumor response to sunitinib. 2010 , 10, 695	56
1024	Testicular cancer: Decision tree model has potential to improve NSGCT management. 2010 , 7, 308-10	
1023	Neoadjuvant targeted therapy in renal cell carcinoma. 2010 , 7, doi:10.1038/nrurol.2010.2-c1; author reply doi:10.	1

1022	Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis. 2010 , 79, 27-38	139
1021	Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program. 2010 , 78, 340-7	37
1020	Sunitinib in patients with advanced hepatocellular carcinoma after progression under sorafenib treatment. 2010 , 79, 85-92	33
1019	Sunitinib in patients with metastatic renal cell carcinoma: Birmingham experience. 2010 , 24, 507-10	14
1018	Potential relevance of bell-shaped and u-shaped dose-responses for the therapeutic targeting of angiogenesis in cancer. 2010 , 8, 253-84	80
1017	Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT. 2010 , 194, 157-65	172
1016	Metastatic renal carcinoma: evaluation of antiangiogenic therapy with dynamic contrast-enhanced CT. 2010 , 256, 511-8	114
1015	Cardiotoxicity. 2010 , 21 Suppl 7, vii173-9	51
1014	Sunitinib for metastatic renal cell carcinoma. 2010 , 6, 1377-85	3
1013	Progress in the management of advanced renal cell carcinoma (RCC). 2010 , 41 Suppl 1, S57-60	
1012	[New therapeutics strategies in renal cell carcinoma]. 2010 , 97, 53-63	1
1011	[Signalling pathways in renal-cell carcinoma: from the molecular biology to the future therapy]. 2010 , 97, 5-15	8
1010	mRCC stage migration: implications for trial design and analysis. 2010 , 7, 242-244	
1009	The efficacy and safety of sunitinib in korean patients with advanced renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction. 2010 , 40, 980-5	81
1008	Safety profile of new anticancer drugs. 2010 , 9, 301-17	15
1007	LECT2 amyloidosis. 2010 , 77, 757-9	19
1006	Evaluation of current and upcoming therapies in oral mucositis prevention. 2010 , 6, 1751-70	12
1005	Targeted therapies: Sunitinib versus interferon-alpha in metastatic RCC. 2010 , 7, 7-8	9

1004	Noninvasive contrast-enhanced US quantitative assessment of tumor microcirculation in a murine model: effect of discontinuing anti-VEGF therapy. 2010 , 254, 420-9	55
1003	[Impact of immunotherapy in metastatic kidney cancer in Germany after introduction of new target therapy--results of a telephone survey of the German Society of Immuno- and Targeted Therapy (DGFIT)]. 2010 , 41, 122-30	0
1002	Past, present and future of targeted therapy in solid tumors. 2010 , 10, 433-61	26
1001	[Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma]. 2010 , 41, 193-6	0
1000	Targeted therapy and hand-foot skin reaction in advanced renal cell carcinoma. 2010 , 9, 459-70	11
999	Systemic therapy for metastatic renal cell carcinoma in treatment naïve patients: a risk-based approach. 2010 , 11, 2351-62	7
998	[Management of side effects associated with antiangiogenic treatment in renal cell carcinoma]. 2010 , 97, 73-82	1
997	Genetic heterogeneity and chromatin modifiers in renal clear cell carcinoma. 2010 , 6, 897-900	5
996	CT response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapies. 2010 , 9, 15-9	98
995	Mechanism of synergistic antitumor effect of sorafenib and interferon- β in treatment of renal cell carcinoma. 2010 , 184, 2549-56	15
994	Arterial embolization for the management of gastrointestinal hemorrhage from metastatic renal cell carcinoma. 2010 , 21, 741-4	9
993	[Renal cell carcinoma: antiangiogenic therapies and management of the complications. A case report]. 2010 , 20 Suppl 1, S27-32	
992	Development of a research agenda for percutaneous renal tumor ablation: proceedings from a multidisciplinary research consensus panel. 2010 , 21, 1807-16	3
991	[Mechanisms of resistance to inhibitors of the VEGF pathway]. 2010 , 30, 40-1	
990	[Papillary renal cell carcinoma: morphological subtypes, clinical and histopathological considerations]. 2010 , 20, 393-401	2
989	Novel targeted therapies for prostate cancer. 2010 , 37, 105-19, Table of Contents	8
988	[Recommendations Onco-Urology 2010: Kidney cancer]. 2010 , 20 Suppl 4, S319-39	19
987	[Role of surgery (cytoreductive nephrectomy and metastasectomy) in the management of metastatic renal cell carcinoma: a literature review]. 2010 , 20, 1175-83	0

986	Tumor infiltrated hilar and mediastinal lymph nodes are an independent prognostic factor for decreased survival after pulmonary metastasectomy in patients with renal cell carcinoma. 2010 , 184, 1888-94	38
985	Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib. 2010 , 11, 2187-98	11
984	Molecular diagnosis and therapy of kidney cancer. 2010 , 61, 329-43	135
983	Tyrosine kinase inhibitors to treat liver cancer. 2010 , 15, 13-26	19
982	Expression of hypoxia-inducible protein 2 in renal cell carcinoma: A promising candidate for molecular targeting therapy. 2010 , 1, 697-701	5
981	Fatal necrotizing pancreatitis during combined treatment with erlotinib and sunitinib. 2010 , 70, 364-5	15
980	Current concepts in the management of renal osseous metastasis. 2010 , 24, 363-368	
979	Targeted therapy in non-small-cell lung cancer—is it becoming a reality?. 2010 , 7, 401-14	205
978	Present state of target therapy for disseminated renal cell carcinoma. 2010 , 2, 393-8	9
977	Comparison of three rapamycin dosing schedules in A/J Tsc2 ^{+/-} mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors. 2010 , 8, 14	30
976	A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic renal cell carcinoma. 2010 , 8, 8	25
975	Response to sorafenib in a patient with metastatic xp11 translocation renal cell carcinoma. 2010 , 30, 799-804	10
974	Accurate molecular classification of renal tumors using microRNA expression. 2010 , 12, 687-96	88
973	Aspects pratiques de la prescription du sunitinib. 2010 , 20, F6-F12	
972	Renal cell carcinoma bone metastases: clinical advances. 2010 , 2, 75-83	33
971	Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates. 2010 , 1, 12-25	200
970	Antitumour and immune-adjuvant activities of protein-tyrosine kinase inhibitors. 2010 , 16, 184-92	26
969	Mitochondria as targets in angiogenesis inhibition. 2010 , 31, 113-31	23

968	A substantial and confusing variation exists in handling of baseline covariates in randomized controlled trials: a review of trials published in leading medical journals. 2010 , 63, 142-53	111
967	Targeted therapies of cancer: angiogenesis inhibition seems not enough. 2010 , 299, 1-10	48
966	Treating the individual: The need for a patient-focused approach to the management of renal cell carcinoma. 2010 , 36, 16-23	42
965	Bevacizumab as a treatment option in advanced renal cell carcinoma: an analysis and interpretation of clinical trial data. 2010 , 36, 216-23	15
964	Esophagogastric cancer: targeted agents. 2010 , 36, 235-48	48
963	Pathways mediating VEGF-independent tumor angiogenesis. 2010 , 21, 21-6	237
962	Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy. 2010 , 13, 16-28	183
961	VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management. 2010 , 46, 439-48	211
960	Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours. 2010 , 46, 901-11	45
959	Loss of expression of TIMP3 in clear cell renal cell carcinoma. 2010 , 46, 1430-7	37
958	Amplification of epidermal growth factor receptor gene in renal cell carcinoma. 2010 , 46, 859-62	10
957	Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET. 2010 , 46, 2432-40	62
956	The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma. 2010 , 46, 2926-35	125
955	Unusual presentation of a renal cell carcinoma. 2010 , 76, e27-e30	
954	Sunitinib deregulates tumor adaptation to hypoxia by inhibiting HIF-1alpha synthesis in HT-29 colon cancer cells. 2010 , 398, 205-11	19
953	The relationship of vascular endothelial growth factor and coagulation factor (fibrin and fibrinogen) expression in clear cell renal cell carcinoma. 2010 , 75, 608-14	32
952	Comparison of the UCLA Integrated Staging System and the Leibovich score in survival prediction for patients with nonmetastatic clear cell renal cell carcinoma. 2010 , 75, 1365-1370; 1370.e1-3	25
951	Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy. 2010 , 76, 430-4	72

950	Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial. 2010 , 76, 923-6	81
949	Neoadjuvant treatment of renal cell carcinoma. 2010 , 28, 69-73	5
948	Role of biomarkers to predict outcomes and response to therapy. 2010 , 28, 97-101	4
947	Mammalian target of rapamycin: a new target in prostate cancer. 2010 , 28, 134-8	16
946	Complete remission achieved with angiogenic therapy in metastatic renal cell carcinoma including surgical intervention. 2010 , 28, 139-44	23
945	A survey of therapy for advanced renal cell carcinoma. 2010 , 28, 121-33	22
944	Metabolism considerations for kinase inhibitors in cancer treatment. 2010 , 6, 1175-93	78
943	Axitinib (AG-013736). 2010 , 184, 33-44	38
942	Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies. 2010 , 10, 529	179
941	Sorafenib in metastatic renal cell carcinoma with sarcomatoid differentiation. 2010 , 73, 262-4	3
940	Bleeding complications of antiangiogenic therapy: pathogenetic mechanisms and clinical impact. 2010 , 125 Suppl 2, S55-7	33
939	Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial. 2010 , 375, 641-8	97
938	Chemo-immunotherapy in RCC: the end of a story. 2010 , 375, 613-4	7
937	Is advanced renal cell carcinoma becoming a chronic disease?. 2010 , 376, 574-5	10
936	Pancreatic Metastases from Renal Cell Carcinoma Presenting as Intestinal Obstruction. 2010 , 66, 275-7	1
935	The therapy of kidney cancer with biomolecular drugs. 2010 , 36 Suppl 3, S16-20	29
934	Clinical Applications of Kinase Inhibitors in Solid Tumors. 2010 , 615-631	1
933	Endothelial alpha3beta1-integrin represses pathological angiogenesis and sustains endothelial-VEGF. 2010 , 177, 1534-48	49

932	Kinase targets in renal-cell carcinomas: reassessing the old and discovering the new. 2010 , 11, 571-8	42
931	[Renal cell carcinoma: which criteria to define antiangiogenic treatment failure? A case report]. 2010 , 20 Suppl 1, S23-6	
930	Genitourinary cancer predisposition syndromes. 2010 , 24, 861-83	3
929	Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma. 2010 , 184, 859-64	97
928	Novel inhibitors in development for hepatocellular carcinoma. 2010 , 19, 615-29	24
927	Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. 2010 , 28, 1061-8	1944
926	From Molecular to Modular Tumor Therapy. 2010 ,	5
925	The promise of biomarkers for personalized renal cancer care. 2010 , 77, 755-7	15
924	Imaging angiogenesis of genitourinary tumors. 2010 , 7, 69-82	22
923	Methods of Cancer Diagnosis, Therapy, and Prognosis. 2010 ,	
922	Angiogenesis Imaging Using 68Ga-RGD PET: Preliminary Report from Seoul National University Hospital. 2010 , 6, 56-59	1
921	Benefits from pharmacological and pharmacokinetic properties of sunitinib for clinical development. 2010 , 6, 1005-15	11
920	Dynamic contrast-enhanced magnetic resonance imaging of sunitinib-induced vascular changes to schedule chemotherapy in renal cell carcinoma xenograft tumors. 2010 , 3, 293-306	17
919	[Is the cytoreductive nephrectomy still necessary in case of metastases?]. 2010 , 20 Suppl 1, S33-7	0
918	Phase 1 study of combination treatment with PTK 787/ZK 222584 and cetuximab for patients with advanced solid tumors: safety, pharmacokinetics, pharmacodynamics analysis. 2010 , 12, 206-13	13
917	[Leg ulcerations and sunitinib]. 2010 , 137, 626-9	1
916	Contemporary management of renal tumors with venous tumor thrombus. 2010 , 184, 833-41; quiz 1235	126
915	Principles of Clinical Cancer Genetics. 2010 ,	2

914	Patient-based strategy for systemic treatment of metastatic renal cell carcinoma. 2010 , 10, 585-96	19
913	Ramucirumab (IMC-1121B): a novel attack on angiogenesis. 2010 , 6, 1085-94	52
912	Drugs that act on the immune system. 2010 , 675-704	
911	Long-term management of patients with metastatic renal cell carcinoma on targeted agents. 2010 , 10, 1883-9	7
910	Renal cell carcinoma in children and adolescents. 2010 , 10, 1967-78	26
909	Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. 2010 , 28, 2131-6	160
908	Everolimus (RAD001) in the treatment of advanced renal cell carcinoma: a review. 2010 , 15, 236-45	51
907	Q-TWiST analysis of patients receiving temsirolimus or interferon alpha for treatment of advanced renal cell carcinoma. 2010 , 28, 577-84	27
906	Antiangiogenic drugs in oncology: a focus on drug safety and the elderly - a mini-review. 2010 , 56, 303-9	54
905	Optimizing the use of sunitinib in metastatic renal cell carcinoma: an update from clinical practice. 2010 , 28, 856-64	30
904	A structured review and guide through studies on health-related quality of life in kidney cancer, hepatocellular carcinoma, and leukemia. 2010 , 28, 312-22	29
903	Immunochemotherapy-associated protein patterns in tumour tissue and serum of patients with metastatic renal cell carcinoma. 2010 , 116, 197-207	3
902	Synthesis and evaluation of novel 5-sulfonyl-indolin-2-ones as potent cytotoxic agents. 2011 , 2, 1054	5
901	Sunitinib in relapsed or refractory diffuse large B-cell lymphoma: a clinical and pharmacodynamic phase II multicenter study of the NCIC Clinical Trials Group. 2011 , 52, 833-41	16
900	Patient benefit-risk preferences for targeted agents in the treatment of renal cell carcinoma. 2011 , 29, 977-88	34
899	New targeted therapies for renal cell carcinoma. 2011 , 20, 933-45	1
898	Motesanib and advanced NSCLC: experiences and expectations. 2011 , 20, 859-69	9
897	Optimizing treatment for metastatic renal cell carcinoma. 2011 , 11, 1901-11	4

- 896 Clinical practice guidelines for the treatment of metastatic renal cell carcinoma: today and tomorrow. **2011**, 16 Suppl 2, 45-50 62
- 895 Long-term response and postsurgical complete remissions after treatment with sunitinib malate, an oral multitargeted receptor tyrosine kinase inhibitor, in patients with metastatic renal cell carcinoma. **2011**, 29, 282-5 6
- 894 Allogeneic hematopoietic cell transplantation for renal cell carcinoma: ten years after. **2011**, 11, 763-73 7
- 893 The clinical development of FLT3 inhibitors in acute myeloid leukemia. **2011**, 20, 1377-95 47
- 892 Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma. **2011**, 29, 1997-2003 139
- 891 Monitoring sunitinib-induced vascular effects to optimize radiotherapy combined with soy isoflavones in murine xenograft tumor. **2011**, 4, 110-21 16
- 890 Pleiotropic stromal effects of vascular endothelial growth factor receptor 2 antibody therapy in renal cell carcinoma models. **2011**, 13, 49-59 15
- 889 Methods of Cancer Diagnosis, Therapy, and Prognosis. **2011**,
- 888 Derrame pericárdico con inminente taponamiento cardíaco secundario a inhibidor de la tirosina quinasa. Reporte de un caso. **2011**, 18, 119-123
- 887 Noncardiac vascular toxicities of vascular endothelial growth factor inhibitors in advanced cancer: a review. **2011**, 16, 432-44 69
- 886 [Treatment of metastatic renal cell carcinoma]. **2011**, 21, 233-44 0
- 885 L'impact des thérapies ciblées chez le patient atteint de cancer au stade palliatif. **2011**, 10, 51-63
- 884 Pathological, immunohistochemical and cytogenetic features of papillary renal cell carcinoma with clear cell features. **2011**, 185, 30-5 34
- 883 [Case report of kidney cancer from JOUM 2010]. **2011**, 21 Suppl 2, S27-33 0
- 882 Cardiotoxicity of novel molecular targeted therapies of cancer. **2011**, 21, 78-85
- 881 The value of cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy. **2011**, 185, 54-9 58
- 880 [Rationale for the local treatment of metastases]. **2011**, 92, 821-4
- 879 [The neutrophil gelatinase-associated lipocalin, or LCN 2, marker of aggressiveness in clear cell renal cell carcinoma]. **2011**, 21, 851-8 13

878	Molecular mechanisms of hypertension and heart failure due to antiangiogenic cancer therapies. 2011 , 7, 299-311	10
877	Diffusion MR imaging for monitoring of treatment response. 2011 , 19, 181-209	105
876	[Evaluation of information about prophylactic treatment and management of hand-foot reactions caused by antiangiogenic therapies]. 2011 , 138, 565-71	
875	bFGF and PDGF-BB have a synergistic effect on the proliferation, migration and VEGF release of endothelial progenitor cells. 2011 , 35, 545-51	37
874	Cytoreductive Nephrectomy Preceding Adjuvant Immunotherapy for Metastatic Renal Cell Carcinoma: 8 Years' Experience in a UK Tertiary Referral Centre. 2011 , 4, 101-107	
873	Blocking the interaction of vascular endothelial growth factor receptors with their ligands and their effector signaling as a novel therapeutic target for cancer: time for a new look?. 2011 , 20, 1413-34	9
872	Tyrosine kinase inhibitors with antiangiogenic properties for the treatment of non-small cell lung cancer. 2011 , 20, 61-74	9
871	Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma. 2011 , 185, 439-44	98
870	Allogeneic stem cell transplantation for renal cell carcinoma. 2011 , 11, 901-11	11
869	Systemic therapy for metastatic non-clear-cell renal cell carcinoma: recent progress and future directions. 2011 , 25, 853-69	20
868	A phase II trial of panobinostat, a histone deacetylase inhibitor, in the treatment of patients with refractory metastatic renal cell carcinoma. 2011 , 29, 451-5	75
867	Imaging in renal cell carcinoma. 2011 , 25, 687-715	21
866	Vascular Endothelial Growth Factor and Tumour-Associated Macrophages. 2011 , 105-115	
865	The Feasibility of BCG and Sunitinib Combination Therapy for Transitional Cell Carcinoma. 2011 , 22, 19-27	3
864	Drug delivery strategies for therapeutic angiogenesis and antiangiogenesis. 2011 , 8, 485-504	39
863	Targeted terapien tegen kanker. 2011 , 54, 266-271	3
862	Economic evaluation of everolimus versus sorafenib for the treatment of metastatic renal cell carcinoma after failure of first-line sunitinib. 2011 , 14, 846-51	21
861	Adjuvant and neoadjuvant therapies in high-risk renal cell carcinoma. 2011 , 25, 765-91	22

860	Bevacizumab plus interferon- α versus sunitinib for first-line treatment of renal cell carcinoma in Italy: a cost-minimization analysis. 2011 , 31, 507-17	10
859	Vascular endothelial growth factor-targeted therapy for the treatment of renal cell carcinoma. 2011 , 71, 1179-91	22
858	Systemic therapies for metastatic renal cell carcinoma in older adults. 2011 , 28, 635-49	13
857	Axitinib for the management of metastatic renal cell carcinoma. 2011 , 11, 113-26	102
856	Encyclopedia of Cancer. 2011 , 3160-3160	
855	Imaging in Diagnosis and Staging of Urologic Cancers: Magnetic Resonance Imaging. 2011 , 118-140	
854	Principles of Anticancer Drug Development. 2011 ,	
853	Principles of Immunopharmacology. 2011 ,	3
852	New insights into the biology of renal cell carcinoma. 2011 , 25, 667-86	53
851	Immunotherapy for renal cell carcinoma. 2011 , 25, 793-812	22
850	Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma. 2011 , 25, 813-33	40
849	The role of surgery in advanced renal cell carcinoma: cytoreductive nephrectomy and metastasectomy. 2011 , 25, 753-64	17
848	mTOR inhibitors in advanced renal cell carcinoma. 2011 , 25, 835-52	93
847	Future directions in renal cell carcinoma: 2011 and beyond. 2011 , 25, 917-35	17
846	Clinical and molecular prognostic factors in renal cell carcinoma: what we know so far. 2011 , 25, 871-91	27
845	Management of treatment-related toxicity with targeted therapies for renal cell carcinoma: evidence-based practice and best practices. 2011 , 25, 893-915	19
844	The MASCC Textbook of Cancer Supportive Care and Survivorship. 2011 ,	6
843	Emerging Therapeutic Targets in Ovarian Cancer. 2011 ,	1

842	Encyclopedia of Cancer. 2011 , 3198-3203	
841	New targeted therapies for gastric cancer. 2011 , 20, 595-604	19
840	Protein kinase C β s a cancer marker and target for anticancer therapy. 2011 , 63, 19-29	37
839	Evaluation of a new prognostic score (Munich score) to predict long-term survival after resection of pulmonary renal cell carcinoma metastases. 2011 , 202, 158-67	74
838	Sunitinib for the treatment of metastatic renal cell carcinoma. 2011 , 37, 178-84	37
837	Cardiovascular effects of systemic cancer treatment. 2011 , 37, 300-11	147
836	Novel angiogenesis inhibitors: addressing the issue of redundancy in the angiogenic signaling pathway. 2011 , 37, 344-52	31
835	Vascular endothelial growth factor inhibition: conflicting roles in tumor growth. 2011 , 53, 115-29	16
834	Clinical genomics of renal epithelial tumors. 2011 , 204, 285-97	71
833	Randomised controlled trials in oncology closed early for benefit: trends in methodology, results, and interpretation. 2011 , 47, 854-63	2
832	Blinded independent central review of progression in cancer clinical trials: results from a meta-analysis. 2011 , 47, 1772-8	73
831	Better survival in patients with metastasised kidney cancer after nephrectomy: a population-based study in the Netherlands. 2011 , 47, 2023-32	29
830	The use of 24-h ambulatory blood pressure monitoring (ABPM) during the first cycle of sunitinib improves the diagnostic accuracy and management of hypertension in patients with advanced renal cancer. 2011 , 47, 1660-8	21
829	An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer. 2011 , 47, 1511-20	75
828	Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination. 2011 , 47, 1955-61	91
827	Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma. 2011 , 47, 2592-602	96
826	Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure. 2011 , 47, 2706-14	29
825	Uterine sarcomas--recent progress and future challenges. 2011 , 78, 30-40	29

824	MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. 2011 , 11, 856-61	213
823	Characterization of novel checkpoint kinase 1 inhibitors by in vitro assays and in human cancer cells treated with topoisomerase inhibitors. 2011 , 89, 259-68	9
822	Management of tyrosine kinase inhibitor-induced hand-foot skin reaction: viewpoints from the medical oncologist, dermatologist, and oncology nurse. 2011 , 9, 13-23	33
821	Tumor size is a potential predictor of response to tyrosine kinase inhibitors in renal cell cancer. 2011 , 77, 831-5	15
820	A phase II study of presurgical sunitinib in patients with metastatic clear-cell renal carcinoma and the primary tumor in situ. 2011 , 78, 832-7	26
819	Potential use of circulating endothelial cells as a biomarker of renal cell carcinoma. 2011 , 29, 237-43	4
818	Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma. 2011 , 29, 756-63	9
817	The role of targeted therapy in ovarian cancer. 2011 , 47 Suppl 3, S116-30	41
816	Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial. 2011 , 12, 673-80	193
815	Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. 2011 , 12, 1143-50	194
814	Rare case of renal cell carcinoma presenting as a cutaneous horn. 2011 , 8, 230-232	
813	Vaccination therapy in renal cell carcinoma: current position and future options in metastatic and localized disease. 2011 , 10, 837-52	12
812	Brain-specific angiogenesis inhibitor 1 is a putative factor for inhibition of neovascular formation in renal cell carcinoma. 2011 , 185, 2353-8	12
811	External validation of the Leibovich prognosis score for nonmetastatic clear cell renal cell carcinoma at a single European center applying routine pathology. 2011 , 186, 1773-7	60
810	Initial patterns of care with oral targeted therapies for patients with renal cell carcinoma. 2011 , 77, 825-830.e117	
809	Interleukin-6: a potential biomarker of resistance to multitargeted receptor tyrosine kinase inhibitors in castration-resistant prostate cancer. 2011 , 78, 968.e7-11	16
808	Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. 2011 , 378, 1931-9	1406
807	Pancreatic metastases from renal cell carcinoma: the state of the art. 2011 , 17, 4747-56	102

806	Clinical experience and critical evaluation of the role of everolimus in advanced renal cell carcinoma. 2011 , Volume 3, 43-48	
805	Clinical experience and critical evaluation of the role of sorafenib in renal cell carcinoma. 2011 , Volume 3, 69-82	
804	VEGF and HIF in Renal Cell Carcinogenesis. 2011 , 1, 60-67	
803	Successful treatment of T4 renal cell carcinoma after a neoadjuvant targeted therapy using sunitinib: report of a case. 2011 , 58, 95-8	3
802	Metastatic Renal Cell Carcinoma. 387-394	
801	Biomarkers of Renal Cancer. 2011 , 313-350	4
800	Sunitinib induced immune thrombocytopenia in patient with metastatic renal cell carcinoma. 2011 , 1,	2
799	Functional MRI techniques demonstrate early vascular changes in renal cell cancer patients treated with sunitinib: a pilot study. 2012 , 11, 259-65	33
798	Critical appraisal of pazopanib as treatment for patients with advanced metastatic renal cell carcinoma. 2011 , 273	5
797	Characteristics of human Ewing/PNET sarcoma models. 2011 , 31, 174-82	23
796	Tyrosine kinase inhibitors for metastatic renal cell carcinoma. 2011 , 49, 129-32	2
795	Pharmacotherapy of patients with metastatic renal-cell carcinoma [algorithm vs. Polish reality [Polish version: Leczenie farmakologiczne chorych na rozszianego raka nerki [algorytm a polskie realia p. 299]. 2011 , 5, 293-304	
794	Immunological effects of multikinase inhibitors for kidney cancer: a clue for integration with cellular therapies?. 2011 , 2, 333-8	37
793	Early experience with targeted therapy and dendritic cell vaccine in metastatic renal cell carcinoma after nephrectomy. 2011 , 37, 180-5; discussion 185-6	5
792	Management of cardiac and pulmonary treatment-related side effects. 2011 , 67-94	2
791	[Managing side-effects of targeted therapies in renal cancer:surgical complications]. 2011 , 98, S61-7	1
790	[Toxicities of targeted therapies and their management in renal cancer: methodology of guidelines]. 2011 , 98, S3-6	0
789	[Management of side effects of targeted therapies in renal cancer: pulmonary side effects]. 2011 , 98, S95-S115	

- 788 The current role of lymph node dissection in the management of renal cell carcinoma. **2011**, 2011, 816926 4
- 787 [Management of side-effects of targeted therapies in renal cancer: gastrointestinal side-effects]. **2011**, 98, S69-78 1
- 786 Sunitinib Inhibits Cell Proliferation and Alters Steroidogenesis by Down-Regulation of HSD3B2 in Adrenocortical Carcinoma Cells. **2011**, 2, 27 21
- 785 Renal cell cancer: what can we learn from pre-operative studies?. **2011**, 1, 51
- 784 [Management of side effects of targeted therapies in renal cancer: stomatological side effects (mucositis, epistaxis)]. **2011**, 98, S117-26 2
- 783 Metastatic renal cancer: evolution of five complete response cases after the antiangiogenic discontinuation. **2011**, 2
- 782 [Management of side effects of targeted therapies in renal cancer: iatrogenic side effects]. **2011**, 98, S79-94
- 781 Surgery and target agents for renal cell carcinoma treatment: the path between proper interaction. **2011**, 78 Suppl 18, 9-15
- 780 Role of immunotherapy for renal cell cancer in 2011. **2011**, 9, 1011-8 21
- 779 Antitumor effect of the vascular-disrupting agent ZD6126 in a murine renal cell carcinoma model. **2011**, 38, 455-64 2
- 778 FLT3 inhibitors: a story of the old and the new. **2011**, 18, 71-6 41
- 777 Molecular predictors of response to antiangiogenesis therapies. **2011**, 17, 134-41 44
- 776 Tumor fistulization associated with targeted therapy: computed tomographic findings and clinical consequences. **2011**, 35, 86-90 18
- 775 Neoadjuvant and adjuvant strategies in renal cell carcinoma: more questions than answers. **2011**, 22 Suppl 1, S4-8 6
- 774 Knowledge of hereditary renal cancer syndromes: a pending issue for oncologists. **2011**, 22 Suppl 1, S15-20 4
- 773 Safety and efficacy of molecularly targeted agents in patients with metastatic kidney cancer with renal dysfunction. **2011**, 22, 794-800 22
- 772 Exposure-response relationships in patients with metastatic renal cell carcinoma receiving sunitinib: maintaining optimum efficacy in clinical practice. **2011**, 22, 377-83 14
- 771 Sarcomatoid-variant renal cell carcinoma: treatment outcome and survival in advanced disease. **2011**, 34, 454-9 68

770	Renal cell carcinoma: immunotherapy revisited. 2011 , 8, 335-338	
769	Molecular basis of hypertension side effects induced by sunitinib. 2011 , 22, 1-8	34
768	Complete response to sunitinib in a patient with relapsed irresectable renal cell carcinoma. 2011 , 22, 817-21	2
767	Combined immunochemotherapy in selected patients with metastatic renal cell carcinoma: HLA class II genotype can help to predict response to therapy. 2011 , 34, 196-201	4
766	Renal cell cancer: the unmet needs. 2011 , 22 Suppl 1, S1-3	1
765	Update on targeted therapies for clear cell renal cell carcinoma. 2011 , 23, 283-9	51
764	Therapeutic rationale for mTOR inhibition in advanced renal cell carcinoma. 2011 , 6, 214-21	43
763	EMMPRIN promotes angiogenesis, proliferation, invasion and resistance to sunitinib in renal cell carcinoma, and its level predicts patient outcome. 2013 , 8, e74313	32
762	The contributions of HIF-target genes to tumor growth in RCC. 2013 , 8, e80544	43
761	First-in-human phase I study of PRS-050 (Angiocal), an Anticalin targeting and antagonizing VEGF-A, in patients with advanced solid tumors. 2013 , 8, e83232	41
760	Prognostic Value of Quantitative Metabolic Metrics on Baseline Pre-Sunitinib FDG PET/CT in Advanced Renal Cell Carcinoma. 2016 , 11, e0153321	5
759	Nivolumab versus Cabozantinib: Comparing Overall Survival in Metastatic Renal Cell Carcinoma. 2016 , 11, e0155389	19
758	Kinase Gene Expression Profiling of Metastatic Clear Cell Renal Cell Carcinoma Tissue Identifies Potential New Therapeutic Targets. 2016 , 11, e0160924	14
757	Comparative Gene Expression Profiling of Primary and Metastatic Renal Cell Carcinoma Stem Cell-Like Cancer Cells. 2016 , 11, e0165718	23
756	Recent developments in receptor tyrosine kinases targeted anticancer therapy. 2016 , 9, 80-90	15
755	Dendritic Cell Vaccines Presenting Autologous Tumor Antigens from Self-renewing Cancer Cells in Metastatic Renal Cell Carcinoma. 2018 , 3, 93-101	1
754	A Rare Case of Sunitinib-Induced Exfoliative Esophagitis. 2016 , 3, e155	2
753	The evolving landscape of metastatic renal cell carcinoma. 2012 , 299-302	8

752	Improving outcomes in metastatic clear cell renal cell carcinoma by sequencing therapy. 2014 , e228-38	10
751	Developing an algorithm for the management of Renal Cell Carcinoma: focus on metastatic disease. 2017 , 8, 15-21	1
750	Anti-Vasculogenic Activity of a Polysaccharide Derived from Brittle Star via Inhibition of VEGF, Paxillin and MMP-9. 2017 , 15, 179-185	1
749	Pathophysiological mechanisms of cardiotoxicity in chemotherapeutic agents. 2020 , 9,	23
748	[Novelties in the treatment for advanced renal-cell cancer]. 2011 , 152, 655-62	1
747	Management of metastatic renal cell carcinoma - mini review. 2015 , 2, 75-83	4
746	The Role of Everolimus in Renal Cell Carcinoma. 2015 , 2, 187-194	3
745	The Evolving Treatment Landscape of Advanced Renal Cell Carcinoma in Patients Progressing after VEGF Inhibition. 2017 , 4, 10-18	3
744	Nivolumab in Renal Cell Carcinoma: Current Trends and Future Perspectives. 2018 , 5, 15-18	11
743	Characterisation of the Morphological, Functional and Molecular Changes in Sunitinib-Resistant Renal Cell Carcinoma Cells. 2018 , 5, 1-9	8
742	Anti-VEGF Therapy Induces Proteinuria through Endothelial Disorganization Leading to Nephron Decrease in Podocytes. 021-028	3
741	Individual approach in choosing second-line targeted therapy for metastatic renal cell carcinoma. 2018 , 14, 68-78	2
740	Changing paradigm of immunooncology in advanced kidney cancer: nivolumab and ipilimumab combination in the first line therapy. 2019 , 15, 125-130	1
739	Cabozantinib: from studies to clinical practice. 2019 , 15, 28-41	5
738	Sunitinib as salvage treatment including potent anti-tumor activity in carcinomatous ulcers for patients with multidrug-resistant metastatic breast cancer. 2016 , 7, 57894-57902	2
737	Prognostic significance of ST6GalNAc-1 expression in patients with non-metastatic clear cell renal cell carcinoma. 2018 , 9, 3112-3120	3
736	Eosinophil percentage elevation as a prognostic factor for overall survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitor. 2016 , 7, 68943-68953	6
735	MiR-99b-5p expression and response to tyrosine kinase inhibitor treatment in clear cell renal cell carcinoma patients. 2016 , 7, 78433-78447	25

734	Low CCL-21 expression associates with unfavorable postoperative prognosis of patients with metastatic renal cell carcinoma. 2017 , 8, 25650-25659	5
733	Acidic pH reduces VEGF-mediated endothelial cell responses by downregulation of VEGFR-2; relevance for anti-angiogenic therapies. 2016 , 7, 86026-86038	19
732	Meta-analysis on the association of VEGFR1 genetic variants with sunitinib outcome in metastatic renal cell carcinoma patients. 2017 , 8, 1204-1212	5
731	Pazopanib, a novel multi-kinase inhibitor, shows potent antitumor activity in colon cancer through PUMA-mediated apoptosis. 2017 , 8, 3289-3303	27
730	Vascular endothelial growth factor gene polymorphisms and the risk of renal cell carcinoma: Evidence from eight case-control studies. 2017 , 8, 8447-8458	10
729	Immunotherapy: incorporation in the evolving paradigm of renal cancer management and future prospects. 2017 , 8, 17313-17327	19
728	Prognostic and predictive value of VHL gene alteration in renal cell carcinoma: a meta-analysis and review. 2017 , 8, 13979-13985	28
727	Prognostic role of N-Acetylgalactosaminyltransferase 10 in metastatic renal cell carcinoma. 2017 , 8, 14995-15003	3
726	Sulfatinib, a novel kinase inhibitor, in patients with advanced solid tumors: results from a phase I study. 2017 , 8, 42076-42086	23
725	Plasma cytokine and angiogenic factors associated with prognosis and therapeutic response to sunitinib vs everolimus in advanced non-clear cell renal cell carcinoma. 2017 , 8, 42149-42158	3
724	Acquired tumor cell resistance to sunitinib by increased invasion and epithelial-mesenchymal transition in LL/2 murine lung cancer. 2017 , 8, 68270-68279	2
723	The addition of abemaciclib to sunitinib induces regression of renal cell carcinoma xenograft tumors. 2017 , 8, 95116-95134	19
722	Effects of VEGF and VEGFR polymorphisms on the outcome of patients with metastatic renal cell carcinoma treated with sunitinib: a systematic review and meta-analysis. 2017 , 8, 68854-68862	5
721	Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: a multicenter retrospective analysis. 2017 , 8, 100708-100716	20
720	NY-ESO-1 as a potential immunotherapeutic target in renal cell carcinoma. 2014 , 5, 5209-17	1
719	Overexpression of CAPN2 promotes cell metastasis and proliferation via AKT/mTOR signaling in renal cell carcinoma. 2017 , 8, 97811-97821	8
718	The pyrazolyl-urea GeGe3 inhibits tumor angiogenesis and reveals dystrophin myotonic protein kinase (DMPK)1 as a novel angiogenesis target. 2017 , 8, 108195-108212	7
717	Tumor exome sequencing and copy number alterations reveal potential predictors of intrinsic resistance to multi-targeted tyrosine kinase inhibitors. 2017 , 8, 115114-115127	1

716	An open label, single-armed, exploratory study of apatinib (a novel VEGFR-2 tyrosine kinase inhibitor) in patients with relapsed or refractory non-Hodgkin lymphoma. 2018 , 9, 16213-16219	6
715	High competing risks minimize real-world utility of adjuvant targeted therapy in renal cell carcinoma: a population-based analysis. 2018 , 9, 16731-16743	4
714	Suppression of SOCS3 enhances TRAIL-induced cell growth inhibition through the upregulation of DR4 expression in renal cell carcinoma cells. 2018 , 9, 31697-31708	4
713	Second-line treatment after sunitinib therapy in patients with renal cell carcinoma: a comparison of axitinib and mammalian target of rapamycin inhibitors. 2018 , 9, 37017-37025	1
712	A combination of YM-155, a small molecule survivin inhibitor, and IL-2 potently suppresses renal cell carcinoma in murine model. 2015 , 6, 21137-47	17
711	Impact of systemic targeted agents on the clinical outcomes of patients with brain metastases. 2015 , 6, 18945-55	43
710	The sum of gains and losses of genes encoding the protein tyrosine kinase targets predicts response to multi-kinase inhibitor treatment: Characterization, validation, and prognostic value. 2015 , 6, 26388-99	8
709	Inhibition of endoplasmic reticulum chaperone protein glucose-regulated protein 78 potentiates anti-angiogenic therapy in renal cell carcinoma through inactivation of the PERK/eIF2 β pathway. 2015 , 6, 34818-30	11
708	Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses. 2015 , 6, 39538-49	23
707	Beyond evidence-based data: scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma. 2016 , 7, 21259-71	14
706	Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer. 2016 , 7, 24088-96	9
705	Everolimus affects vasculogenic mimicry in renal carcinoma resistant to sunitinib. 2016 , 7, 38467-86	19
704	FOXC2 and CLIP4 : a potential biomarker for synchronous metastasis of \geq 7-cm clear cell renal cell carcinomas. 2016 , 7, 51423-51434	14
703	Glutaminase inhibition in renal cell carcinoma therapy.. 2019 , 2, 356-364	7
702	Improving our understanding of papillary renal cell carcinoma with integrative genomic analysis. 2016 , 4, 143	12
701	Immunobiology and immunotherapy in genitourinary malignancies. 2016 , 4, 270	10
700	Precision Oncology: Identifying Predictive Biomarkers for the Treatment of Metastatic Renal Cell Carcinoma. 2016 , 5, S76-S80	16
699	New Isatin-Indole Conjugates: Synthesis, Characterization, and a Plausible Mechanism of Their in vitro Antiproliferative Activity. 2020 , 14, 483-495	7

698	The role of sunitinib in the therapy of metastatic renal cell carcinoma. 2020 , 136-145	2
697	Sunitinib in the Treatment of Thyroid Cancer. 2019 , 26, 963-972	33
696	Tyrosine Kinase Inhibitor-Induced Hypertension: Role of Hypertension as a Biomarker in Cancer Treatment. 2019 , 17, 618-634	11
695	Integrating mHealth in Oncology: Experience in the Province of Trento. 2015 , 17, e114	35
694	Cytokine therapy for renal cell cancer: the evolving role of immunomodulation. 2011 , 8, 347-358	1
693	Overall survival and response to radiation and targeted therapies among patients with renal cell carcinoma brain metastases. 2019 , 1-9	18
692	Phase II testing of sunitinib: the National Cancer Institute of Canada Clinical Trials Group IND Program Trials IND.182-185. 2007 , 14, 154-61	31
691	State-of-the-art treatment of metastatic renal cell carcinoma. 2009 , 16 Suppl 1, S16-23	4
690	Molecular targeting to treat gastric cancer. 2014 , 20, 13741-55	20
689	Clinically relevant GSK-3 β inhibitor 9-ING-41 is active as a single agent and in combination with other antitumor therapies in human renal cancer. 2020 , 45, 315-323	8
688	Different immunological effects of the molecular targeted agents sunitinib, everolimus and temsirolimus in patients with renal cell carcinoma. 2020 , 56, 999-1013	2
687	Guillain-Barre syndrome induced by pembrolizumab and sunitinib: A case report. 2020 , 13, 38-42	5
686	Overexpression of B7-H4 promotes renal cell carcinoma progression by recruiting tumor-associated neutrophils via upregulation of CXCL8. 2020 , 20, 1535-1544	2
685	Radiographical efficacy of systemic treatment for bone metastasis from renal cell carcinoma. 2020 , 20, 267	3
684	Risks associated with sunitinib use and monitoring to improve patient outcomes. 2014 , 29, 23-6	1
683	Renal adverse effects of sunitinib and its clinical significance: a single-center experience in Korea. 2014 , 29, 40-8	21
682	Mathematical modeling of regulatory T cell effects on renal cell carcinoma treatment. 2013 , 18, 915-943	18
681	Towards new treatment options for renal cell carcinoma: development and clinical results of tivozanib, a selective VEGFR tyrosine kinase inhibitor. 2012 , 1, 207-8	1

680	Sequence of treatment in locally advanced and metastatic renal cell carcinoma. 2015 , 4, 310-25	15
679	Chinese guidelines on the management of renal cell carcinoma (2015 edition). 2015 , 3, 279	11
678	Notch1 in Tumor Microvascular Endothelial Cells and Tumoral miR-34a as Prognostic Markers in Locally Advanced Triple-Negative Breast Cancer. 2019 , 22, 562-578	10
677	Future Cancer Therapy with Molecularly Targeted Therapeutics: Challenges and Strategies. 2011 , 19, 371-389	6
676	The impact of histology on survival for patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy. 2014 , 30, 38-42	4
675	Histological reclassification, histochemical characterization and c-kit immunoeexpression in renal cell carcinoma. 2008 , 24, 343-7	6
674	Molecular targeted therapy in advanced renal cell carcinoma: A review of its recent past and a glimpse into the near future. 2009 , 25, 427-36	8
673	How to critically appraise a clinical practice guideline. 2011 , 27, 498-502	5
672	Appraisal and use of a prognostic study from the urological literature. 2011 , 27, 508-12	1
671	Saudi Oncology Society and Saudi Urology Association combined clinical management guidelines for renal cell carcinoma. 2016 , 8, 136-40	5
670	Endoscopic ultrasound-guided fine needle aspiration cytology of metastatic renal cell carcinoma to the pancreas: A multi-center experience. 2016 , 13, 24	25
669	First-line tyrosine kinase inhibitors in metastatic renal cell carcinoma: A regional cancer center experience. 2017 , 54, 626-630	2
668	Saudi Oncology Society and Saudi Urology Association combined clinical management guidelines for renal cell carcinoma 2017. 2018 , 10, 123-132	1
667	Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea. 2009 , 41, 67-72	57
666	Metastatic renal cell carcinoma in a supraclavicular lymph node with no known primary: a case report. 2012 , 44, 215-8	10
665	Efficacy and safety of everolimus in korean patients with metastatic renal cell carcinoma following treatment failure with a vascular endothelial growth factor receptor-tyrosine kinase inhibitor. 2014 , 46, 339-47	4
664	Sunitinib treatment for metastatic renal cell carcinoma in patients with von hippel-lindau disease. 2013 , 45, 349-53	15
663	Efficacy and Safety of Sunitinib in Japanese Patients with Metastatic Renal Cell Carcinoma. 2011 , 02, 335-341	3

662	Efficacy and Safety of Axitinib as First-Line Therapy in Japanese Patients with Metastatic Renal Cell Carcinoma. 2015 , 06, 670-678	1
661	Current approach in the treatment of hepatocellular carcinoma. 2010 , 2, 348-59	69
660	Liver cancer: Targeted future options. 2011 , 3, 38-44	29
659	Characteristics of Human Ewing/PNET Sarcoma Models. 2011 , 31, 174-182	1
658	Combination drug regimens for metastatic clear cell renal cell carcinoma. 2020 , 11, 541-562	10
657	Nasal metastases from renal cell carcinoma are associated with Memorial Sloan-Kettering Cancer Center poor-prognosis classification. 2011 , 30, 144-8	8
656	Contemporary approach to diagnosis and classification of renal cell carcinoma with mixed histologic features. 2013 , 32, 303-11	15
655	Nonneoplastic kidney diseases in adult tumor nephrectomy and nephroureterectomy specimens: common, harmful, yet underappreciated. 2009 , 133, 1012-25	34
654	Elemele induces apoptosis in human renal-cell carcinoma 786-0 cells through inhibition of MAPK/ERK and PI3K/Akt/ mTOR signalling pathways. 2012 , 13, 2739-44	63
653	High mobility group box 1 protein is methylated and transported to cytoplasm in clear cell renal cell carcinoma. 2013 , 14, 5789-95	23
652	Prognostic and predictive value of hematologic parameters in patients with metastatic renal cell carcinoma: second line sunitinib treatment following IFN-alpha. 2013 , 14, 2101-5	25
651	Prognostic value of hematologic parameters in patients with metastatic renal cell carcinoma using tyrosine kinase inhibitors. 2014 , 15, 3801-4	14
650	Factors Prognostic for Survival in Japanese Patients Treated with Sunitinib as First-line Therapy for Metastatic Clear Cell Renal Cell Cancer. 2015 , 16, 5687-90	7
649	Metastatic Renal Cell Carcinoma Classified as Good Risk: The Easiest Choice Has Become the Hardest. 2021 , 66, 196-198	1
648	Evolving Patterns of Metastasis in Renal Cell Carcinoma: Do We Need to Perform Routine Bone Imaging?. 2021 , 8, 13-19	
647	Immunotherapies in Genitourinary Oncology: Where Are We Now? Where Are We Going?. 2021 , 13,	4
646	Cost-Effectiveness Analysis of First-Line Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma in the United States. 2021 , 38, 5662-5670	0
645	Histone demethylase KDM4D inhibition suppresses renal cancer progression and angiogenesis through JAG1 signaling. 2021 , 7, 284	2

- 644 Circular RNA circSNX6 promotes sunitinib resistance in renal cell carcinoma through the miR-1184/GPCPD1/ lysophosphatidic acid axis. **2021**, 523, 121-134 2
- 643 Grundlagen der systemischen Therapie. **2007**, 55-96
- 642 TRAIL Modulators. **2007**, 219-234
- 641 Nierentumoren. **2008**, 825-855
- 640 II ??????????. **2008**, 119, 285-292
- 639 Palliation in Renal Cancer. **2008**, 507-528
- 638 Inhibiteurs de tyrosine kinase du VEGFR: modalit s d'administration et toxicit . **2008**, 39-51
- 637 Associations: chimioth rapie, th rapies cibl es. **2008**, 143-148
- 636 Emerging Molecular Therapies: Drugs Interfering With Signal Transduction Pathways. **2008**, 317-365
- 635 Primary Neoplasms of the Kidney. **2008**, 455-460
- 634 Angiogenesis Inhibitors as Enabling Agents for the Chemotherapeutic Treatment of Metastatic Disease. **2008**, 63-80
- 633 Mol cules inhibitrices des r cepteurs du VEGF. **2008**, 65-78
- 632 Cancer of the Kidney. **2008**, 1613-1634
- 631 Systemic Therapy. **2008**, 449-483
- 630 Novel therapies in advanced renal cell carcinoma: management of adverse events from sorafenib and sunitinib. **2008**, 105, 232-7 12
- 629 Novel Therapies in Advanced Renal Cell Carcinoma [Management of Adverse Events from Sorafenib and Sunitinib: In Reply. 78
- 628 Sunitinib (SUTENT) for the treatment of metastatic renal cell carcinoma. **2008**, 8, 1723-31 1
- 627 Grundlagen der systemischen Therapie. **2009**, 123-167

626 Chemokines in Renal Cell Carcinoma: Implications for Tumor Angiogenesis and Metastasis. **2009**, 249-265

625 Pediatric Renal Tumors. **2009**, 541-573

1

624 Hepatic Metastasis 12 Years after Nephrectomy for Renal Cell Carcinoma. **2009**, 34, 642-645

623 Vascular Endothelial Growth Factor: Basic Biology and Clinical Applications. **2009**, 11-21

622 Principles of Modern Chemotherapy and Endocrine Therapy. **2009**, 1345-1352

621 Combined Targeting of EGFR and Angiogenesis in Aerodigestive Carcinomas. **2009**, 297-307

620 The Impact of Molecularly Targeted Therapy in Multi-Modality Therapy. **2009**, 191-219

619 Sunitinib and Axitinib in Renal Cell Carcinoma. **2009**, 151-165

618 Developments in the Management of Genitourinary Malignancies: Prostate Cancer and Renal Cell Carcinoma. **2009**, 533-544

617 Role of the Immune System in Cancer Development and Therapeutic Implications. **2009**, 129-145

616 Therapieschemata in der Uroonkologie. **2009**, 1-15

615 Targeted Therapy for Metastatic Renal Cell Carcinoma: Overview. **2009**, 1-12

614 Nierenzellkarzinom. **2009**, 331-369

613 Modulation of Protein Stability: Targeting the VHL Pathway. **2009**, 45-63

612 Contributions of Targeted Agents. **2009**, 215-223

611 EGFR and HER2: Relevance in Renal Cell Carcinoma. **2009**, 287-303

610 Sunitinib-Induced Cardiotoxicity Is Mediated by Off-Target Inhibition of AMP-Activated Protein Kinase. **2009**,

609 Targeted therapies for renal cell carcinoma: more gains from using them again. **2009**, 16 Suppl 1, S45-51

2

- 608 Classification of Anticancer Drugs Based on Therapeutic Targets. **2010**, 3-35 1
- 607 Metastatic Renal Cell Carcinoma: Use of Bcl-2 and Fas to Predict Responses to Immunotherapy. **2010**, 137-145
- 606 Recent advances in management of renal cancer. **2009**, 1,
- 605 Renal Cell Cancer. **2010**, 17-31
- 604 Quality of Life in Advanced Renal Cell Carcinoma: Effect of Treatment with Cytokine Therapy and Targeted Agents. **2010**, 2905-2922
- 603 Neurocutaneous Syndromes and Associated CNS Tumors. **2010**, 223-246 1
- 602 Current status and future issue of molecular targeted agents in solid tumors: lessons learned from renal cell carcinoma. **2010**, 25, 134-142 2
- 601 Cancer of the Genitourinary Tract. **2010**, 233-277
- 600 Biologisch zielgerichtete medikamentöse Therapie. **2010**, 265-275
- 599 Systems Biology: A Therapeutic Target for Tumor Therapy. **2010**, 265-285
- 598 DRUGS USED IN CANCER CHEMOTHERAPY. **2010**, 1-229
- 597 Cancer of the Kidney. **2010**, 883-900
- 596 Solid Tumors. **2010**, 603-615
- 595 Benigne Nierentumoren. **2010**, 223-226
- 594 Renal Cell Carcinoma. **2010**, 411-418
- 593 Tumorerkrankungen und medikamentöse Therapie. **2010**, 3-25
- 592 Immuntherapeutika und Zytostatika. **2010**, 649-664
- 591 [Clinical studies on renal cell carcinoma]. **2010**, 101, 558-64

- 590 Treatment of Metastatic Kidney Cancer. 343-350
- 589 Glial Brain Tumors: Antiangiogenic Therapy. **2011**, 109-119
- 588 Types of alternative splice variants of transcription factor 19 and their expression patterns in clear cell renal cell carcinoma tissues. **2010**, 30, 706-710
- 587 Novel Anti-angiogenic Therapies in Ovarian Cancer. **2011**, 51-72
- 586 Challenges and Successes in Developing Effective Anti-angiogenic Agents. **2011**, 347-401
- 585 Experimental Animal Models for Investigating Renal Cell Carcinoma Pathogenesis and Preclinical Therapeutic Approaches. **2011**, 287-305
- 584 Neoplasms of the Kidney and Bladder. **2011**, 1049-1068
- 583 Chemotherapeutic Agents for Urologic Oncology. **2011**, 175-186 0
- 582 Saudi Oncology Society clinical management guidelines for renal cell carcinoma. **2011**, 3 Suppl, S3-5 2
- 581 Encyclopedia of Cancer. **2011**, 3238-3241
- 580 Cancer du rein. **2011**, 469-484
- 579 Evaluation and Management of Liver Metastases from Non-gastrointestinal Cancer. **2011**, 381-399 1
- 578 Molecular Biology for Urologists. **2011**, 161-174
- 577 Cancer of the Kidney. **2011**, 447-463
- 576 Neoadjuvant Therapy for Locally Advanced Renal Cell Carcinoma with Sorafenib in a Reference Center in Mexico. **2011**, 02, 356-359
- 575 Sunitinib Induced Immune Thrombocytopenia. **2011**, 61, 175-177
- 574 A case of seventeen pancreatic metastases from renal cell carcinoma resected by total pancreatectomy. **2011**, 26, 517-523 1
- 573 Diagnosis and treatment of gastric metastasis of clear cell renal cell carcinoma: a case report and review of literatures. **2011**, 31, 575-577

572 Combination therapy & future directions in RCC. **2011**, 126-142

571 Rare Tumors of the Urinary Tract. **2012**, 403-419

570 Variant Renal Cell Carcinoma Histologies: Therapeutic Considerations. **2012**, 249-264

569 Cytokines in the Management of Advanced Renal Cell Cancer. **2012**, 187-196

568 Angiogenesis Inhibitor Therapy in Renal Cell Cancer. **2012**, 197-207

567 Toxicity Management of Renal Cell Cancer Patients on Targeted Therapies. **2012**, 265-283

566 Principles of Medical Oncology and Chemotherapy. **2012**, 3-13

565 Metastasectomy. **2012**, 123-140

564 Adjuvant Systemic Therapy for Renal Cell Carcinoma. **2012**, 173-186

563 Cytoreductive Nephrectomy. **2012**, 109-121

562 Somatic Alterations and Targeted Therapy. **2012**, 51-101

561 Kidney and Ureteral Carcinoma. **2012**, 1145-1165

560 Facharzt Hämatologie Onkologie - Pages e1-e61. **2012**, e1-e61

559 The effectiveness of interferon-alpha subtypes alternation for metastasis from renal cell carcinoma. **2012**, 33, 323-8

558 Targeting the VEGF Pathway in Renal Cell Carcinoma. **2012**, 115-133

557 A case of metastatic renal cell carcinoma in the nasal cavity diagnosed by epistaxis. **2012**, 21, 213-216

1

556 Angiopoietins and Other Non-VEGF Antiangiogenic Targets in Advanced Renal Cell Carcinoma. **2012**, 135-160

555 Immuntherapeutika und Zytostatika. **2012**, 679-696

2

- 554 A Case of Metastatic Renal Cell Carcinoma to the Maxillary Sinus Treated with Tyrosine Kinase Inhibitor. **2012**, 55, 717 2
- 553 A case of metastatic renal cell carcinoma treated effectively by gemcitabine and sunitinib. **2012**, 65, 227-9 1
- 552 Discovery of Sunitinib as a Multitarget Treatment of Cancer. 323-342
- 551 Overcoming VEGF resistance in renal cancer: biologic and therapeutic implications. **2012**, 2, 615-621
- 550 Metastatic renal cell carcinoma: Current scenario and future trends. **2012**, 1, 30-5 2
- 549 Urologic Oncology. **2013**, 95-123
- 548 Dermatologic Side Effects of Systemic Anticancer Therapy. **2013**, 381-419 1
- 547 Genitourinary Cancer. **2013**, 247-292 1
- 546 Renal Carcinoma Surveillance Counterpoint: Japan. **2013**, 381-382
- 545 A medical oncologist is the most qualified specialist to provide systemic therapy for patients with advanced renal cell carcinoma. **2007**, 1, S70-3
- 544 Chemotherapy and Novel Systemic Approaches in the Treatment of Metastatic Castration Resistant Prostate Cancer. **2013**, 901-923
- 543 Sustained long-term clinical and radiological response with sunitinib for metastatic renal-cell carcinoma (RCC). **2013**, 02, 29-31
- 542 Management of Non-clear Cell Renal Cell Carcinoma. **2013**, 373-385
- 541 Adjuvant Systemic Therapy, Immunotherapy, and Targeted Treatment. **2013**, 335-347
- 540 Surgical Approaches to Treatment of Renal Cell Carcinoma. **2013**, 699-711
- 539 Targeted Therapy in the Management of Elderly Patients with Pancreatic Metastases from Renal Cell Carcinoma. **2013**, 04, 15-21
- 538 Biomarkers of Response and Resistance to Anti-angiogenic Treatment. **2013**, 181-198
- 537 R. **2013**, 930-969

- 536 Rare Secondary Tumors of the Pancreas. **2013**, 175-188
- 535 Unified Approaches to Surgery and Systemic Therapy for Renal Cell Carcinoma. **2013**, 155-177
- 534 Long lasting response to second-line everolimus in kidney cancer. **2013**, 1, 166-8
- 533 [Treatment of hemodialyzed patient by targeted therapy in metastatic renal cell carcinoma: a case report]. **2013**, 104, 605-8 1
- 532 Molecular Biology and Genetics. **2013**, 19-37
- 531 Treatment Efficacy of Targeted Therapies for Metastatic Renal Cell Carcinoma: A Review after Seven Years of Experience. **2013**, 04, 22-29 1
- 530 The Efficacy and Cost of Biological Targeted Agents in Oncology.
- 529 Papillary Renal Cell Carcinoma Presented With Supraclavicular Lymph Node Metastasis Without Renal Primary Lesion. **2013**, 4, 50-53 3
- 528 Immuntherapeutika und Zytostatika. **2013**, 667-685
- 527 Angiogenesis in Diseases and Therapy. **2013**, 3-16
- 526 Review on targeted treatment of patients with advanced-stage renal cell carcinoma: a medical oncologist's perspective. **2013**, 14, 609-17 7
- 525 Angiogenesis in Gynecologic Cancers. **2013**, 357-385
- 524 Analysis of the Reasons for Dose Reduction or Discontinuation of Sunitinib in Korean Patients. **2013**, 30, 210-219
- 523 Immunotherapy in Renal Cell Carcinoma. **2014**, 125-147
- 522 MET Inhibitors. **2013**, 209-234 0
- 521 Targeted therapies. **2014**, 55-66 1
- 520 Defining the Starting Dose: Should It Be mg/kg, mg/m², or Fixed?. **2014**, 69-87
- 519 The Role of Phase III Trials in Modern Drug Development. **2014**, 763-783

- 518 Psychosocial Issues in Oncology: Clinical Management of Psychosocial Distress, Health-Related Quality of Life, and Special Considerations in Dermatologic Oncology. 60-68 1
- 517 Kidney and Ureter. **2014**, 443-464 0
- 516 Heart, Coronary Arteries, Aorta and Great Vessels, Arteries and Veins, Microcirculation. **2014**, 287-323
- 515 Hypoglycemic Coma in a Patient with Metastatic Renal Cell Carcinoma Treated with Sunitinib. **2014**, 87, 501 1
- 514 Resistance to Antiangiogenic Treatments via Upregulation of Substitution Pathways. **2014**, 397-419
- 513 Retroperitoneal Venous Diseases. **2014**, 1-42
- 512 Aspect post-thérapeutique du cancer du rein. **2014**, 167-179
- 511 Nierenzellkarzinom. **2014**, 347-397
- 510 Knochenmetastasen bei urologischen Malignomen. **2014**, 177-192
- 509 Kidney Cancer. **2014**, 309-323
- 508 Post-extraction wound healing failure with long-term bone exposure related to sunitinib, a molecularly targeted drug. **2014**, 60, 494-498
- 507 Antiangiogenic Drugs in Cancer Therapy: Effect on Advanced Renal Cell Carcinoma. **2014**, 375-382
- 506 Nierenzellkarzinom. **2014**, 139-156
- 505 Encyclopedia of Cancer. **2014**, 1-6
- 504 Acute acalculous cholecystitis in patients with clear cell renal cell carcinoma treated with sunitinib: report of two cases. **2014**, 6, 302-4 2
- 503 Cancer of the Kidney. **2014**, 1416-1444.e5 1
- 502 Mechanisms of Cardiac Dysfunction Associated with Cancer Therapeutics. **2012**, 291-316
- 501 Angiogenesis: focus on renal cancer. **2014**, 49-67

- 500 The use of molecular imaging combined with genomic techniques to understand the heterogeneity in cancer metastasis. **2014**, 1, 20140065
- 499 The Role of Targeted Therapy in Special Populations. **2015**, 417-439
- 498 EGFR and HER2: Relevance in Renal Cell Carcinoma. **2015**, 285-302 1
- 497 Principles of Chemotherapy for Genitourinary Cancer. **2015**, 277-297
- 496 Development and Incorporation of Biomarkers in RCC Therapeutics. **2015**, 527-539
- 495 Lungenmetastasen des Nierenzellkarzinoms. **2015**, 113-122
- 494 Side Effects of Targeted Therapy. **2015**, 377-416
- 493 Medical Management of Metastatic Renal Cell Carcinoma. **2015**, 401-412
- 492 Development of Combination Therapy with Targeted Agents. **2015**, 349-375
- 491 Toxicity Management of Renal Cell Cancer Patients on Targeted Therapies. **2015**, 365-384
- 490 Angiogenesis Inhibitor Therapy in Renal Cell Cancer. **2015**, 281-294
- 489 Renal Cancer. **2015**, 395-403
- 488 Retroperitoneal Venous Diseases. **2015**, 3821-3854
- 487 Medikamentöse Therapie des metastasierten Nierenzellkarzinoms. **2015**, 1-10
- 486 Biomarkers for Renal Cell Carcinoma. **2015**, 59-82
- 485 Cytoreductive Nephrectomy. **2015**, 157-171
- 484 Hypertriglyceridemia Associated with Use of Sunitinib to Treat a Metastatic Pancreatic Neuroendocrine Tumor. **2015**, 88, 101
- 483 Targeted Therapies in Kidney Cancer. **2015**, 197-210

- 482 Adjuvant Systemic Therapy for Renal Cell Carcinoma. **2015**, 229-243
- 481 Variant Renal Carcinoma Histologies: Therapeutic Considerations. **2015**, 345-364
- 480 Renal Cell Carcinoma: From Molecular Biology to Targeted Therapies. **2015**, 555-575
- 479 Long-term use of targeted afinitor therapy for metastatic renal cell carcinoma. **2015**, 4, 78
- 478 A Case of Metastatic Renal Cell Carcinoma Invasion in External Auditory Canal. **2015**, 58, 717
- 477 Molecular targeted therapy of renal cell carcinoma. **2015**, 18, 86-90
- 476 E28 Literaturhinweise und Internetadressen. **2015**, e1-e79
- 475 Specific Clinic Problems in Cancer Therapy Cardiac Toxicity Complications. **2015**, 187-235
- 474 Surgical and Medical Options in the Management of Renal Cell Carcinoma. **2015**, 183-208
- 473 Metastasectomy. **2015**, 173-194
- 472 Molecular Biomarkers and Treatments for Renal Cell Carcinoma. **2015**, 1-18
- 471 Clarification of Mechanism and Risk Factors of Adverse Drug Reactions Using Pharmacokinetic-Pharmacodynamic Analysis. **2015**, 41, 205-214 ○
- 470 Inkstų piktybinė naviklo invazija Venos chirurginio gydymo rezultatai. **2015**, 21, 224-230
- 469 Efficacy and toxicity of sunitinib in metastatic renal cell carcinoma patients in Egypt. **2015**, 16, 1971-6 1
- 468 Metastatic renal cell cancer and hypercalcaemia. **2015**, 143-154
- 467 HOODS: finding context-specific neighborhoods of proteins, chemicals and diseases. **2015**, 3, e1057 1
- 466 Kidney. 354-367
- 465 Encyclopedia of Cancer. **2016**, 4000-4005

- 464 Inhibitors of Upstream Inducers of STAT Activation. **2016**, 177-190
- 463 Molecular Targeted Anticancer Drugs. **2016**, 175-238
- 462 Neuro-Ophthalmologic Manifestations of Systemic and Intracranial Disease. **2016**, 649-776
- 461 Interferon alfa. **2016**, 158-208
- 460 Soluble Guanylyl Cyclase (sGC) in Mechanisms of Hypotensive and Antiaggregatory Effects Induced by Teraphtal (TP, sodium salt 4,5-carboxyphtalocyanin-cobalt). **2016**, 9, 138-147 1
- 459 Cardiovascular Emergencies. **2016**, 179-190
- 458 Urologic Oncology. **2016**, 77-107
- 457 Nierenzellkarzinom. **2016**, 55-66
- 456 Emerging and Recently Described Subtypes of Renal Carcinoma. **2016**, 125-140
- 455 Evaluation of Targeted Therapy for Locally Advanced or Metastatic Renal Cell Carcinoma in Tunisia. **2016**, 06, 197-204
- 454 Medikamentöse Therapie des metastasierten Nierenzellkarzinoms. **2016**, 387-394
- 453 Indications for Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors. **2016**, 179-188
- 452 Oncology Gold Standard. Practical consensus recommendations 2016 for treatment of advanced clear cell renal cell carcinoma. **2016**, 5, 167-175 1
- 451 Managing metastatic renal cell carcinoma-challenges, pitfalls, and outcomes in the real world. **2016**, 37, 260-264 1
- 450 Melanoma. **2017**, 81-94
- 449 Forthcoming Drugs for Metastatic Renal Cell Carcinoma Therapy. **2017**, 333-349
- 448 Tyrosine Kinase Inhibitors: Sorafenib, Sunitinib, Axitinib, and Pazopanib. **2017**, 253-272
- 447 Systemic and Sequential Therapy in Advanced Renal Cell Carcinoma. **2017**, 1-20

- 446 A clinical study of three cases of multiple resected pancreatic metastases from renal cell carcinoma. **2017**, 32, 912-919 1
- 445 Principles of Cancer Targeted Therapy in Older Adults. **2017**, 1-15
- 444 Molecules, Drugs, and First-Line Therapies: A Guide for the Cardiologist. **2017**, 91-106
- 443 Immunotherapy for Renal Cell Cancer (RCC). **2017**, 295-317
- 442 Endothelial Growth Factor Receptors in Angiogenesis. **2017**, 3-22
- 441 Renal Cell Carcinoma Involving the Inferior Vena Cava. **2017**, 75-106 1
- 440 Optimization of Therapy by Pharmacokinetic/Pharmacodynamic Analyses. **2017**, 369-381
- 439 Refractory Mechanisms. **2017**, 351-367
- 438 Features of expression matrix metalloproteinases, their tissue inhibitors and renal cancer. **2017**, 6, 6
- 437 Kidney. 354-367
- 436 Renal Cell Carcinoma. **2017**,
- 435 Application of the American society of clinical oncology frameworks to compare tyrosine kinase inhibitors used in first line treatment of metastatic renal cell carcinoma: had we solved the mystery?. **2017**, 17, 1061-1070 1
- 434 Capillary density has no value as an early biomarker of bevacizumab efficacy in metastatic colorectal cancers: a prospective clinical trial. **2018**, 9, 12599-12608 1
- 433 Toxicity management of angiogenesis inhibitors: resolution of expert panel. **2017**, 11, 157-163
- 432 Nierenzellkarzinom. **2018**, 189-232
- 431 Side Effects of Medical Cancer Therapy in Genitourinary Malignancies. **2018**, 179-212
- 430 Diarrhea, Constipation, and Obstruction in Cancer Management. **2018**, 421-436 1
- 429 A case of osteonecrosis of the jaw in a patient receiving sunitinib. **2018**, 64, 83-87

- 428 Adult Kidney Neoplastic Pathology. **2018**, 1-119
- 427 Kidney Cancer in Older Adults. **2018**, 1-11
- 426 Quelle strat gie th rapeutique pour les stades m tastatiques ?. **2018**, 20, 211-219
- 425 Renal Cell Carcinoma with Sarcomatoid Features. **2019**, 105-128
- 424 The Impact of Combination Therapy of Sunitinib with Interferon-Alpha on Survival of Patients with Loco Regional and Metastatic Clear Renal Cell Carcinoma. **2018**, In Press,
- 423 Pre-surgical Treatment of Renal Cell Carcinoma. **2019**, 247-262
- 422 Renal cell carcinoma. **2018**, 1, 1-18 0
- 421 Cytoreductive Nephrectomy and Metastasectomy for Renal Cell Carcinoma. **2019**, 299-311
- 420 Clinical evaluation of the effectiveness of treatment of the hand-foot syndrome & skin toxicity of antitumor target therapy with multi-kinase inhibitors. **2018**, 12, 140-149 1
- 419 Metastatic Surgery in Advanced Renal Cell Carcinoma. **2019**, 615-640
- 418 Systemic and Sequential Therapy in Advanced Renal Cell Carcinoma. **2019**, 595-614
- 417 The Role of the VEGF Signaling Pathway in Tumor Angiogenesis. **2019**, 1-16
- 416 Molecular Heterogeneity of Renal Cell Carcinoma. **2019**, 529-536
- 415 Re: Comparison of immediate deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME randomized clinical trial.. **2019**, 8, S208-S210
- 414 A Case of Cobalamin Deficiency and Macrocytic Anemia Secondary to Sunitinib. **2019**, 11, e4310 0
- 413 Sequential Treatment Based on Sunitinib and Sorafenib in Patients with Metastatic Renal Cell Carcinoma. **2019**, 11, e4244 2
- 412 Therapy Management Using Modified 2-Weeks-On/1-Week-Off Dosing Schedule in Patients With Metastatic Renal Cell Carcinoma Receiving Sunitinib: A Hypothetical, Illustrative Case Scenario. **2019**, 10, 483-493
- 411 Stereotactic body radiation therapy for oligometastatic renal cell carcinoma: improving outcomes in an otherwise radioresistant malignancy. **2019**, 7, S98

- 410 Outcome of third-line sunitinib after sequential therapy with cytokines and sorafenib in metastatic renal cell carcinoma. **2019**, 11, 505-510
- 409 Hematuria in the Critically Ill Cancer Patients. **2020**, 949-958 1
- 408 Defining an Individualized Treatment Strategy for Metastatic Renal Cancer. **2020**, 437-452
- 407 Unified Approaches to Surgery and Systemic Therapy for Renal Cell Carcinoma. **2020**, 411-435
- 406 Management of Non-Clear Cell Renal Cell Carcinoma. **2020**, 307-323
- 405 Surgical Consideration in Renal Tumors. **2020**, 3-20
- 404 Evaluation of immunotherapy and targeted therapy treatment on renal cell carcinoma: A Bayesian network analysis. **2020**, 19, 261-270
- 403 Real-world evidence on first-line treatment for metastatic renal cell carcinoma with non-clear cell and sarcomatoid histologies: are sunitinib and pazopanib interchangeable?. **2019**, 13, 973
- 402 Neurological Complications of Targeted Therapies. **2020**, 341-363
- 401 Renal Cell Carcinoma. **2020**, 123-133
- 400 Kidney Cancer in Older Adults. **2020**, 689-699
- 399 Klassifikation und medikamentöse Therapie des Nierenzellkarzinoms. **2020**, 163-187
- 398 Tolerability of Alternative Dosing Schedules for Sunitinib: A Systematic Review and Meta-Analysis. **2020**, 61, 837-843 1
- 397 Prognostic value of maximum standard uptake value, metabolic tumor volume, and total lesion glycolysis of 18F-FDG PET/CT in patients with renal carcinoma: A protocol for systematic review and meta analysis. **2020**, 99, e19988 3
- 396 Hand-foot syndrome and survival in patients with advanced non-small-cell lung cancer receiving anlotinib: a subgroup analysis of data from the ALTER 0303 study. **2020**, 25, 1492-1498 2
- 395 Real-world use of sorafenib for advanced renal cell carcinoma patients with cardiovascular disease: nationwide survey in Japan. **2020**, 20, 615-623 1
- 394 CORR Insights : Assessment of Predictive Biomarkers of the Response to Pazopanib Based on an Integrative Analysis of High-grade Soft-tissue Sarcomas: Analysis of a Tumor Sample from a Responder and Patients with Other Soft-tissue Sarcomas. **2020**, 478, 2477-2479
- 393 Medical Management of Renal Cell Cancer.

- 392 Sunitinib: An Unusual Cause of Pneumothorax in a Patient With Metastatic Chromophobe Renal Cell Carcinoma. **2020**, 12, e9586 0
- 391 Overall survival improvement in patients with metastatic clear-cell renal cell carcinoma between 2000 and 2020: a retrospective cohort study. **2021**, 1-8 3
- 390 Sarcomatoid Renal Cell Carcinoma: The Present and Future of Treatment Paradigms. **2021**, 1-13
- 389 Immune Checkpoint Inhibitors for Genitourinary Cancers: Treatment Indications, Investigational Approaches and Biomarkers. **2021**, 13, 0
- 388 Ten years-experience of sunitinib in the treatment of advanced pan-NETs: an update on safety profile. **2021**, 1-8
- 387 Clinicopathological Study of the Immunohistological Expression of mTOR and Phosphorylated mTOR in Renal Cell Carcinoma. **2020**, 66, 206-212
- 386 Nierenzellkarzinom beim geriatrischen Patienten. **2020**, 205-218
- 385 Exploiting Kinase Inhibitors for Cancer Treatment: An Overview of Clinical Results and Outlook. **2020**, 125-153
- 384 CheckMate 214 trial: Immune checkpoint regulators for advanced renal cell carcinoma. **2020**, 36, 231-233 0
- 383 Long-Term Outcomes in Clear-Cell Renal Cell Carcinoma Patients Treated with Complete Metastasectomy. **2020**, 4, 177-183 1
- 382 Urological Cancer. **2021**, 77-93
- 381 Cardiovascular Toxicities of Targeted Therapy. **2020**, 165-178
- 380 Outcomes of Multi-disciplinary Management of Metastatic Renal Cell Carcinoma. **2019**, 11, e5901 1
- 379 Pseudoprogression in patients with renal cell carcinoma during immunotherapy. **2019**, 9, 47-58
- 378 Targeted Therapies. **2020**, 1-13
- 377 Axitinib plus Immuncheckpoint-Inhibitor: evidenz- und expertenbasierte Konsensusempfehlungen für die Behandlungsoptimierung und das Management von therapieassoziierten Nebenwirkungen. **2020**, 7, 180-189
- 376 Principles of Cancer Targeted Therapy in Older Adults. **2020**, 881-894
- 375 Tolerability and outcome of sunitinib by giving 4/2 schedule versus 2/1 schedule in metastatic renal cell carcinoma patients: a prospective randomized multi-centric Egyptian study. **2020**, 24, 221-228

- 374 Immunotherapy in Bladder and Renal Cancers. **2020**, 451-474
- 373 [MiT family translocation renal cell carcinomas: Natural history, molecular features and multidisciplinary management]. **2020**, 107, 272-280
- 372 The Future Therapy of Renal Cell Carcinoma? Non-Invasive Physical Plasma as an Innovative Oncological Therapy Modality. **2021**, 12, 602-610 ○
- 371 Association of sunitinib concentration and clinical outcome in patients with metastatic renal cell carcinoma treated with a 2-week-on and 1-week-off schedule. **2021**, ○
- 370 Nivolumab in metastatic renal cell carcinoma: results from the Turkish Oncology Group Kidney Cancer Consortium database. **2021**, 17, 4861-4869 1
- 369 Combination therapy with immune checkpoint inhibitors in advanced renal cell carcinoma: A meta-analysis of randomized controlled trials. **2021**, 232, 108876 ○
- 368 Neurologic Complications of Genitourinary Cancer. **2008**, 459-480
- 367 Targeted Therapy in Renal Cell Carcinoma. **2008**, 305-316
- 366 Targeted Therapy in Melanoma. **2008**, 183-211
- 365 Quelle place pour la chirurgie en phase m̄tastatique?. **2008**, 175-181
- 364 Les traitements antiangioḡhiques modifient-ils l'histoire naturelle de la maladie en phase m̄tastatique?. **2008**, 183-195
- 363 La gūrison du cancer du rein m̄tastatique est-elle envisageable?. **2008**, 207-211
- 362 Bon usage des antiangioḡhiques: le point de vue du pharmacien. **2008**, 53-65
- 361 Efficacit̄ des antiangioḡhiques dans le cancer du rein. **2008**, 105-122
- 360 Antiangiogenic Therapy for Normalization of Tumor Vasculature and Microenvironment. **2008**, 577-592
- 359 Clinical Development of Sunitinib Malate. **2008**, 689-706
- 358 Neue Arzneimittel 2006. **2008**, 37-110
- 357 Medical Oncology. **2008**, 528-780

356	Kidney and Ureter Cancers. 2008 , 271-282	
355	Nierenzellkarzinom. 2014 , 347-397	0
354	Nierenzellkarzinom. 2014 , 139-156	0
353	Long-term follow-up results of patients with sarcomatoid RCC: A retrospective evaluation of a single center experience. 2020 , 4, 803-807	
352	[French ccAFU guidelines - update 2020-2022: management of kidney cancer]. 2020 , 30, S2-S51	3
351	Patients with metastatic renal cell carcinoma treated with cabozantinib in the Czech Republic: analysis of four cancer centers. 2020 ,	
350	Low DAPK1 expression correlates with poor prognosis and sunitinib resistance in clear cell renal cell carcinoma. 2020 , 13, 1842-1858	3
349	Cytoreductive surgery in the era of targeted molecular therapy. 2015 , 4, 301-9	2
348	Management of kidney cancer: Canadian Kidney Cancer Forum Consensus Statement. 2008 , 2, 175-82	15
347	Adjuvant and neoadjuvant small-molecule targeted therapy in high-risk renal cell carcinoma. 2009 , 16 Suppl 1, S60-6	6
346	A pilot study of monoclonal antibody cG250 and low dose subcutaneous IL-2 in patients with advanced renal cell carcinoma. 2007 , 7, 14	20
345	A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma. 2007 , 7, 13	39
344	Management of metastatic renal cell carcinoma in patients with poor prognosis. 2010 , 2, 123-32	10
343	Major Advances in the Treatment of Cancer: What does a Non-Oncologist need to know?. 2008 , 8, 137-48	5
342	Critical appraisal of pazopanib as treatment for patients with advanced metastatic renal cell carcinoma. 2011 , 3, 273-85	1
341	Progression-free survival as a clinical trial endpoint in advanced renal cell carcinoma. 2011 , 18 Suppl 2, S11-9	13
340	Molecular aspects of renal cell carcinoma: a review. 2011 , 1, 240-254	57
339	Are all multi-targeted tyrosine kinase inhibitors created equal? An in vitro study of sunitinib and pazopanib in renal cell carcinoma cell lines. 2011 , 18, 5819-25	15

338	Peptoid and Positron Emission Tomography: an Appealing Combination. 2011 , 1, 76-79	17
337	Systemic therapy for metastatic renal cell carcinoma: a review and update. 2012 , 14, 65-78	17
336	Pazopanib and anti-VEGF therapy. 2010 , 2, 35-40	
335	Circulating biomarkers of response to sunitinib in gastroenteropancreatic neuroendocrine tumors: current data and clinical outlook. 2012 , 16, 151-61	5
334	Metastatic Renal cell Carcinoma Presenting as a clear-cell Tumor in Tongue: A Case Report. 2014 , 26, 185-90	11
333	Stability of preclinical models of aggressive renal cell carcinomas. 2014 , 7, 2950-62	5
332	Single nucleotide polymorphisms in VEGF gene are associated with an increased risk of osteosarcoma. 2014 , 7, 8143-9	9
331	An update on current management of advanced renal cell cancer, biomarkers, and future directions. 2014 , 1, 1-10	4
330	Inhibition of ßsecretase by retinoic acid chalcone (RAC) induces G2/M arrest and triggers apoptosis in renal cell carcinoma. 2015 , 8, 2400-7	2
329	Increased expression of metastasis-associated in colon cancer-1 in renal cell carcinoma is associated with poor prognosis. 2015 , 8, 3857-63	4
328	Sunitinib for patients with locally advanced or distantly metastatic dermatofibrosarcoma protuberans but resistant to imatinib. 2015 , 8, 8288-94	28
327	Therapeutic challenges in renal cell carcinoma. 2015 , 3, 77-90	9
326	Sunitinib malate (SU-11248) reduces tumour burden and lung metastasis in an intratibial human xenograft osteosarcoma mouse model. 2015 , 5, 2156-68	15
325	Decreased expression of mucin 18 is associated with unfavorable postoperative prognosis in patients with clear cell renal cell carcinoma. 2015 , 8, 11005-14	6
324	Sunitinib Induced Immune Thrombocytopenia. 2015 , 14, 1295-7	3
323	Prognostic role of PPAR-ß and PTEN in the renal cell carcinoma. 2015 , 8, 12668-77	17
322	Proposal of "cyclic therapy", a novel treatment strategy with targeted agents for advanced renal cell carcinoma. 2013 , 2, 324-7	
321	Biomarkers for tyrosine kinase inhibitors in renal cell cancer. 2012 , 1, 216-22	

- 320 Modifying sunitinib schedule in advanced kidney cancer patients: Reflections from the results of the renal EFFECT trial. **2012**, 1, 120-2 1
- 319 Tivozanib: a novel VEGFR inhibitor for kidney cancer. **2013**, 2, 114-6
- 318 The complexity of sunitinib dosing in renal cell cancer patients. **2012**, 1, 194-6
- 317 Anti-vascular endothelial growth factor therapies at the crossroads: linifanib for non-small cell lung cancer. **2016**, 5, 78-81 5
- 316 Ethical Issues in the Management of Renal Cell Carcinoma. **2015**, 13, 10-17 1
- 315 Hydroxyl-HIF2-alpha is potential therapeutic target for renal cell carcinomas. **2016**, 6, 2263-2276 7
- 314 Alpinumisoflavone suppresses tumour growth and metastasis of clear-cell renal cell carcinoma. **2017**, 7, 999-1015 7
- 313 Kidney Cancer: Current Progress in Treatment. **2011**, 2, 158-165 5
- 312 Experience of Sorafenib as First-Line Treatment in Metastatic Renal Cell Carcinoma in a Tertiary Care Centre. **2018**, 12, 197-203
- 311 ADP-ribosylation factor-like 4C is a predictive biomarker of poor prognosis in patients with renal cell carcinoma. **2019**, 9, 415-423 4
- 310 Immune reaction by cytoreductive prostatectomy. **2019**, 7, 64-79 2
- 309 PPAR δ mediates sunitinib resistance via NF- κ B activation in clear cell renal cell carcinoma. **2018**, 11, 2389-2400 3
- 308 The current role of cytoreductive nephrectomy for metastatic renal cell carcinoma. **2021**, 37, 13-19 1
- 307 Overcoming sunitinib resistance with tocilizumab in renal cell carcinoma: Discordance between in vitro and in vivo effects. **2021**, 586, 42-48 0
- 306 Addition of Salvage Immunotherapy to Targeted Therapy in Patients with Metastatic Renal Cell Carcinoma. **2021**, 28, 5019-5024
- 305 Cabozantinib plus immunotherapy combinations in metastatic renal cell and urothelial carcinoma. **2022**, 18, 21-33 2
- 304 Gut Microbiota and Sunitinib-Induced Diarrhea in Metastatic Renal Cell Carcinoma: A Pilot Study. **2021**, 13, 8663-8672 0
- 303 Combination Therapy in Renal Cell Carcinoma: the Best Choice for Every Patient?. **2021**, 23, 147 2

- 302 Novel cut-off values of time from diagnosis to systematic therapy predict the overall survival and the efficacy of targeted therapy in renal cell carcinoma: A long-term, follow-up, retrospective study. **2021,** 0
- 301 Subcutaneous Interleukin-2 Monotherapy for Metastatic Renal Cell Carcinoma in Korean Patients. **2021, 19, 252-260**
- 300 [Angiogenesis inhibitors: mechanism of action and nephrotoxicity]. **2021,** 1
- 299 Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma. **2021, 6, 100304** 0
- 298 Landscape of Immunotherapy in Genitourinary Malignancies.. **2021, 1342, 143-192** 0
- 297 Encyclopedia of Gerontology and Population Aging. **2021, 4895-4908**
- 296 The role of toceranib phosphate in dogs with non-mast cell neoplasia: A systematic review.. **2022,** 0
- 295 Combination therapies in clinical trials for renal cell carcinoma: how could they impact future treatments?. **2021,** 0
- 294 Cancer and the Aging Population. **2022, 319-329**
- 293 MiR-155 regulates mA level and cell progression by targeting FTO in clear cell renal cell carcinoma.. **2021, 91, 110217** 0
- 292 Hypoxia signaling and oxygen metabolism in cardio-oncology.. **2022, 165, 64-75** 1
- 291 Nierenzellkarzinom. **2015, 1-12**
- 290 Metastasiertes Nierenzellkarzinom: Status der Therapie 2015.
- 289 Prognostic Immunophenotyping Clusters of Clear Cell Renal Cell Carcinoma Defined by the Unique Tumor Immune Microenvironment.. **2021, 9, 785410** 0
- 288 Experience of successful use of axitinib in therapy of metastatic renal cell carcinoma after immunotargeted therapy. **2021, 146-149**
- 287 Phase Ib/II trial of Ibrutinib and Nivolumab in Patients with Advanced Refractory Renal Cell Carcinoma1. **2021, 5, 181-187**
- 286 Gene Expression Analysis of Aggressive Adult Xp11.2 Translocation Renal Cell Carcinoma at Clinical Stage T1N0M0 to Identify Potential Prognostic and Therapeutic Biomarkers.. **2022, 10,**
- 285 Radiation necrosis in renal cell carcinoma brain metastases treated with checkpoint inhibitors and radiosurgery: An international multicenter study.. **2022,** 2

- 284 Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.. **2022**, 20, 71-90 20
- 283 Systemic Injection of Oncolytic Vaccinia Virus Suppresses Primary Tumor Growth and Lung Metastasis in Metastatic Renal Cell Carcinoma by Remodeling Tumor Microenvironment.. **2022**, 10, 0
- 282 Drug-Specific Orofacial Complications of Novel Anti-cancer Therapies. **2022**, 153-169
- 281 Antiangiogenic drugs as chemosensitizers in hematological tumors. **2022**, 111-125
- 280 Immunotherapy: A new standard in the treatment of metastatic clear cell renal cell carcinoma.. **2022**, 13, 28-38 2
- 279 Oral Mucositis. **2022**, 49-97 1
- 278 The Frontline Immunotherapy-Based Treatment of Advanced Clear Cell Renal Cell Carcinoma: Current Evidence and Clinical Perspective.. **2022**, 10, 2
- 277 A glance at the emerging diagnostic biomarkers in the most prevalent genitourinary cancers.. **2022**, 29, 2072-2084
- 276 Update on the treatment of metastatic renal cell carcinoma.. **2022**, 13, 1-8 1
- 275 Toceranib phosphate in the management of canine insulinoma: A retrospective multicentre study of 30 cases (2009-2019).. **2022**, 9, e27
- 274 A novel FBW7/NFAT1 axis regulates cancer immunity in sunitinib-resistant renal cancer by inducing PD-L1 expression.. **2022**, 41, 38 1
- 273 Resistance to antiangiogenic treatments: A review. **2022**, 147-197
- 272 Comparative Evaluation of Safety and Efficacy of Alternate Schedule (AS) of Sunitinib in Asian and Non-Asian Patient Population for the Treatment of Metastatic Renal Cell Cancer (mRCC): A Meta-Analysis. **2022**, 1-15
- 271 Recent Advances in First-Line Management of Metastatic Renal Cell Carcinoma.
- 270 Global management of brain metastasis from renal cell carcinoma.. **2022**, 171, 103600
- 269 Efficacy and Safety of First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.. **2022**, 37, 14-26 4
- 268 Angiomatosis of the Retina and the Cerebellum (von Hippel-Lindau Syndrome). **2022**, 333-342
- 267 Salvage nivolumab and ipilimumab after prior anti-PD-1/PD-L1 therapy in metastatic renal cell carcinoma: A meta-analysis.. **2022**, 1

- 266 Real-World Experience with Nivolumab in Metastatic Renal Cell Carcinoma Patients Who Have Progressed on Prior Therapies: A Single-Center Study from India.
- 265 Severe tyrosine-kinase inhibitor induced liver injury in metastatic renal cell carcinoma patients: two case reports assessed for causality using the updated RUCAM and review of the literature.. **2022**, 22, 49 3
- 264 Adaptive dosing of sunitinib in a metastatic renal cell carcinoma patient: when in silico modeling helps to go quicker to the point.. **2022**, 89, 565
- 263 Cardiotoxicity and Chemotherapy-The Role of Precision Medicine.. **2021**, 9, 0
- 262 Chemotherapeutic Drug-Regulated Cytokines Might Influence Therapeutic Efficacy in HCC.. **2021**, 22, 4
- 261 Methoden klinischer Prüfung in der Onkologie. **2021**, 1-53
- 260 Systematic review and cost-effectiveness of pharmacokinetically guided sunitinib individualized treatment for patients with metastatic renal cell carcinoma.. **2022**, 14, 17588359221085212
- 259 Medikamentöse Therapie des metastasierten Nierenzellkarzinoms. **2022**, 1-9
- 258 Renal Cell Carcinoma in Older Adults with Frailty. **2022**, 371-381
- 257 Tyrosine kinases: their role in hepatocellular carcinoma. **2022**, 133-148
- 256 Target therapy in cancer treatment. **2022**,
- 255 Overview of clinical management for older patients with renal cell carcinoma.. **2022**, 0
- 254 Tumor lysates cancer vaccine. **2022**, 21-49
- 253 First-line Immune Checkpoint Inhibitor Combinations in Metastatic Renal Cell Carcinoma: Where Are We Going, Where Have We Been?. **2022**, 82, 439 0
- 252 Synthesis of Novel Urea and Sulfonamide Derivatives of Isatin Schiff Bases as Potential Anti-cancer Agents. **2022**, 19,
- 251 Nivolumab VERSUS Cabozantinib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma: A Real-World Comparison.. **2022**, 2
- 250 Recent pharmacological approaches for the treatment of renal cell carcinoma.. **2022**, 1-9
- 249 REchallenge of NIVolumab (RENIVO) or Nivolumab-Ipilimumab in Metastatic Renal Cell Carcinoma: An Ambispective Multicenter Study.. **2022**, 2022, 3449660 1

248	Elevated SNRPA1, as a Promising Predictor Reflecting Severe Clinical Outcome Effecting Tumor Immunity for ccRCC, Is Related to Cell Invasion, Metastasis, and Sunitinib Sensitivity.. 2022 , 13, 842069	3
247	Molecular Biomarkers of Prognosis in Advanced Renal Cell Carcinoma Patients Treated With Pazopanib Plus Interferon Alpha (INF-2A) in a Phase I/II Study by the Spanish Oncology Genitourinary Group.. 2022 ,	
246	Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma.. 2022 ,	2
245	Therapeutic potential of CDK4/6 inhibitors in renal cell carcinoma.. 2022 ,	2
244	Cardiotoxicity Induced by Protein Kinase Inhibitors in Patients with Cancer.. 2022 , 23,	0
243	Cutaneous Metastases and Long-Term Survival of a Patient With Clear Cell Renal Carcinoma.. 2022 , 14, e23598	0
242	Treatment Equity in the Immunotherapy Era: Options for Patients with Both Autoimmune Disease and GU Cancers.. 2022 , 12,	
241	Immune Checkpoint Inhibitor Combination Therapy versus Sunitinib as First-Line Treatment for Favorable-IMDC-Risk Advanced Renal Cell Carcinoma Patients: A Meta-Analysis of Randomized Clinical Trials.. 2022 , 10,	1
240	"PROBE"ing the Role of Cytoreductive Nephrectomy in Advanced Renal Cancer.. 2022 , 6, 3-9	0
239	Oral targeted therapy dose adaptation in older patients with cancer: a real-life French cohort.. 2022 ,	
238	Extended Disease Control with Unconventional Cabozantinib Dose Increase in Metastatic Renal Cell Carcinoma. 2022 , 6, 69-79	
237	PD-L1 Upregulation by the mTOR Pathway in VEGFR-TKI-Resistant Metastatic Clear Cell Renal Cell Carcinoma.. 2022 ,	
236	Real-World Metastatic Renal Cell Carcinoma Treatment Patterns and Clinical Outcomes in The Netherlands.. 2022 , 13, 803935	0
235	Recent Advances in Medical Therapy for Urological Cancers.. 2022 , 12, 746922	2
234	Personalizing First-Line Management of Metastatic Renal Cell Carcinoma: Leveraging Current and Novel Therapeutic Options.. 2022 , 1-9	0
233	Efficacy of second-line ICIs combined with TKIs among patients with metastatic renal cell carcinoma: a real-world study.. 2022 ,	
232	Tivozanib in renal cell carcinoma: a systematic review of the evidence and its dissemination in the scientific literature.. 2022 , 22, 381	0
231	Impact of Body Mass Index on Survival Outcomes of Patients with Metastatic Renal Cell Carcinoma in the Immuno-oncology Era: A Systematic Review and Meta-analysis.. 2022 , 39, 62-71	

230	Nephrotoxicity From Molecularly Targeted Chemotherapeutic Agents.. 2021 , 28, 415-428.e1	
229	Immunotherapy and Metastatic Renal Cell Carcinoma: A Review of New Treatment Approaches.. 2021 , 12,	3
228	From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit.. 2021 ,	1
227	Metastatic renal cell carcinoma, the possibility of targeted therapy. Case.. 2021 , 138-144	1
226	Cardiovascular Safety Assessment in Cancer Drug Development.. 2021 , 10, e024033	1
225	Case Report: Early Ga-PSMA-PET Metabolic Assessment and Response to Systemic Treatment for First-Line Metastatic Clear Cell Renal Cell Carcinoma; About Two Clinical Cases.. 2021 , 11, 782166	1
224	Anti-VEGF Therapy in Refractory Pituitary Adenomas and Pituitary Carcinomas: A Review. 2021 , 11, 773905	0
223	Metastatic Tumours: Cytoreductive Nephrectomy. 2022 , 211-222	
222	Metastatic Renal Cancer: Systemic Therapy. 2022 , 193-202	
221	Sunitinib-related high-grade proteinuria and allograft dysfunction in a kidney recipient: a rare case report.. 2022 , 23, 150	1
220	Comparison of cytoreductive partial versus radical nephrectomy in metastatic renal cell carcinoma: To be on the horns of a dilemma.. 2022 , 3915603221092096	0
219	Analysis of a Real-World Progression Variable and Related Endpoints for Patients with Five Different Cancer Types.. 2022 , 1	1
218	Role of Sam68 in Sunitinib induced renal cell carcinoma apoptosis.. 2022 ,	
217	Cardio-onco-metabolism: metabolic remodelling in cardiovascular disease and cancer.. 2022 ,	0
216	Immunotherapy and Checkpoint Inhibitors in Urologic Cancer.. 2022 , 49, 323-334	
215	Image_1.TIF. 2020 ,	
214	Image_2.TIF. 2020 ,	
213	Image_3.TIF. 2020 ,	

212 Image_4.TIF. 2020,

211 Table_1.DOC. 2020,

210 Table_2.DOCX. 2020,

209 Table_3.DOCX. 2020,

208 Table_4.DOCX. 2020,

207 Data_Sheet_1.docx. 2019,

206 Table_1.xlsx. 2019,

205 Table_2.xlsx. 2019,

204 Image_1.tif. 2020,

203 Image_2.tif. 2020,

202 Image_3.tif. 2020,

201 Image_4.tif. 2020,

200 Table_1.docx. 2020,

199 Table_2.docx. 2020,

198 Table_3.docx. 2020,

197 Data_Sheet_1.PDF. 2020,

196 Data_Sheet_2.PDF. 2020,

195 Data_Sheet_3.PDF. 2020,

194 Data_Sheet_4.PDF. 2020,

193 Data_Sheet_5.PDF. 2020,

192 Image_1.pdf. 2020,

191 Image_2.pdf. 2020,

190 Image_3.pdf. 2020,

189 Image_4.pdf. 2020,

188 Image_5.pdf. 2020,

187 Image_6.pdf. 2020,

186 Table_1.XLSX. 2020,

185 Table_10.XLSX. 2020,

184 Table_11.XLSX. 2020,

183 Table_12.XLSX. 2020,

182 Table_13.XLSX. 2020,

181 Table_14.XLSX. 2020,

180 Table_2.XLSX. 2020,

179 Table_3.XLSX. 2020,

178 Table_4.XLSX. 2020,

177 Table_5.XLSX. 2020,

176 Table_6.XLSX. 2020,

175 Table_7.XLSX. 2020,

174 Table_8.XLSX. 2020,

173 Table_9.XLSX. 2020,

172 Table_1.DOCX. 2020,

171 DataSheet_1.pdf. 2020,

170 DataSheet_2.docx. 2020,

169 Data_Sheet_1.docx. 2019,

168 Ga-PSMA-11 PET/CT Parameter Correlates with Pathological VEGFR-2/PDGFR- β Expression in Renal Cell Carcinoma Patients.. 2022, 1

0

167 Economic burden of renal cell carcinoma: Part I--an updated review. 2011, 29, 315-29

12

166 A Retrospective Study of First-Line Therapy Involving Immune Checkpoint Inhibitors in Patients With Poor Risk Metastatic Renal Cell Carcinoma.. 2022, 12, 874385

165 Interindividual Variability in Cytochrome P450 3A and 1A Activity Influences Sunitinib Metabolism and Bioactivation.. 2022,

1

164 Re: Adjuvant Pembrolizumab After Nephrectomy in Renal-cell Carcinoma.. 2022,

163 A Phase II, Single-Arm Trial of Sunitinib and Erlotinib in Advanced Renal Cell Carcinoma. 2022,

162 Developments in personalized therapy for metastatic renal cell carcinoma.. 2022, 1-9

0

161 Prospective phase II study of sunitinib rechallenge in metastatic renal cell carcinoma: The Etry \square study from the Italian Group of Onco-Nephrology (G.I.O.N.). 239936932210936

160 Kidney Cancer Models for Pre-Clinical Drug Discovery: Challenges and Opportunities. 2022, 12,

159 Thyroid Dysfunction from Treatments for Solid Organ Cancers. 2022,

0

158	Complementary roles of surgery and systemic treatment in clear cell renal cell carcinoma.. 2022,	0
157	RNF7 inhibits apoptosis and sunitinib sensitivity and promotes glycolysis in renal cell carcinoma via the SOCS1/JAK/STAT3 feedback loop.. 2022, 27, 36	1
156	Integration of Tumor Microenvironment in Patient-Derived Organoid Models Help Define Precision Medicine of Renal Cell Carcinoma.. 2022, 13, 902060	1
155	Improving the Prediction of Potential Kinase Inhibitors with Feature Learning on Multisource Knowledge.. 2022, 1	0
154	Kidney Cancer. 2022, 233-245	
153	Local Investigators Significantly Overestimate Overall Response Rates Compared to Blinded Independent Central Reviews in Uncontrolled Oncology Trials: A Comprehensive Review of the Literature. 2022, 13,	1
152	Genomic and transcriptomic landscape of advanced renal cell cancer to individualize treatment strategy.	
151	Clinicopathological and Prognostic Value of Necroptosis-Associated lncRNA Model in Patients with Kidney Renal Clear Cell Carcinoma. 2022, 2022, 1-21	2
150	Trends of First-Line Targeted Therapy in Korean Patients With Metastatic Clear Cell Renal Cell Carcinoma: Sunitinib Versus Pazopanib, a Multicenter Study. 2022, 20, 115-122	
149	PBX1, EMCN and ERG are associated with the sub-clusters and the prognosis of VHL mutant clear cell renal cell carcinoma. 2022, 12,	0
148	First-line therapy for metastatic renal cell carcinoma. 205141582210929	
147	Pembrolizumab in advanced renal cell carcinoma: a meta-analysis providing level 1a evidence. 2022, 100875	0
146	Clinical activity of immunotherapy-based combination first-line therapies for metastatic renal cell carcinoma: the right treatment for the right patient. 2022, 109, 2S4-2S18	0
145	Tumor Cell-Induced Platelet Aggregation as an Emerging Therapeutic Target for Cancer Therapy. 12,	0
144	Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma.	
143	A Molecularly Characterized Preclinical Platform of Subcutaneous Renal Cell Carcinoma (RCC) Patient-Derived Xenograft Models to Evaluate Novel Treatment Strategies. 12,	0
142	A study of pazopanib safety and efficacy in patients with advanced clear cell renal cell carcinoma and ECOG Performance Status 2 (Pazo2): an open-label, multicentre, single arm, phase II trial. 2022,	1
141	Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline.	7

- 140 Tumor shrinkage patterns of nivolumab monotherapy in metastatic renal cell carcinoma.
- 139 The Role of Cytoreductive Nephrectomy in the Treatment of Metastatic Renal Cell Carcinoma. **2022**, 12, 6168-6172
- 138 Real-World Treatment with Nivolumab or Cabozantinib for Metastatic Renal Cell Carcinoma (mRCC) in the Veneto Region of Italy: Results of AMOUR Study. ○
- 137 Association of Energy Expenditure and Efficacy in Metastatic Renal Cell Carcinoma Patients Treated with Nivolumab. **2022**, 14, 3214 ○
- 136 RCC Real-World Data: Prognostic Factors and Risk Stratification in the Immunotherapy Era. **2022**, 14, 3127 ○
- 135 Combination therapy regimens in the treatment of metastatic renal cell carcinoma: A review. **2022**, 24, 191-198
- 134 Tivozanib for the treatment of advanced renal cell carcinoma.
- 133 Facts and hopes for immunotherapy in renal cell carcinoma. 2
- 132 The value measurement of emerging therapeutics in renal cell carcinoma: ASCO value framework and ESMO-MCBS. **2022**, 22, ○
- 131 Dose Individualization of Oral Multi-Kinase Inhibitors for the Implementation of Therapeutic Drug Monitoring. **2022**, 45, 814-823
- 130 Statin use improves the efficacy of nivolumab in patients with advanced renal cell carcinoma. **2022**, 172, 191-198 ○
- 129 Renal Tumors. **2023**, 285-308
- 128 The Challenges of Novel Therapies in the Care of the Critically Ill Cancer Patient. **2023**, 448-458
- 127 Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of Metastatic Renal Cell Carcinoma (mRCC). **2015**, 44, 406-414 3
- 126 The role of hepatic and pancreatic metastatectomy in the management of metastatic renal cell carcinoma: A systematic review. **2022**, 101819
- 125 Recent advances in the molecular basis of chemotherapy resistance and potential application of epigenetic therapeutics in chemorefractory renal cell carcinoma. ○
- 124 Knowledge mapping and research hotspots of immunotherapy in renal cell carcinoma: A text-mining study from 2002 to 2021. 13, ○
- 123 Insights on the molecular targets of cardiotoxicity induced by anticancer drugs: A systematic review based on proteomic findings. **2022**, 134, 155250 ○

- 122 Major Adverse Cardiovascular Events in Patients With Renal Cell Carcinoma Treated With Targeted Therapies. **2022**, 4, 223-234 ○
- 121 Next Wave of Targets in the Treatment of Advanced Renal Cell Carcinoma. **2022**, 29, 5426-5441 ○
- 120 Overexpressed lncRNA FTX promotes the cell viability, proliferation, migration and invasion of renal cell carcinoma via FTX/miR-4429/UBE2C axis. **2022**, 48, 1
- 119 Role of metastasectomy in the management of renal cell carcinoma. 9, ○
- 118 A randomized, double-blind, single-dose, parallel phase I clinical trial to compare the bioequivalence, immunogenicity, and safety of bevacizumab biosimilar and bevacizumab in healthy Chinese subjects. 1-9
- 117 Is Cytoreductive Nephrectomy Still Beneficial for Patients With Metastatic Renal Cell Carcinoma in the Contemporary Immunotherapy Era?. **2022**, 20, 139-150
- 116 XL-ing at induction of apoptosis in kidney cancer through inhibition of BCL-XL.
- 115 Updating Clear Cell Renal Cell Carcinoma (a Tribute to Prof. Ondrej Hes). **2022**, 14, 3990
- 114 2021 Consensus Statements on the Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma From the Korean Renal Cancer Study Group (KRCS). **2022**, 20, 151-162
- 113 Raman and fluorescence micro-spectroscopy applied for the monitoring of sunitinib-loaded porous silicon nanocontainers in cardiac cells. 13,
- 112 Epidemiology of Renal Cell Carcinoma: 2022 Update. **2022**, 2
- 111 Comprehensive analysis to identify the RP1178C19.2/ E2F7 axis as a novel biomarker for treatment decisions in clear cell renal cell carcinoma. **2022**, 25, 101525 ○
- 110 Systemic Treatments and Related Side Effects in Thyroid Cancer. **2022**, 153-170 ○
- 109 Tratamiento contemporáneo del cáncer renal avanzado: de la vigilancia a la inmunoterapia. **2022**, 20, 342-346 ○
- 108 Substanzen gegen molekulare Zielstrukturen. **2022**, 1-14 ○
- 107 Clinical characteristics and outcomes of tyrosine kinase inhibitor-related lower GI adverse effects. ○
- 106 circFOXO3 Induced by KLF16 Modulates Clear Cell Renal Cell Carcinoma Growth and Natural Killer Cell Cytotoxic Activity through Sponging miR-29a-3p and miR-122-5p. **2022**, 2022, 1-24 ○
- 105 A metabolic reprogramming-related prognostic risk model for clear cell renal cell carcinoma: From construction to preliminary application. 12, ○

104	Chimeric Antigen Receptor (CAR) T-cell Treatment in Renal Cell Carcinoma: Current clinical trials and future directions. 2022 , 1-10	0
103	Immunotherapy in advanced kidney cancer: an alternative meta-analytic method using reconstructed survival data in case of proportional hazard assumption violation. 12,	0
102	ACSL3 is a potential prognostic biomarker for immune infiltration in clear cell renal cell carcinoma. 9,	1
101	Grade 3/4 Adverse Event Costs of Immuno-oncology Combination Therapies for Previously Untreated Advanced Renal Cell Carcinoma.	0
100	Lenvatinib plus pembrolizumab combination therapy for adult patients with advanced renal cell carcinoma. 1-11	2
99	Analysis of genomes and transcriptomes of clear cell renal cell carcinomas identifies mutations and gene expression changes in the TGF-beta pathway. 13,	0
98	Sunitinib in patients with favorable and intermediate risk metastatic renal cell carcinoma □ Lithuanian National Cancer Institute experience.	0
97	NEK2 Serves as a Novel Biomarker and Enhances the Tumorigenicity of Clear-CellRenal-Cell Carcinoma by Activating WNT/ECatenin Pathway. 2022 , 2022, 1-9	0
96	Systemic therapies for metastatic renal cell carcinoma in the second-line setting: A systematic review and network meta-analysis. 2022 , 101, e30333	0
95	Concomitant Use of Sulforaphane Enhances Antitumor Efficacy of Sunitinib in Renal Cell Carcinoma In Vitro. 2022 , 14, 4643	1
94	The relationship between systemic immune inflammation index and survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors. 2022 , 12,	1
93	Clinical impact of early response to first-line VEGFR-TKI in patients with metastatic renal cell carcinoma on survival: A multi-institutional retrospective study.	0
92	Cutaneous Reactions to Oncologic Targeted Therapy. 2022 , 303-316	0
91	Tratamiento del cáncer de riñón metastásico. 2022 , 54, 1-13	0
90	Long-Term Response to Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma. 2022 , 10, 2444	0
89	Clinical-radiomic model in advanced kidney cancer predicts response to tyrosine kinase inhibitors. 2022 , 24,	1
88	Small molecule inhibitors targeting the cancers. 2022 , 3,	0
87	A multicenter study assessing survival in patients with metastatic renal cell carcinoma receiving immune checkpoint inhibitor therapy with and without cytoreductive nephrectomy. 2022 ,	0

- 86 Hereditary Cancer Syndromes: Risk Assessment and Genetic Counseling. 1-28 ○
- 85 Renal Cell Carcinoma. 1-10 ○
- 84 Tumor Angiogenesis. 1-30 ○
- 83 Contemporary vs historical survival rates in metastatic clear cell renal carcinoma according to race/ethnicity. ○
- 82 Alternative Complement Pathway Signature Determines Immunosuppression and Resistance to Immunotherapy Plus Tyrosine Kinase Inhibitor Combinations in Renal Cell Carcinoma. **2022**, ○
- 81 Epigenetics in advanced renal cell carcinoma: Potential new targets. **2022**, 180, 103857 ○
- 80 Chirurgische Therapie von Lungenmetastasen. **2022**, 1-20 ○
- 79 Avelumab plus axitinib combination in treating metastatic renal cell carcinoma. **2022**, 16, 263-266 ○
- 78 A retrospective study of patients treated with by oral anticancer drugs: Impact of pharmacy consultation. **2022**, 5, e00033 ○
- 77 Construction of a novel choline metabolism-related signature to predict prognosis, immune landscape, and chemotherapy response in colon adenocarcinoma. 13, ○
- 76 Contemporary Drug Therapy for Renal Cell Carcinoma Evidence Accumulation and Histological Implications in Treatment Strategy. **2022**, 10, 2840 ○
- 75 Bone metastases from renal cell carcinoma: 4 years after aggressive surgeries and anti-angiogenic therapy. **2022**, 10, ○
- 74 Bcl-2, JAK and mTOR Inhibitors. **2022**, 293-313 ○
- 73 Site-specific patterns of early response to nivolumab plus ipilimumab therapy in advanced renal cell carcinoma patients compared with tyrosine-kinase inhibitors. **2022**, 113, 109443 ○
- 72 Cell-Surface Receptors: EGFR- and VEGFR-Targeted Agents. **2022**, 153-172 ○
- 71 Therapeutic sequencing in advanced renal cell carcinoma: How to choose considering clinical and biological factors. **2023**, 181, 103881 ○
- 70 Can Molecular Classifications Help Tailor First-line Treatment of Metastatic Renal Cell Carcinoma? A Systematic Review of Available Models. **2023**, 47, 12-19 ○
- 69 Improved overall survival of metastatic renal cell carcinoma patients in the era of modern tyrosine kinase inhibitors and immune checkpoint inhibitors: results from a real-life, population-based Austrian study comprising three decades of follow-up. **2022**, 14, 175883592211340 1

68	Guiding treatment selection with immunotherapy compared to targeted therapy agents in patients with metastatic kidney cancer. 2022 , 7, 131-149	1
67	SGLT-2 Inhibitors in Cancer Treatment Mechanisms of Action and Emerging New Perspectives. 2022 , 14, 5811	1
66	Identification and validation of the molecular subtype and prognostic signature for clear cell renal cell carcinoma based on neutrophil extracellular traps. 10,	1
65	Methodological and reporting standards for quality of life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) credit. 2022 ,	0
64	Reactualization of sunitinib in the treatment of metastatic renal cell carcinoma. 2022 , 65-72	0
63	The road to systemic therapy in Von Hippel-Lindau (VHL) disease: are we there yet?. 2022 ,	0
62	Platelet-Derived Growth Factor B Is a Key Element in the Pathological Bone Formation of Ankylosing Spondylitis.	1
61	Optimization of first-line systemic therapy in patients with advanced clear cell renal cell carcinoma.	0
60	Immune-based treatment re-challenge in renal cell carcinoma: A systematic review and meta-analysis. 12,	0
59	First-line therapy for elderly patients with advanced renal cell carcinoma in the immuno-oncology era: a network meta-analysis.	0
58	GATA4 regulates mitochondrial biogenesis and functions during cardiac development and rescues cardiac and mitochondrial functions impaired by TKIs.	0
57	Manipulation of Amino Acid Levels with Artificial Diets Induces a Marked Anticancer Activity in Mice with Renal Cell Carcinoma. 2022 , 23, 16132	0
56	Cardiotoxicity of Selected Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Renal Cell Carcinoma. 2023 , 11, 181	0
55	Cáncer renal. Descripción poblacional en una institución académica. 2016 , 21,	0
54	Exploring the chemotherapeutic potential of currently used kinase inhibitors: An update. 13,	0
53	Sunitinib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers. 2023 , 100929	0
52	Prognostic role of the innate immune signature CD163 and Batimastat signal calreticulin in clear cell renal cell carcinoma.	0
51	Integrative single-cell analysis reveals transcriptional and epigenetic regulatory features of clear cell renal cell carcinoma.	0

50	Bone Metabolism Effects of Medical Therapy in Advanced Renal Cell Carcinoma. 2023 , 15, 529	0
49	Pleiotropic Devitalization of Renal Cancer Cells by Non-Invasive Physical Plasma: Characterization of Molecular and Cellular Efficacy. 2023 , 15, 481	1
48	Combining Sunitinib and Bevacizumab for the Management of Advanced Renal Cell Carcinoma: A Phase I/II Trial.	0
47	Belzutifan (MK-6482): Biology and Clinical Development in Solid Tumors.	0
46	Sunitinib-induced small bowel wall edema as a prognostic marker in metastatic renal cell carcinoma. 2023 , 0	0
45	Cuproptosis-Related MiR-21-5p/FDX1 Axis in Clear Cell Renal Cell Carcinoma and Its Potential Impact on Tumor Microenvironment. 2023 , 12, 173	0
44	Etude r̄trospective des cancers r̄naux dans le service d̄oncologie m̄dicale CHU Annaba (2008-2016).. 2022 , 9, 46-49	0
43	Cytoreductive nephrectomy for synchronous metastatic renal cell carcinoma. Is there enough evidence?. 2022 , 94, 476-485	0
42	Theranostic Applications of Glycosaminoglycans in Metastatic Renal Cell Carcinoma. 2023 , 15, 266	1
41	Clear Cell Renal Cell Carcinoma: From Biology to Treatment. 2023 , 15, 665	2
40	Adjuvant Therapy for High-Risk Localized Renal Cell Carcinoma: Current Landscape and Future Direction. Volume 16, 49-64	0
39	Development of drugs targeting hypoxia-inducible factor against tumor cells with VHL mutation: Story of 127 years.	0
38	Single-cell Deconvolution of a Specific Malignant Cell Population as a Poor Prognostic Biomarker in Low-risk Clear Cell Renal Cell Carcinoma Patients. 2023 , 83, 441-451	0
37	Metastasis in renal cell carcinoma: Biology and treatment. 2023 , 7, 100094	0
36	Real-world Treatment Patterns and Clinical Outcomes for Metastatic Renal Cell Carcinoma in the Current Treatment Era. 2023 , 49, 110-118	0
35	Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial. 2023 , 401, 821-832	1
34	Metastatic Renal Cell Carcinoma to the Scalp: A Case Report With Review of Literature. 2023 ,	0
33	Top 100 most-cited articles on renal cell carcinoma: A bibliometric analysis. 2023 , 102, e32926	0

- 32 Discovery of canine drug toceranib phosphate as a repurposed agent against human hepatocellular carcinoma. **2023**, 43, 928-944 ○
- 31 Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial. **2023**, 24, 213-227 ○
- 30 The Gut Microbiome and Metastatic Renal Cell Carcinoma. **2023**, 12, 1502 ○
- 29 Targeted Agents in Patients with Metastatic Renal Cell Carcinoma on Dialysis: Myths and Reality. 66-77 ○
- 28 Downstream Targets of VHL/HIF-1 α Signaling in Renal Clear Cell Carcinoma Progression: Mechanisms and Therapeutic Relevance. **2023**, 15, 1316 1
- 27 Stereotactic body radiation therapy to the kidney for metastatic renal cell carcinoma: A narrative review of an emerging concept. **2023**, 35, 100692 ○
- 26 The Changing Landscape of Immunotherapy for Advanced Renal Cancer. **2023**, 50, 335-349 ○
- 25 Analysis of Anti-Angiogenesis-Related Adverse Events Associated with Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitors (VEGFR-TKIs) in Patients with Metastatic Renal Cell Carcinoma. **2023**, 18, 247-255 ○
- 24 Sequential treatment of metastatic renal cell carcinoma patients after first-line vascular endothelial growth factor targeted therapy in a real-world setting: epidemiologic, noninterventional, retrospective-prospective cohort multicentre study. ○
- 23 Factors Affecting the Comprehension of Outpatients Receiving Cancer Chemotherapy. **2023**, 46, 505-510 ○
- 22 The role of cytoreductive nephrectomy and systemic therapy in the management of tumour thrombus in patients with metastatic renal cell carcinoma. ○
- 21 Stereotactic ablative radiotherapy for unresectable inferior vena cava tumor thrombus in a patient with renal cell carcinoma: a case report. **2023**, 199, 420-424 ○
- 20 Antitumor Therapy Targeting the Tumor Microenvironment. **2023**, 2023, 1-16 ○
- 19 Kidney cancer treatment in the aging population. **2023**, 60, 20-24 ○
- 18 The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF. **2023**, 175586 ○
- 17 The emerging role of long non-coding RNAs in renal cell carcinoma progression and clinical therapy via targeting metabolic regulation. 14, ○
- 16 Atypical Nelson Syndrome Following Right Partial and Left Total Nephrectomy With Incidental Bilateral Total Adrenalectomy of Renal Cell Carcinoma: A Chat Generative Pre-Trained Transformer (ChatGPT)-Assisted Case Report and Literature Review. **2023**, ○
- 15 Hepatotoxicity of Small Molecule Protein Kinase Inhibitors for Cancer. **2023**, 15, 1766 ○

- 14 Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1). **2023**, ○
- 13 Treatment strategies for clear cell renal cell carcinoma: Past, present and future. 13, ○
- 12 Establishment and validation of a novel anoikis-related prognostic signature of clear cell renal cell carcinoma. 14, ○
- 11 Trends in health care spending on kidney cancer in the United States, 1996–2016. ○
- 10 Tailoring treatment with cabozantinib or pazopanib in patients with metastatic renal cell carcinoma: does it affect outcome?. 1-10 ○
- 9 Target Hyperactive ERK Signaling for Cancer Therapy. **2023**, 1-39 ○
- 8 Inflammatory Networks in Renal Cell Carcinoma. **2023**, 15, 2212 ○
- 7 Pembrolizumab plus lenvatinib for radically unresectable or metastatic renal cell carcinoma in the Japanese population. 1-9 ○
- 6 Cytoreductive Nephrectomy and Metastatic Renal Cell Carcinoma: State of the Art and Future Perspectives. **2023**, 59, 767 ○
- 5 Three tyrosine kinase inhibitors cause cardiotoxicity by inducing endoplasmic reticulum stress and inflammation in cardiomyocytes. **2023**, 21, ○
- 4 Combining Multikinase Tyrosine Kinase Inhibitors Targeting the Vascular Endothelial Growth Factor and Cluster of Differentiation 47 Signaling Pathways Is Predicted to Increase the Efficacy of Antiangiogenic Combination Therapies. ○
- 3 An Optimized LC-MS/MS Method for Quantification of Sunitinib and N-Desethyl Sunitinib in Human Plasma and Its Application for Therapeutic Drug Monitoring. **2023**, Publish Ahead of Print, ○
- 2 Targeted therapy. **2023**, 205-411 ○
- 1 A phase II study of alternating sunitinib and temsirolimus therapy in patients with metastatic renal cell carcinoma. ○